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Glossary of abbreviations 
 
 
 
2’5’-oas 2’5’-oligoadenylate synthetase 
5-FU  5-fluorouracil 
AO Acridine Orange 
AVOs Acidic Vesicular Organelles 
CMA Chaperone Mediated Autophagy 
CMV Cytomegalovirus 
CTL Cytotoxic T lymphocytes 
EBV Epstein Barr Virus 
EC50 Effective concentration inducing 50% cell death 
ER Endoplasmic Reticulum 
GFP Green Fluorescent Protein 
HBSS Hank’s Balanced Salt Solution 
HSV-1 Herpes Simplex Virus 1 
IFNα  Interferon alpha 
IFNβ Interferon beta 
IFNγ Interferon gamma 
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MDH Monodansylamylamine 
MHC Major Histocompatibility Complex 
MIIC MHC Class II compartment 
NFκB Nuclear Factor κB 
PARP Poly(ADP-ribose) polymerase 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
pfu Plaque-Forming Unit 
PERK PKR-like endoplasmic reticulum-localised eIF2α kinase 
pGEM pGEM 
PI 3-K Phosphatidylinositol 3-kinase 
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PI(3)P  Phosphatidylinositol 3-phosphate 
PKR dsRNA-dependant protein kinase 
qPCR Quantitative (or “Real Time”) PCR 
TCID50  Tissue Culture Infectious Dose 50%; dose of virus required to 
infect 50% of cells 
VAI  VA-RNAI; Virus-associated RNA I 
VA-RNAI  
 
VAI; Virus-associated RNA I 
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Abstract 
 
Virus-Associated RNA I (VA-RNAI; VAI) of adenovirus is a non-
translated RNA molecule known to interact with several dsRNA-binding 
molecules in host cells. Adenovirus lacking VA-RNAI shows reduced 
replication and toxicity in normal tissues but replicates with high efficiency 
in some cancer cell lines.  
In this work, efficient replication of VA-RNAI-deleted adenovirus 
dl331 was confirmed to be independent of cancer cells’ k-ras mutation 
status, leaving the basis of its selectivity unknown.  
VA-RNAI expression was necessary to prevent dsRNA-dependent 
phosphorylation of eIF2α in Suit-2 and HCT116 cells, with a smaller effect 
in PANC-1 and none in MiaPaCa2. 
VA-RNAI was shown to suppress virus-induced autophagy in two cell 
lines, whether expressed from the virus or a plasmid. Unexpectedly, the 
viral protein E1A was observed to colocalise with autophagic vesicles. VA-
RNAI was also shown to prevent starvation-induced autophagy in 
susceptible cell lines. 
RNA was collected from normal NHBE cells infected with VA-RNAI-
deleted dl331 or VA-RNAI-intact control dl309 viruses. Microarray 
analysis of these samples showed a significant change in gene expression as 
VA-RNAI accumulated in the cells. Most notably, several genes involved in 
cell cycle progression were upregulated during infection with dl331 when 
compared to dl309. RT-qPCR showed a similar pattern of gene regulation in 
Suit-2 cells responding to infection. 
Cell cycle analysis of infected Suit-2 cells showed a transient 
accumulation of cells in S-phase  in response to dl309 but not dl331 at the 
approximate time that VA-RNAI reached its highest level.  
This work has demonstrated that VA-RNAI's ability to block eIF2α 
phosphorylation inhibits the induction of autophagy after infection or 
starvation. Given the newly understood importance of autophagy in cancer 
pathogenesis and the  responses of malignant cells to radiation and 
chemotherapeutic drugs, this new function is potentially important for the 
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design of future oncolytic adenoviruses. However, this activity is not 
sufficient to explain support for replication of VA-RNAI-deleted viruses in 
cancer cell lines. Data from the microarray and cell cycle analyses suggest 
that VA-RNAI may play a further role in modulating the host cell’s 
replication cycle, although the mechanism for this is currently unclear. 
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1 Introduction 
1.1  Adenovirus host immune response and cancer therapy 
1.1.1 Classification and host range of Adenovirus 
The family Adenoviridae is divided into two genera: Aviadenoviruses, 
which are limited to infecting birds; and Mastadenoviruses, whose hosts 
include human, simian, murine, bovine, equine, porcine, and canine species. 
Despite conserved epitopes between the coat proteins of closely related 
adenoviruses, there is no known antigen common to all types. 
Human adenoviruses are a diverse group, with 51 serotypes identified 
to date, divided into subgroups A to G (see Table 1). These vary in tissue 
tropism and severity of symptoms, with these ranging from subclinical to 
diarrhoea or keratitis.  
During this introduction I will focus on human adenovirus types 2 and 
5, the best-studied serotypes. Ads2 and 5 are both members of subgroup C, 
have very similar genome structures and share tropism towards the lower 
respiratory tract. Together they are responsible for 5-10% of respiratory 
tract illness observed in children.2 Infections are self-contained, with 
mortality usually associated only with immunocompromised patients. 
 
Table 1: Human Adenovirus Subgroups and Serotypes3 
Subgroup Tissue Tropism Serotypes 
A GI tract 12, 18, 31 
B Urinary Tract, Lung 3, 7, 11, 14, 16, 21, 34, 35, 
50 
C Upper / Lower Respiratory 
Tract 
1, 2, 5, 6 
D Eye, GI Tract 8-10, 13, 15, 17, 19, 20, 22-
30, 32, 33, 36-39, 42-49, 51 
E Respiratory Tract 4 
F-G GI Tract 40, 41 
 
2 
 
 
1.1.2 Physical composition of the viral particle 
Adenoviruses are dsDNA-based viruses encased in non-enveloped 
icosahedral capsids, approximately 90nm in diameter with a mass of 
150x106 daltons.4 Biochemical analysis of purified virus particles shows a 
composition by mass of 13% DNA and 87% protein. Analysis of purified 
DNA shows a composition of 22% adenine, 21% thymidine, 27% guanine 
and 29% cytosine. This contrasts with the DNA of their mammalian and 
avian hosts, in which adenine and thymine predominate.5  
 
Figure 1 - Representation of Adenovirus capsid structure: (a) shows a 
representation of the general capsid structure; (b) shows a 3D image of the 
icosahedron with hexon in dark blue, penton base in light blue, hexon in 
green, protein IX in red and protein IIIa in yellow (c) shows the detailed 
structure of a face of the icosohedron (From Vellinga et al 20054) 
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1.1.2.1 Capsid Structure 
The adenovirus capsid is primarily constructed from 252 protein 
subunits referred to as capsomeres. 240 of these are trimers of hexon protein 
and 12 are pentamers of penton base protein (Figure 1). Hexon trimers 
interlock to form the faces of the icosahedral capsid. The capsid’s vertices 
are penton base structures, from which long trimeric “fibre” proteins stand 
upright from the capsid surface. This fibre structure is the main attachment 
domain of adenovirus; changes in its length and the structure of its C-
terminal globular knob domain determine the virus’s tropism and 
antigenicity.6  
Beneath the penton and fibre structure lie hexamers of protein VI, 
which penetrates the capsid and interacts with protein V in the core.4 
Similarities between pVI and pVII suggest that pVI may also be able to 
directly bind to the viral chromosome. pVI protein may also be involved in 
adenovirus’s escape from the endosome during infection by disrupting the 
compartment’s membrane in a pH-independent manner.7  
The icosahedron’s edges are lined with protein IIIa. This protein is 
believed to penetrate the capsid to interact with the histone-like protein VII. 
It also plays a role in the stable assembly of the icosahedron’s faces.4 
The smallest of the minor capsid proteins is pIX. Homotrimers of pIX 
aggregate to form structures known as Groups-Of-Nine (GONs), which 
stabilise the centres of the icosahedron’s faces. Mutant adenoviruses lacking 
pIX can be propagated in culture with approximately the same efficiency as 
wild-type virus, but the resulting particles are less thermostable.8 
1.1.2.2 Core structure 
The virus’s core is composed of 34-48kb of linear, non-segmented, 
double-stranded DNA strongly associated with several viral polypeptides. 
Precursor terminal protein (pTP) is covalently bound to inverted 
terminal repeats at each end of the viral genome. Bound in this position, 
pTP is used during the infection to prime the viral transcription complex. 
Protein VII is the most abundant protein component of the viral core, 
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with between 1170 and 1350 copies present in each particle. Its role is 
analogous to histone in eukaryotic nuclei, binding the viral DNA into a 
compact nucleosome-like structure. 
Protein V and peptide µ (also called pX) assist in stabilising this 
structure.9 Protein V is also believed to link the viral chromosome to the 
capsid shell.2 
1.1.2.3 Genome  
 
 
Figure 2 - (From Davison, Benko and Harrach, 200310): Mastadenovirus 
genome 
Adenoviruses are a large and diverse group, with genomes ranging 
between 34-48kb in length. Adenoviruses types 2 and 5 have genomes of 
approximately 35.9kb. The genome is flanked by 103bp inverted terminal 
repeats, which act as recognition sites for the transcription and replication 
primer protein pTP. 
The structure of a typical Mastadenovirus genome is shown in Figure 2. 
The genome contains two origins of replication, located at the inverted 
terminal repeat at the 5’ end of each strand. Transcription units are loosely 
divided into “early” or “late” genes, with genes encoded closest to the 5’ 
end of their strand generally being expressed earlier in the infection. 
Many adenoviral mRNAs undergo splicing to produce several 
polypeptides with distinct, although often related functions. For example, 
two proteins are produced by splice forms of the immediate / early gene 
E1A. Together, these induce the host cell to enter S phase and promote 
expression of additional viral genes. 
 
5 
1.1.3 Adenovirus Life Cycle 
1.1.3.1 Attachment and internalisation 
The virus first attaches to its target cells via binding domains of the 
globular knob proteins carried at the tips of fibre capsomeres. Different 
subtypes of adenovirus target different host cell surface proteins.11 One 
notable example is CD46, a complement regulatory protein. This molecule 
is a target for many adenoviral subtypes, presumably due to its expression 
on a wide range of tissue types.12  
For adenovirus types 2 and 5 the primary attachment receptor on host 
cells is the Coxsackie and Adenovirus Receptor (CAR). CAR has two 
immunoglobulin-like extracellular domains and is involved in mediating 
homotypic cell adhesion.13 It is found in specialised intercellular junctions 
including the tight junction of polarised epithelial cells.14 These sites seem 
inaccessible to virus, so infections via CAR may require disruption of the 
junctions or physical damage to the epithelium. 
 The distribution of CAR expression in humans is not well known. 
However, CAR mRNA has been found in a wide range of organs including 
the lungs, liver, pancreas and intestine.11 
Blocking CAR using monoclonal antibodies significantly reduces viral 
attachment and entry but does not completely prevent successful infection. 
The initial attachment step of Ads 2 and 5 also involves binding to Heparin 
Sulphate Glycosaminoglycans (HS GAGs). 
HS GAGs are a heterogeneous family of long, heavily sulphated 
carbohydrates which are abundant within the extracellular matrix and the 
cellular glycocalyx.11 Proteins usually bind to HS GAGs via basic domains; 
the KKTK motif contained in the fibre shaft of Ads 2 and 5 is a putative HS 
GAG-binding motif. Inactivating HS GAGs by treating cells with heparin 
lyases significantly reduces adenoviral attachment and entry. 
Simultaneously blocking CAR and inactivating HS GAGs entirely prevents 
viral replication.15 
In addition to binding CAR, most adenoviruses bind a secondary 
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“entry” receptor. For adenovirus types 2 and 5, RGD motifs in the penton 
base structure interact with integrins on the cell surface such as αvβ3, αvβ5, 
α3β1 or α5β1. This behaviour is highly conserved among adenoviruses, as 
the RGD motifs have been found in all but two (Ads 40 and 41, in serotype 
F) of the adenoviruses sequenced to date.11 Viral binding to αvβ3 leads to 
conformational change in the integrins, possibly triggering an intracellular 
signal. Uptake of Ad5 is associated with activation of integrin-dependent 
PI(3) Kinase. Substrates of PI(3) kinase have been linked with cell cycle 
progression and regulation of vesicle trafficking.16 
Interestingly, mutating the RGD motif in Ad2 slows but does not 
prevent viral uptake,17 suggesting that this RGD-integrin interaction is not 
essential for viral entry to the host cell. 
Electron microscopic analysis of infected cells detected Ads type 2 and 
5 in clathrin-coated pits and vesicles. Later work has confirmed that viral 
entry to epithelial cells is a clathrin-dependent process, specifically 
macropinocytosis.18 
Macropinocytosis is mediated by a wide range of membrane-bound 
receptors including lectins and several of the integrins bound by Ads 2 and 
5. Processive macropinocytosis is involved in the uptake of large bodies 
such as bacteria and apoptotic cells. These are then enveloped into large 
endocytic vesicles for degradation by acidic conditions and a range of 
degradative enzymes. 
Once the virus has been endocytosed, it must escape from the 
endosome to the cytosol and translocate to the nucleus. The process of 
endosomal escape is poorly understood, but involves rapid disassembly of 
the viral particle. Within 10 minutes of endocytosis and before acidification 
of the endosome, half of the fibre proteins are released from the capsid; after 
30 minutes over 90% of particles have shed their fibres.19 Following this, 
penton base structures are dissociated, followed by release of the capsid-
stabilising proteins IIIa and VIII.20 
Soon afterwards, acidification of the endosome allows activation of the 
viral cytosine protease p23. This protease cleaves pVI, freeing the packaged 
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genome from its association with hexons and other outer coat proteins. 
When the endosome reaches pH 6.0 the viral genome and its remaining 
associated proteins are able to escape to the cytosol. This process requires a 
pH-dependent conformational change in penton, exposing the protein’s 
hydrophobic regions.21 Additionally, at low pH the virus binds selectively to 
αvβ5 integrins. The cytoplasmic domain of β5 contains a TVD motif which 
mediates membrane penetration, although no cellular proteins are known to 
bind to it.22 
After endosomal escape the partially degraded capsid is translocated to 
the nucleus. This trafficking is achieved by at least two separate pathways. 
Firstly, viral binding to extracellular integrins activates the second 
messenger cAMP, which activates the protein kinase PKA. Together, these 
molecules are responsible for phosphorylating cellular motor proteins, 
upregulating transport toward the cell nucleus.23 The second pathway 
requires activation of p38/MAPK to suppress motility toward the cell 
periphery. These two pathways combined create a net movement toward the 
cell nucleus.24 
When the capsid reaches the perinuclear envelope it docks with a 
nuclear pore complex (NPC) and sheds most of its remaining protein 
components. This process is dependent on active p23, which completes 
degradation of the already weakened pVII. After this disassembly step the 
viral DNA, associated with the terminal protein pTP and stabilising proteins 
V, VII and µ is translocated into the nucleus. This translocation may be 
aided by the classical nuclear localisation signal carried at the end of pTP. 
1.1.3.2 Early Viral Gene Expression 
The first adenoviral gene to be expressed is the “early” gene E1A, 
under the control of a constitutively active promoter sequence. Two 
polypeptides are produced from this gene as a result of differential splicing. 
The larger polypeptide (E1A 13s) contains conserved regions CR1, 2, 3 & 
4; the smaller polypeptide (E1A 12s) contains only CR1, 2 & 4.  
The CR 2 domain of both E1A types is able to bind the retinoblastoma 
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(Rb) family of proteins including pRB, p107 and p130.25 Rb proteins bind 
cellular transcription factor E2F, blocking its activity and thus arresting the 
cell cycle in G1 phase.  However, E1A is able to displace and sequester Rb 
proteins, freeing E2F to initiate transcription of its target genes.26 The genes 
upregulated by this action include CDK2 along with cyclins A and E27 and 
are sufficient to drive the cell into S-phase. 
The CR1 domain also acts to push cells into S-phase, through 
interactions with cAMP response element-binding protein (CBP) and P300. 
These highly related proteins share an ability to acetylate histones, changing 
their conformation. This conformational change may allow additional 
proteins to associate with promoter or enhancer regions of CBP/p300’s 
target genes. They may also share the ability to acetylate and regulate a 
variety of transcription factors including p53, NF-κB and c-Myc.28 
The CR3 domain of E1A 13s acts as a transcription factor to initiate 
expression of the remaining adenoviral early genes (E2, E3, E4). Unusually, 
the CR3 is not a sequence-specific DNA binding protein. Instead, it 
associates with the DNA-binding domains of cellular transcription factors 
bound to early adenoviral promoters.27 
The CR4 domain binds to a cellular transcription regulatory protein 
called E1A c-terminal-binding protein (CtBP). This inactivates CtBP’s 
inhibitory functions and allows upregulation of transcription. CR4 also 
contains a nuclear localisation signal, allowing newly synthesised E1A to 
move to the nucleus and help to drive the cell through S-phase. 
One consequence of E1A’s activity is the induction and stabilisation of 
p53. This would lead to cell cycle arrest and apoptosis if not blocked by 
E1B-55K, a product of the next viral gene to be expressed. E1B-55K is a 
component of the viral ubiquitin ligase complex. It recognises p53 and 
marks it for destruction by the proteosome. E1B also plays a role in 
upregulating the export of viral mRNA from the nucleus, for translation in 
the cytoplasm.29 
Similarly, E1A’s activity leads to the degradation of BCL-2 family 
member MCL-1, which would lead to release of cytochrome C and trigger 
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an apoptosis pathway. E1B-19K mimics MCL-1 by sequestering pro-
apoptotic BAK and BAX, saving the cell from apoptosis.27 
The next section of the viral genome to be transcribed is the E2 region, 
which encodes the terminal binding protein pTP, a DNA polymerase with 
proofreading ability and DNA binding protein. Once these products have 
accumulated to a sufficient concentration, replication of the viral genome is 
able to begin. Briefly, the pTP binds to the inverted terminal repeats at each 
end of the viral genome. Here it acts as a primer for DNA replication. This 
process depends on the viral ssDNA binding protein and DNA polymerase, 
responsible for strand separation and duplication, respectively. The cellular 
protein nuclear factor II is also required. 
Transcripts from the E3 gene encode non-secreted proteins whose 
primary functions are the suppression of host immune responses against the 
virus. These functions will be discussed in the section “Interactions with the 
immune system.” 
E4 gene products interact with a wide range of cellular pathways to 
improve the efficiency of viral replication. Targets include components of 
apoptosis, cell cycle control, DNA repair and posttranslational modification 
of proteins. These functions are divided between at least six distinct 
polypeptides, transcribed from different origins within the E4 region but 
sharing the same termination signal.30 
E4 ORF1 slowly accumulates in the cytoplasm during the infection, 
reaching high levels at late stages. Its sequence and predicted protein 
structure are similar to dUTP phosphatase enzymes, involved in nucleotide 
metabolism. While it lacks dUTP phosphatase’s enzymatic activity, it is 
known to bind to similar targets such as DLG, MUPP1 and MAGI-1. The 
role these interactions play during the course of infection is unknown, but 
this ORF is critical in Ad9-induced tumourogenesis.31 
The E4 ORF2 is conserved among human adenoviral serotypes,32 but 
its function is currently unknown. 
E4 ORF3 augments viral DNA replication, late protein synthesis and 
shutoff of host protein synthesis. It also prevents concatenation of viral 
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DNA strands. These activities are dependent on the protein’s ability to 
stabilise late viral mRNAs and bind to cellular proteins. One of E4 ORF3’s 
target proteins is DNA-dependent protein kinase (DNA-PK), an essential 
element of the double-strand break repair system. DNA-PK is inhibited by 
this interaction, blocking the process of V(D)J joining, which could 
otherwise lead to concatenation of viral genome sequences. E4 ORF3 also 
appears to bind E1B 55k, the viral ubiquitin ligase. This interaction results 
in the polyubiquitination of certain virally induced structures within the 
nucleus during specific phases of the infection. 
E4 ORF4 represses the activity of the cellular protein phosphatase 2A 
(PP2A). Inhibition of this serene-threonine phosphatase influences several 
cellular pathways, including: the downregulation of virus-induced 
signalling; and regulation of viral and cellular gene expression at both 
transcription and translation levels.30 This interaction is also required for 
induction of p53-independent cell death.33 E4 ORF4 translocates to 
cytoplasmic sites and associates with an actin-myosin complex. Once there, 
it triggers a myosin II motor to begin de novo actin polymerisation, 
recruiting endosomes to the sites. This eventually leads to nuclear 
shrinkage, polarised membrane blebbing and cell death.34 
E4 ORF6 is involved in several aspects of the replication cycle. 
Pathways ORF6 is involved with include late viral mRNA splicing and 
transport, viral DNA synthesis and host cell shut-off.30 These functions are 
dependent on interaction with several viral and cellular proteins. For 
example, a complex with E1B-55k binds viral mRNA for selective export 
from the nucleus and may be involved in its splicing. This complex also 
interacts with p53, leading to its rapid degradation.35 ORF6 also interacts 
with E4 ORF3 to inhibit DNA-PK (see above). 
The overall effect of early gene expression is to create an ideal 
environment for the manufacture and eventual release of new viral particles. 
The host cell is now in S-phase, intracellular responses against the virus 
have been circumvented (discussed below), host cell shutdown has begun 
and the viral DNA polymerase has accumulated in the nucleus. 
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1.1.3.3 Late Gene Expression and Viral Assembly 
Expression of intermediate and late genes of adenovirus begins after 
replication of the viral genome. The late genes are grouped in a single 
transcription unit of approximately 29kb in length, the major late 
transcription unit (MLTU). This transcription unit is controlled by a single 
promoter sequence. Activation of this promoter is strongly upregulated by 
E1A and also requires a cis-acting change in the viral chromosome (perhaps  
related to the histone acetylation activity of CREB/p300) and an additional 
viral transcription factor. 
Transcription from the MLTU produces a wide range of mRNAs 
through use of several poly(A) signals and splice sites. The resulting 
transcripts are grouped into five families labelled L1 – L5, based on 
termination at common poly(A) sites. The protein products of these genes 
are mostly structural components of the new viral capsids. One key non-
structural protein produced at the late stage of infection is the adenoviral 
death protein (ADP), which plays a key role in causing cell death, enabling 
the virus progeny to escape. 
The earliest step in capsid assembly is the formation of hexon 
capsomeres. This takes place in the cytoplasm assisted by an unknown 
chaperone protein. Completed capsomeres associate with viral protein VI, a 
structural protein located underneath hexon capsomeres in mature particles. 
Protein VI transports the hexon capsomeres to the nucleus via an importin 
α/β-dependent mechanism.36 As capsid proteins and copies of the genome 
accumulate in the nucleus, immature particles are assembled. It is not clear 
whether this process involves insertion of pTP-bound DNA into an empty 
capsid37 or the assembly of capsids around a nucleoprotein core.38 After 
formation of this complete particle, a maturation process occurs. This 
involves cleavage of several viral proteins (including pVI) by viral cytosine 
protease p23.19 
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1.1.3.4 Escape from the Cell 
Relatively little is known about how the mature virus particles escape 
from the cell, although it is known to involve the cell’s death. The 
adenovirus death protein (ADP) is required for efficient cell lysis and 
adenoviral escape.39,40 Unusually, ADP is encoded by the E3 region but 
controlled by the major late promoter. Consequentially, ADP only reaches 
high levels within the cell (usually associated with the endoplasmic 
reticulum or other intracellular membrane-bound bodies) at late times after 
infection.39 Other methods of cell killing may also be involved. One 
possibility is the cytotoxic activity of E4 ORF4, described above. 
After cell death, adenovirus must escape the immediate surroundings to 
disperse and infect surrounding tissues. To aid this escape, adenovirus fibre 
disrupts CAR-mediated intercellular adhesion. This disruption of cell-cell 
contact weakens or distorts the epithelium, allowing the virus to filter 
between the cells and emerge at the apical side.41 
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1.1.4 The immune response of host cells to adenovirus 
Free virus particles are susceptible to detection by the cellular arm of 
the innate immune response, and subsequent presentation of antigens to the 
adaptive immune system. Immature antigen-presenting cells such as 
macrophages and dendritic cells can be found throughout various tissues  
and especially at the mucosal epithelia. These immature APCs tend to have 
a high level of phagocytic activity, constantly sampling their environment.42 
Generally, when a pathogen is engulfed in this manner, it is degraded 
along with the rest of the phagophore content and passed to an endosomal 
compartment. Within these compartments are the innate pattern recognition 
receptors (PRRs), germline-encoded receptors that recognise antigens such 
as the lipo-polysaccharides and unmethylated CpG DNA motifs typical of 
bacteria and viruses. Also among the main viral patterns recognised by 
PRRs is dsRNA, a common by-product of viral replication.  
During an adenovirus infection, recognition of the virus is primarily 
dependent on TLR9 and TLR2.43 Recognition of an antigen leads to a 
signalling cascade, possibly through MyD88,44 that leads to secretion of 
inflammatory cytokines (e.g. IL-6, TNFα) and interferons to upregulate the 
innate immune response, and to the maturation of the dendritic cell.43,45 
The mature dendritic cells migrate to local draining lymph nodes, 
where they present the antigens on MHC molecules along with a co-
stimulatory molecule, such as B7 (CD28 ligand) or CD40, whose expression 
is upregulated during the maturation process.42 
The next step is dependent on the route of presentation of the antigen. 
An adenovirus is typically able to escape the phagosome to infect a 
dendritic cell, so its antigens will likely be presented via the MHCI 
pathway. This results in presentation of the antigens to CD8+ T 
lymphocytes. Presentation of the antigen to a CD8+ T lymphocyte with a 
complementary T cell receptor (TCR) results in the activation and 
proliferation of that T cell. Activated CD8+ T lymphocytes are then able to 
migrate from the lymph node to the site of infection, by binding to epithelial 
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cells expressing adherence proteins upregulated by infection or by cytokines 
secreted by infected cells and/or activated dendritic cells. 
Upon encountering an infected cell, the CD8+ T lymphocyte is then 
able to recognise it through an interaction between the T cell receptor (TCR) 
and the MHCI-bound antigen on the cell surface, along with co-stimulatory 
molecules. For the majority of cells, the lymphocyte will trigger a signalling 
cascade in the infected cell leading to a programmed cell death, halting that 
infection. Alternatively, it may signal professional antigen-presenting cells 
to destroy the contents of its autophagosomes and further contribute to the 
antiviral response through the secretion of pro-inflammatory cytokines 
and/or the continued phagocytosis and subsequent destruction of free virus 
particles.46  
The innate response against viral infection primarily depends on the 
induction of type 1 interferons (IFNα and IFNβ) and the recruitment of 
cytotoxic NK cells. Broadly, the IFNs act as autocrine and paracrine signals, 
upregulating antiviral genes to create a hostile environment within cells. NK 
cells monitor levels of MHC1 complexes displayed on cell surfaces. An 
unusually low level of MHC1 expression is a common indicator of viral 
infection; when NK cells encounter this, the infected cell is killed.46,47 
Although important for the wider spread of the virus throughout its 
host, the adaptive immune response will not be the main focus of this 
introduction. VA-RNAI’s most well established function is involved in the 
control of the intracellular response to viral infection. 
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1.1.5 The intracellular Response 
Several pathways trigger the intracellular response to Adenoviral 
infection. The best known of these involves dsRNA-dependent Protein 
Kinase (PKR). More recently a second pathway dependent on the RNA 
helicase RIG-i was found. In both cases the detection of dsRNA leads to a 
shutdown of protein synthesis and induction of the interferon response.48 
Other dsRNA-sensing molecules (e.g. 2’5’-oligoadenylate synthetase) also 
play a role in this process. In addition to dsRNA, detection of unmethylated 
CpG motifs typical of viral and microbial dsDNA may be detected by Toll-
Like Receptor 9 (TLR9).47 A brief summary of these interactions is 
illustrated in Figure 3.  
 
Figure 3 - Outline of dsRNA (red) and dsDNA (green) -sensing pathways in 
the intracellular immune response 
 
1.1.5.1 dsRNA-dependent Protein Kinase (PKR) 
PKR (also called p68 kinase or DAI) is a ubiquitously expressed serine-
threonine kinase. Its expression is upregulated by interferon although it 
must be activated by binding to dsRNA, leading to conformational change 
and autophosphorylation.49  
Its targets include the B56α subunit of Protein Phosphatase 2A (PP2A) 
 
16 
and the α subunit of eukaryotic initiation factor 2 (eIF2α), inhibiting 
translation. PKR can also regulate transcription via stress-activated protein 
kinase family (e.g. JNK) and IKK, whose phosphorylation leads to 
activation of NF-kB. Finally, activated PKR may promote apoptosis by 
phosphorylation of Fas-Associated Death Domain (FADD), leading to 
activation of the apoptotic caspase pathways (reviewed by Williams, 
200150).  
PKR is expressed at high levels in response to interferon and activated 
by binding dsRNA. It then phosphorylates the α subunit of eukaryotic 
initiation factor 2 (eIF2α, Figure 4). eIF2 is a necessary component of the 
protein synthesis machinery, responsible for loading the chain-initiating 
methionine into the assembling ribosome complex. In its free state, eIF2β 
forms a complex with a tRNAiMet and a molecule of GTP; this complex is 
stabilised by further association with two small ribosomal subunits and 
further initiation subunits. After encountering an mRNA strand, hydrolysis 
of the GTP to GDP provides the energy necessary to add the 60s ribosomal 
subunit to the complex, thus completing the assembly of a complete 
ribosome. PKR’s target, eIF2α, is responsible for supplying eIF2β with its 
next GTP, to enable this process to repeat. Given sufficient availability of 
mRNAs and loaded tRNAs, this supply of GTP by eIF2α can become a 
rate-limiting step for protein synthesis.51 
After phosphorylation by activated PKR, eIF2α irreversibly binds to 
eIF2β and is then unable to fulfil its normal role in the initiation of 
translation. Thus activation of PKR leads to a rate-limiting shortage of 
prepared translation initiation complexes. This non-specifically inhibits the 
translation of mRNA to protein, preventing viral replication within the cell. 
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Figure 4 - eIF2α  is involved in charging the translation initiation complex 
with a primed tRNA. Phosphorylation by PKR causes eIF2α  to bind eIF2β, 
inhibiting this process 
 
1.1.5.2 2’5’-Oligoadenylate Synthetase and RNAse L 
2’5’-oas (also called OAS1) is a dsRNA-dependent enzyme, which uses 
adenosine from ATP to manufacture short chains of 2’5’-linked adenosine 
molecules called 2-5A. The linkages are phosphodiester bonds between the 
2’ and 5’ groups, and the chain takes the general form [ppp5'(A2'p5')2A]. 
This activity is only permitted when the enzyme is bound to dsRNA or 
ssRNA with stable secondary or tertiary structures.52 The resulting 
molecules of oligoadenylate serve to activate the endoribonuclease RNAse 
L, the main effector of this system.  
RNAse L is an 84kDa protein widely expressed in mammalian tissues. 
Analysis of its sequence reveals a 2-5A binding pocket, a domain with 
possible kinase activity and an endonuclease domain. Binding with 2-5A 
causes the enzyme to dimerise, then begin to degrade any RNA molecules it 
encounters. This activity is not selective for viral RNA and therefore 
inhibits all gene expression in the cell. Additionally, at high levels of 
activation extensive rRNA cleavage occurs, possibly contributing to the 
enzyme’s pro-apoptotic activity.53,54 
At least one isozyme of 2’5-oas has a pro-apoptotic function 
independent of RNAse L. The 9-2 isozyme contains a Bcl2-homology 
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domain. Through this the dsRNA-activated enzyme is able to bind and 
inhibit members of the anti-apoptotic Bcl2 protein family.55 
1.1.5.3 Adenosine Deaminase (ADAR) 
ADAR (also called dsRAD or DRADA) is an IFN-inducible RNA 
editing enzyme which catalyses the C-6 deamination of adenosine to inosine 
in cellular pre-mRNAs and some viral RNAs.56 Its known cellular targets 
include the glutamate-gated ion channel GluR receptor, where the mutations 
introduced influence the completed ion channel’s permeability;57 and the 
serotonin 5-HT2c receptor, in which tissue-specific editing of pre-mRNAs 
regulates the receptor’s signal transduction efficiency.58 This editing activity 
can also lead to the specific cleavage of the edited RNA molecules at 
alternating UI IU base pairs.59 
ADAR binds its substrates via three dsRNA binding motifs very similar 
to those found in PKR.56 
Hepatitis C replicons (single-stranded positive sense RNA) are subject 
to extensive editing by ADAR during their course of infection. This editing 
has been suggested as a key factor in their clearance from the cell, through 
accumulation of lethal mutations and possibly degradation by inosine-
specific RNAses.59 
1.1.5.4 RIG-i 
RIG-i’s full name is retinoic acid-inducible protein i, and is also called 
Dddx58. This non-secreted cytosolic protein is a DExH-box RNA helicase, 
able to unwind dsRNA with its intrinsic ATPase activity.60,61 Unusually for 
this type of helicase, it contains tandem caspase recruitment domains 
(CARDs). When the helicase domain of RIG-i binds dsDNA, its CARDs 
initiate a signalling cascade. The details of this cascade are not currently 
known, but result in upregulation of NF-κB, IRF3 and therefore eventually 
IFN-β.62 
Although no interaction between RIG-i and VA-RNAI has been 
identified, RIG-i is known to bind the EBV transcript EBER. EBERs are 
non-translated RNA molecules produced by Epstein-Barr virus. Like VA-
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RNAI, they are predicted to fold into complex stem-loop structures and 
inhibit PKR activity.63 Whether binding PKR is the method by which 
EBERs confer interferon resistance remains controversial.64 Due to these 
structural similarities, EBERs’ ability to bind and activate RIG-i65 suggests 
that VA-RNAI may do the same. 
1.1.5.5 Toll-like receptors 
The TLR family in mammals includes 11 members, each of which 
recognises a distinct pattern associated with microbial pathogens (PAMPs). 
These include a diverse range of molecules, such as bacterial membrane 
component lipopolysaccharide (LPS), peptidoglycan, flagellin and specific 
ssRNA sequences unique to various viruses. They are typically membrane-
associated molecules, with extracellular (or intra-luminal) receptors and 
cytoplasmic signalling domains. The TLRs share a common signalling 
pathway, leading via MyD88 (or TRIF for TLR3) to initiate the IκB kinase 
complex. Phosphorylation of IκB releases the transcription factor NF-κB, a 
key promoter of IFNβ and other inflammatory genes.46 
The TLRs likely to be involved in detection of Adenovirus are TLR3 
and TLR9, which detect dsRNA and unmethylated CpG linkages typical of 
viral dsDNA, respectively. TLRs 7 and 9 detect G/U rich ssRNA typical of 
viruses, so may also be involved. However, all of these are located in 
endosomal compartments.66 It is unclear whether the adenoviral uncoating 
sequence could expose its DNA to TLR9 before endosomal escape. 
Similarly, uptake of adenoviral ssRNA or dsRNA into endosomes has not 
been demonstrated. Therefore the importance of TLRs in the response to 
adenovirus remains undetermined. 
1.1.5.6 The Interferon Response 
The interferon response is the first defence against viral infection. 
Rapidly induced by a range of intracellular receptors, its purpose is to 
prevent viral replication within and spread from the cell. This can result in 
clearance of virus from the cell, but prolonged stimulation by interferon 
leads to the upregulation of pro-apoptotic genes and therefore potentially to 
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cell death.  
Interferons are a family of small, secreted proteins. Within this family 
are several Type I species, IFNs α, β, ω and κ. There is a single type II 
species, IFN γ. The first interferon type to be expressed by a virus-infected 
fibroblast or epithelial cell is IFNβ, although several versions of IFNα 
follow. Although a few genes are responsive only to one species of 
interferon, the functions of type I interferons broadly overlap. IFNγ is 
normally only expressed by Th-1 lymphocytes and NK cells.67 
All interferons act as auto- and paracrine signals. IFNs bind to 
extracellular receptors, activating JAK-STAT (Janus Activated Kinase – 
Signal Transducers and Activators of Transcription) pathways. The JAKs 
are tyrosine kinases, which recruit and phosphorylate STAT molecules with 
the help of SH2 domain-containing adapter molecules. These 
phosphorylated STAT molecules form homo- or heterodimers and 
translocate to the nucleus. In the nucleus, the STAT dimers bind to specific 
promoter sequences to activate transcription of interferon-stimulated genes 
(ISGs).68 Activation of STAT molecules is usually transient due to the 
action of an unknown tyrosine phosphatase.69 
Whether the interferon signal is endogenous or from an external source, 
the cell responds by upregulating over 300 genes.68 This complex network is 
not fully understood and contains apparent contradictions. For example, 
both pro- and anti-apoptotic genes are expressed in response to IFNβ.67 
Crucially, IFNβ stimulates the expression of its own promoters, including 
NFκB, P300 and IRFs 3&7. Production of IFNα is also promoted by these 
ISGs, along with IFNγ in dendritic cells.69 
The genes upregulated by IFNβ include 2’5’-oas, ADAR and PKR, 
described above. This contributes to the creation of an antiviral state within 
the cell, inhibiting a virus’s replication.70 Also upregulated is MHC class I 
and the enzymes that process peptides for MHC display. This increased 
presentation of intracellular peptides on the cell surface increases the 
possibility of discovery by an activated cytotoxic CD8+ T lymphocyte. Type 
I IFN also stimulates the development of TH1 cells, via upregulation of 
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IL-12 receptors in T lymphocytes.46 This drives the activation and 
recruitment of CD8+ T lymphocytes in the adaptive arm of the immune 
response. 
The Mx proteins, also upregulated by IFNs, are a pair of cytoplasmic 
proteins, MxA and MxB (many other types exist in other species).71 They 
belong to the dynamin superfamily of GTPases involved in a range of 
processes including endocytosis and vesicle transport.68 MxA (encoded by 
the Mx1 gene) is rapidly expressed in response to IFN stimulation and is 
associated with a powerful antiviral response. Its mechanism of action has 
been extensively studied but is incompletely understood. MxA’s reported 
activity is limited to RNA viruses and Hepatitis B, an ssDNA virus, which 
uses an RNA intermediate in its genome replication process. As such, this 
antiviral gene may not be relevant to the anti-adenoviral response.71 
Several other antiviral pathways which are unlikely to affect 
Adenovirus – such as the ISG20, an RNAse specific to ssRNA virus 
genomes72 – have been described, but are outside the scope of this 
introduction. 
Members of the P200 protein family are also strongly induced by type I 
interferons. Of special note is P202, a nucleolar protein that binds and 
inhibits many cell factors including NFκB, E2F, c-Myc and Rb. This may 
be a major contributor to IFN’s powerful antiproliferative effect.68 
IFNβ has a delayed pro-apoptotic effect. Although precise details of the 
pathway have not been elucidated, it is generally associated with the 
FADD/caspase-8 apoptotic pathway. Induction of this pathway leads to the 
cytochrome C release, caspase activation cascade and DNA fragmentation 
typical of apoptosis. This is a late effect of interferon stimulation – in vitro 
studies show this activity beginning after 48 hours of exposure to high 
levels of IFNβ. This is likely to be the result of the prolonged upregulation 
of pro-apoptotic ISGs such as caspases 4 & 8, TRAIL, Fas, PKR and 2’5’-
oas.73 
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1.1.5.7 Antiviral autophagy 
Macroautophagy, here referred to simply as “autophagy”, is a process 
by which cytosolic contents are engulfed in a double-membraned 
compartment and degraded as the compartment (an autophagosome) lowers 
its pH and receives input from the lysosomal or endosomal pathways. This 
uptake of cytosolic components can target objects ranging from peptide 
fragments to entire exhausted mitochondria. Most – possibly all – 
mammalian cells maintain a basal level of autophagy as a homeostatic 
mechanism, but it can be upregulated in response to various stress stimuli. 
Autophagy is known to play a role in several viral infections. For 
example, induction of autophagy by upregulation of Beclin 1 in mice 
protects them from lethal Sindbis encephalitis virus.  
Herpes Simplex Virus 1 (HSV-1) prevents the induction of autophagy 
by expressing the neurovirulence protein ICP34.5. ICP34.5 binds to the pro-
autophagic structural protein Beclin 1 to disrupt its activity. Importantly for 
this project, this autophagic degradation of HSV-1 requires the activity of 
phosphorylated PKR to phosphorylate its target eIF2α. In addition to its 
ability to bind Beclin 1, ICP34.5 has a phosphatase activity, which retargets 
the cellular phophatase PP1α to dephosphorylate eIF2α.  
If ICP34.5 is deleted, high levels of autophagy are induced in infected 
cells and the viruses targeted for degradation. At a systemic level, this 
deletion mutant virus is no longer neurovirulent in mice, highlighting the 
importance of autophagy’s protective role.74 
The link between eIF2α and autophagy is not limited to HSV-1 
infection. In both yeast and mammals, the phosphorylation of eIF2α by its 
kinase (GCN2 and PKR, respectively) is required for starvation- and virus-
induced autophagy.75 This finding has implications for many intracellular 
pathogens; as described previously, PKR – eIF2α is among the key 
detectors of virus activity within the cell. The viral genes encoded by 
various viruses to prevent the phosphorylation of eIF2α (e.g. Influenza virus 
NS1, Epstein-Barr virus EBER1 and SM, HIV’s TAT, etc.) may therefore 
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be equally important in protecting those viruses from autophagic 
degradation.76 
Inevitably, some intracellular pathogens have evolved to avoid, or even 
exploit, the autophagic response. Several RNA viruses – e.g. poliovirus, 
equine arterivirus and mouse hepatitis virus – form replication complexes 
on double-membraned vesicles that resemble autophagosomes. Indeed, 
poliovirus replication requires successful induction of autophagy to 
replicate; it has also been proposed that poliovirus subverts the autophagic 
pathway to enable its release from the cell.74,76 Similarly, rotavirus appears 
to induce autophagy deliberately, expressing NSP4 to promote 
autophagosome production and thus create replication sites for itself.77 
Degradation of viruses by autophagy appears to be a key mechanism 
for a cell to fight an infection, but it has wider implications than this. Cells 
of the innate immune system carry pathogen recognition receptors (PRRs) 
also called Toll-like receptors (TLRs). Infected plasmacytoid dendritic cells 
are able to digest viruses by autophagy as described, then present the 
products of this degradation to TLRs in their endosomal and lysosomal 
spaces. Recognition of pathogens (e.g. by a conserved peptide or DNA 
sequence) by the TLRs leads the cell to begin activating an antiviral 
response, including interferon production and possibly presentation of the 
antigen to cells of the adaptive immune system.78 
1.1.5.8 Autophagy in adaptive immunity 
Macroautophagy has also been shown to play a role in adaptive 
immunity. After synthesis in the ER, MHC Class II molecules are stored 
within endosome-like compartments referred to as MHC Class II 
Compartment (MIIC or CIIV). In these compartments they are separated 
from the chaperone invariant chain Ii and its subunit CLIP, and then loaded 
with processed antigens. These antigens are delivered to the compartment 
by fusion with endosomes, which typically contain molecules internalised 
from the extracellular spaces, such as viral particles attached to the cell 
surface. 
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Autophagosomes also constitutively deliver fragments of their degraded 
contents to the MIIC, conveying protein fragments from intracellular 
sources. This activity occurs in both antigen-presenting cells and normal 
epithelial cells.79,80 A strong activation of the “helper” CD4+ T lymphocytes 
is crucial for a robust adaptive immune response.81 This presentation of 
intracellular protein fragments to the adaptive immune system may be 
crucial for the development of cytotoxic responses against cells that have 
become infected or cancerous.81 
One example of this is the display of Epstein Barr Virus’s (EBV) 
nuclear antigen 1 (EBNA1), which is displayed by MHCII complexes in 
infected cells and tumours.82 Unsurprisingly, many intracellular pathogens 
have evolved mechanisms to evade or subvert the autophagic pathways. 
While this suppression may also serve other purposes for the pathogens, it 
seems very plausible that protecting their antigens from display to the 
adaptive immune system is a key part of their survival strategy.83 Indeed, 
induction of macroautophagy in cells expressing influenza virus matrix 
protein 1 (MP1) increases recognition of those cells by CD4+ T-cells. 
Similarly, specifically targeting MP1 to the autophagosome by fusion to 
LC3 leads to an increase in MHCII peptide display and a resulting increase 
in IFNγ production by the CD4+ T cells.84 Cytolytic CD4+ T cells have 
previously been observed associating with endothelial cells expressing 
MHCII85 and are known to play an important role in controlling intracellular 
infections.86,87 Interestingly, IFNγ upregulates both MHCII presentation at 
cell surfaces and the uptake and processing of cytosolic proteins by 
macroautophagy, supporting the idea of macroautophagy as a mechanism 
for immune surveillance of the cytosol.  
This involvement of autophagy in adaptive immunity may be dependent 
on the polarisation of the response toward the T helper cell 1 (Th1) or Th2 
response. As described above, the prototypical Th1 cytokine IFNγ is known 
to upregulate autophagy, and contributes to the elimination of intracellular 
pathogens such as Epstein Barr virus82 and Mycobacterium tuberculosis.88 
TNF-α may have a similar effect, having been shown to aid autophagic 
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elimination of Toxoplasma gondii from infected macrophages.89 In contrast, 
however, the Th2 cytokines IL-4 and IL-13 inhibit starvation-induced 
autophagy and autophagic clearance of Mycobacterium tuberculosis.90 IL-
13 is a potent activator of Class 1 PI 3-kinase and the AKT signal 
transduction pathway,91 the activation of which can act as a potent inhibitor 
of autophagy induction, presumably by preventing the activation of TOR.92 
IL-4 and IL-13 both signal through the receptor IL-4Rα, resulting in 
signalling via the insulin receptor substrate (IRS) and STAT6 pathways. 
This activation of IRS signalling activates the class I PI 3-kinase and Akt 
pathways, inhibiting maturation of phagosomes.93  
The prevailing view is that Th1-mediated immune responses lead to 
inflammation and the activation of cytotoxic CD8+ T lymphocytes ideal for 
fighting an intracellular pathogen, while Th2-mediated responses tend to 
lead to the activation of antibody-secreting B lymphocytes for humoural-
mediated immunity. The upregulation by Th1 cytokines IFNγ and TNF-α of 
macroautophagy and the display of its output on MHCII seem logical in this 
context: together they could lead directly to eradication of an intracellular 
pathogen, or to priming of the adaptive immune system and subsequent 
killing of infected cells.  
Work presented in this thesis indicates that the antiviral autophagy 
pathway is very relevant to the study of VA-RNAI and its effects while 
modulating the intracellular response against the viral infection, among 
other stimuli. The mechanisms of autophagy and its importance in a range 
of cellular processes and stress responses will be described in detail in a 
later section. 
1.1.6 Evasion of the immune response by Adenovirus 
Adenoviruses have evolved mechanisms to circumvent the intracellular 
immune response, either by concealing itself or by blocking relevant 
effector molecules. Most of the known mechanisms are dependent on genes 
in the E3 region. However, a non-translated virus-associated RNA (VA-
RNA) encoded in the L1 region also plays an important role. 
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The E3 gene encodes a family of non-secreted proteins evolved to 
suppress various arms of the antiviral response. They are not essential for 
replication in culture, but deletion of this gene inhibits viral replication in 
immunocompetent hosts. Interestingly, the E3 gene contains NF-κB binding 
sites in its promoter sequence.94 This leads to increased production of E3 
proteins in response to cellular stress signals such as the production of 
interferon. 
A key function of the E3 gene is the inhibition of peptide display on the 
cell surface. Major Histocompatability Complex I (MHC 1) routinely cycles 
between the endoplasmic reticulum and the cytoplasmic membrane. Its role 
is to collect peptide fragments from inside the cell for display on the cell 
surface, for scanning by cytotoxic CD8+ lymphocytes. In this way, foreign 
peptides such as those from a viral infection are displayed to the immune 
system. This behaviour is upregulated by activation of the IFN-dependent 
Jak/STAT pathway. E3-gp19k binds to the heavy chain of class I major 
histocompatability complex (MHC I) in the endoplasmic reticulum, 
blocking this pathway. Additionally, E3-gp19k blocks the activity of TAP, 
the protease responsible for processing proteins into peptides suitable for 
display by MHC I. This inhibition reduces the pool of peptide fragments 
available for display by any remaining MHC activity. Cells infected with 
Adenovirus are thus largely protected from CD8+ lymphocyte-mediated 
killing. 
E3-10.4k and E3-14.5k are also known as receptor internalisation and 
degradation (RID) proteins. These are responsible for the internalisation and 
proteosomal degradation of FAS and TRAIL, two key ligand-induced 
upregulators of apoptosis. Removal of these receptors from the cell surface 
desensitises the cell to pro-apoptotic signals from CD8+ T lymphocytes and 
secreted tumour necrosis factors (TNFs). E3-14.7k plays a similar role to 
these proteins, inhibiting TNF-induced apoptosis. 
E3-11.6k is more commonly known as the Adenovirus Death Protein 
(ADP). It is the only E3 protein known to have a pro-apoptotic function. 
Unlike the other proteins from the E3 gene, ADP is not under the control of 
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the E3 promoter. Instead, its expression is controlled by the same switch 
that activates late gene expression. This control by a late promoter makes 
ADP accumulate at a late stage of the infection. Expression of ADP does 
not directly influence the efficiency of viral replication within the cell, but it 
is required for efficient cell killing and release of virus from the cell. For a 
more complete overview of the E3 proteins and their interactions with the 
whole body immune system, see reviews by Burgert & Blusch95 and 
Horwitz.96 
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1.1.7 VA-RNAI & II 
The gene I will focus on in this 
project is Virus-Associated RNA I 
(VA-RNAI or VAI). VA-RNAI is 
transcribed by RNA polymerase III, 
which recognises its strongly 
conserved extra- and intra-genic 
promoter sequences.97 The resulting 
single-stranded RNA molecule is 156 
nucleotides long and GC-rich. It is 
neither polyadenylated nor translated 
and no additional post-transcriptional 
modifications have been reported. 
Instead the RNA folds into a complex 
secondary structure.1  
Expression of VA-RNAI begins 
relatively late in the replication cycle, 
as it is transcribed along with its 
neighbours in the L1 co-termination 
region. However, after expression 
begins VA-RNAI quickly accumulates 
to levels of up to 108 copies per cell.98 
The predicted secondary structure 
of VA-RNAI is shown in Figure 5, 
reproduced from Ma & Matthews 1996.1 Its main features are two 
imperfectly base-paired dsRNA stems and a more complex central domain 
containing several loop structures. The long stem regions are believed to be 
the primary binding sites recognised by host proteins, generally via dsRNA 
binding motifs. Once bound to its target host proteins, the central domain’s 
loops are necessary for VA-RNAI’s ability to inhibit its targets’ primary 
functions. Known targets of this binding and inhibitory activity are 
discussed below. 
Figure 5 - Secondary Structure 
of VA-RNAI (from Ma & 
Matthews, 19961). Structure 
shown is based on VAI from 
Ad2. 
 
29 
1.1.7.1 VAI’s known interactions with host proteins 
PKR 
As described above, PKR’s normal role is to detect dsRNA produced 
from symmetrical transcription of viral genomes.99 When activated by 
dsRNA, its activity leads to inhibition of translation and upregulation of 
pro-interferon and pro-apoptotic genes.  
VA-RNAI binds to the dsRNA-Binding Motifs of PKR, inhibiting its 
autophosphorylation and activation.100,101,102 Binding occurs via VA-
RNAI’s imperfectly base-paired long stem domains. Inhibition of PKR’s 
function depends on an intact central loop domain.103 The presence of VA-
RNAI in stressed cells does decrease phosphorylation levels of PKR’s 
target, eIF2α104,105,106. Unexpectedly, phosphorylation of eIF2α is not 
always associated with decreased viral replication.106 This suggests that 
additional factors may influence this pathway. 
2’5’-oligoadenylate synthetase 
VA-RNAI binds to and activates 2-5(A) synthetase (OAS1). Mutational 
studies showed that VA-RNAI’s activation of OAS1 is lessened by the 
mismatches in its dsRNA stems. However, the resulting activity of 2’5’-oas 
is sufficient to activate the RNAse L response described above.107  
Adenosine Deaminase 
VA-RNAI also interacts with dsRNA-specific adenosine deaminase 
(ADAR). VA-RNAI is able to bind to these and inhibits the enzyme’s 
activity without becoming a substrate. Binding occurs by VA-RNAI’s stem 
regions associating with ADAR’s dsRNA-binding domains. The inhibitory 
behaviour is dependent on an intact central stem-loop region. This is reliant 
on different parts of the loop than inhibition of PKR.57 
Interestingly, HCV replicon-infected cells transfected with VA-RNAI 
show greatly reduced rates of deamination and a consequent increase in 
viral gene expression and replication.108 Although no work examining 
adenovirus’s interaction with ADAR has been published, it seems plausible 
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that VA-RNAI could play a similar role in protecting adenoviral RNAs 
from ADAR.  
Interferon Induction 
VA-RNAI’s interactions with the interferon response are complex. 
Evidence for its ability to suppress the interferon response has been 
published, with suggestions on the mechanism of this suppression.109 
Possible mechanisms include inhibition of PKR’s ability to upregulate NF-
κB.  
Conversely, VA-RNAI has also been shown to induce interferon 
synthesis.110 The mechanism of this was not determined, but was shown to 
be independent of IRF3. However, this was shown using VA-RNAI 
expressed from plasmid DNA rather than whole virus. Therefore it may not 
be representative of VA-RNAI’s function during a normal infection. 
RNA Interference 
RNA interference (RNAi) is a normal cell response to dsRNA 
expression. The dsRNA is processed into short (21 to 23nt) fragments by an 
RNAse III enzyme called Dicer. The resulting “short interfering” RNAs 
(siRNAs) are incorporated into an RNA-Induced Silencing Complex 
(RISC). This complex goes on to degrade selectively any RNA molecules 
containing the same sequence, downregulating or silencing genes at the 
mRNA level. 
Expression of VA-RNAI during adenoviral infection suppresses the 
RNAi response, reducing the pathway’s efficacy at silencing genes. VA-
RNAI is processed by Dicer and incorporated into the RISC apparently as 
normal. The inhibitory function may simply be due to very high levels of 
VA-RNAI saturating the RNAi pathway. This would block the normal 
functions by competitive inhibition, either at the level of Dicer’s ability to 
process dsRNA into siRNA or formation of RISCs. 
The significance of this effect on the course of adenoviral infection is 
unknown.111  
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1.1.7.2 Relationship with VA-RNAII 
Several serotypes of adenovirus, including types 2 and 5, also carry the 
related gene VA-RNA II (VAII). This sequence is a similar length to VA-
RNAI and shares 67% sequence homology.109 The proposed structure is 
also similar (Figure 6), although a higher proportion of the predicted base 
pairs are mismatched. This increase in mismatched pairs may be responsible 
for VA-RNAII’s relatively poor ability to bind PKR when compared to VA-
RNAI. Although strongly conserved between several adenoviral serotypes, 
deletion of VA-RNAII gives no detectable phenotype.1 
Expression of VA-RNAII is downregulated by an unknown function of 
VAI: certain mutations in the central loop domain of VA-RNAI result in a 
dramatic upregulation of VA-RNAII expression.112  
Figure 6 -  Secondary 
Structure of VA-RNAII. 
Shaded areas indicate 
mismatched pairs. (Ma & 
Matthews 19961). 
Structure shown is based 
on VA-RNAII from Ad2. 
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1.1.8 Adenovirus lacking VA-RNAI as a potential oncolytic 
therapy 
1.1.8.1 Replication-selective adenovirus as a new therapeutic 
for cancer therapy 
The replication cycle of normal cells is a tightly controlled process. In 
order to leave the quiescent G0 state and progress to the replication cycle, 
the cell requires input from a range of signals including those from tyrosine 
kinase receptors, G-protein coupled receptors, TGF-β receptors, integrins 
and nutrient receptors. These extracellular signals are critical during most of 
G1 phase. However, after 80-90% of a cell’s time in G1 has passed, the cell 
becomes committed to replication; all further checkpoints are solely based 
on internal conditions.  
In cancer, cells have developed the ability to bypass the checkpoints 
governing the G0-G1-S phase transitions. Consequentially, these cells are 
constitutively able to synthesise protein and replicate DNA. Many cancers 
acquire additional mutations to inhibit apoptosis and overcome one or more 
of the internal checkpoints. These mutations make the developing cancer 
more resistant to pro-apoptotic or anti-proliferative signals, which may be 
generated by internal or external sources. 
As described above, the first role of adenovirus’s early proteins is to 
force the host cell into S-phase, while inhibiting the pro-apoptotic signals 
this activity generates. Several of the later genes (including VA-RNAI) are 
intended to prevent cellular inhibition of gene expression, whether at 
mRNA or protein level. Both of these functions are largely unnecessary in 
many cancers, as the cellular pathways responsible are already disabled. 
More detailed understanding of adenovirus infections and of the 
molecular biology of cancer have led to the use of mutated adenoviruses as 
anti-cancer agents. The basis of this strategy is to produce viruses that are 
only capable of successful replication in cancer cells, either inhibiting their 
growth or killing them outright. Broadly, two strategies have been use to 
produce selective viruses: deletion of genes whose functions are crucial for 
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replication in normal cells but dispensable in cancer cells; and controlling 
viral gene expression with a tumour-specific promoter. 
dl1520 (also known as “ONYX 015” and “CI-1042”) is an adenovirus 
type 5 mutant lacking functional E1B-55k. As described earlier, this protein 
involved in shutdown of host mRNA export and protein synthesis. It also 
inhibits the activation of p53 and aids nuclear localisation of transcription 
factor YB1. Tumour cells commonly have inactivated p53 and high levels 
of YB1, so can be expected to compensate for E1B-55k’s absence.113 
Adenoviruses dl922-927 and Δ24 have deletions in the CR2 domain of 
E1A. This removes their ability to displace Rb, freeing E2F and pushing the 
cell into S-phase. Since cancer cells commonly have disrupted Rb pathways, 
this function is often dispensable. In contrast, replication in normal 
quiescent cells is seriously compromised for these viruses. 
Tumour-specific promoters have been used to control expression of 
early genes, most commonly E1A or E1B. Expression of these viral 
transcription factors has been placed under the control of genes such as 
prostate specific antigen (PSA) to limit replication to prostate cells. A 
similar approach was to link E1A and E1B to the promoter for hTERT, the 
telomerase gene commonly upregulated in cancers.114 Osteocalcin, 
tyrosinase, E2F-1 and Hypoxia-inducible promoters have all been used to 
target various cancers with varying degrees of success.115 
Viruses constructed to use one or both of these techniques have shown 
good selectivity for cancerous tissues, and high safety levels in clinical 
trials. However, progression to use as a routine therapy has been hindered 
by low cytotoxicity.116 
Several attempts have been made to increase the potency of these 
viruses. Various payload genes have been inserted to achieve this. Directly 
toxic genes such as fusogenic membrane glycoproteins have been used to 
kill infected tumour cells and their immediate neighbours.117 An alternative 
approach is to upregulate lethal viral genes such as the Adenovirus Death 
Protein.115 In a similar approach, dl337 is based on Ad5 lacking anti-
apoptotic E1B-19k. This deletion resulted in increased cell killing through 
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virus-induced apoptosis.118 Another possibility is the expression of enzymes 
locally to convert relatively harmless prodrugs to highly toxic drugs. The 
best characterised of these systems is the use of herpes simplex virus’s 
thymidine kinase gene to convert ganciclovir to ganciclovir triphosphate, 
which inhibits DNA synthesis in the host and neighbouring cells. However, 
this combination has shown limited success in Adenovirus, possibly because 
activated ganciclovir inhibits the adenovirus vector’s own ability to 
replicate.115 
1.1.8.2 VAI-deleted Adenovirus as a potential therapeutic for 
cancer therapy 
Adenoviral mutants lacking functional VA-RNAI are rendered sensitive 
to inhibition by interferon or other stress signals which lead to upregulation 
or activation of PKR.119 Treatment of cells with 2-AP – which blocks PKR 
autophosphorylation and activation – rescues VAI-deleted virus’s 
vulnerability. 
Lack of VAI expression may lead to viral gene expression defects, or 
low levels of gene expression later in infection.120 This is due to the 
production of unusual splice variants of viral proteins.121 However, this 
effect was later shown to be only an indirect consequence of VA-RNAI 
deletion; VA-RNAI is not absolutely necessary for splicing to proceed 
correctly.122 
Deletion of VA-RNAI leads to a six- to ten-fold reduction in the 
replication efficiency of adenovirus grown in certain cell lines.123 In non-
transformed cells, adenovirus lacking VAI and VAII shows a deficiency of 
over 100-fold when compared to wild-type virus.112 This makes VAI-
deleted Adenovirus an appealing candidate for use as an oncolytic vector.  
Two groups have used the VAI-deleted type 5 adenovirus dl331 as a 
therapeutic vector. The first124 targeted human pancreatic cancer cells 
xenografted into mice. This study found that dl331 was able to replicate 
selectively in and kill the cancer cells. The second study, published by our 
group,104 targeted EBV-associated tumours. In this case replication in 
tumour cells was rescued by small EBV-associated RNAs, which are 
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similar to VAI in function. This suggests that VAI-deleted viruses could be 
effective agents against Epstein-Barr virus-associated cancers. 
Efficient replication of VAI-deleted adenovirus correlates strongly – 
although imperfectly – with the host cell line’s ras oncogene mutational 
status. Generally, replication of VAI-deleted adenovirus proceeds at high 
efficiency in cells carrying K-ras mutations, while replication in tumour and 
normal cells with wild-type ras pathways is strongly inhibited.124 However, 
this association does not always hold true.106 The molecular basis of VAI-
deleted adenovirus’s selectivity for cancer cells is not completely 
understood. 
1.2  Functions and Regulation of Autophagy 
1.2.1 Definitions – micro- and macroautophagy 
Autophagy, named for the Greek “self eating”, is a suite of processes 
through which cells degrade proteins collected from the cytosol. A study in 
L929 cells found that a typical cell maintains a population of 2.6x109 
proteins, and is capable of synthesising 4x106 proteins per minute.125 
Maintaining this population requires constant degradation of unneeded 
proteins and organelles. The autophagic pathways are a major mechanism 
for this degradation, whose end products may be used as a source of amino 
acids or energy, or may be displayed to the adaptive immune system for 
immune surveillance of intracellular proteins. Versions of this behaviour are 
observed in a wide range of fungi, yeasts, plants and animals. The pathways 
are generally separated into two groups, microautophagy and 
macroautophagy. 
1.2.2 Microautophagy 
Microautophagy refers to the degradation of small components from the 
cytosol, taken up into lysosomes directly via invaginations of the lysosomal 
membranes. These invaginations bud off to form free vacuoles within the 
lysosome, and are degraded along with their contents.79 Microautophagy is 
known to take two forms, “lead[ing] to the degradation of soluble 
components or to the selective uptake of entire organelles”79. Regulation of 
the first form of microautophagy appears to be largely dependent on the 
availability of nutrients to the cell. In yeast, for example, microautophagy is 
induced in response to nitrogen starvation, as reported by activation of the 
TOR and EGO signalling complexes. 126 
The second form of microautophagy, the degradation of organelles, 
appears to be very important. A well-characterised example of this process 
is the controlled lysosomal engulfment and destruction of peroxisomes in a 
process dubbed micropexophagy.127 More recently, investigation is 
proceeding into the microautophagic degradation of exhausted 
mitochondria, “mitophagy”. The exact regulation of this process is not yet 
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understood, especially the details of how lysosomes are able to recognise 
and specifically degrade exhausted mitochondria while allowing fresh 
mitochondria to survive. It has been shown, however, that fission followed 
by selective fusion of mitochondria leads to the accumulation of a 
mitochondrial sub-population with reduced membrane potential and 
displaying reduced levels of the fusion protein OPA1.128 In yeast, other 
genes have been shown to be involved in this recognition and regulation, 
including Uth1p, Aup1p, Mdm38p and possibly YMe1p.129 This regulation 
is quite complex and does not appear to be a simple starvation response. 
Rather, it appears to be a precisely regulated system that constantly 
monitors and regulates the mitochondrial population within the cell.129,130 
1.2.3 Chaperone-mediated Autophagy 
Chaperone-mediated autophagy is a major protelysis pathway in most 
cell types and particularly under conditions of nutrient starvation. Cytosolic 
proteins are recruited by chaperone molecules and transported to lysosomes, 
where they are unfolded and imported to the lysosomal lumen for 
subsequent degradation.  
Most known substrates for chaperone-mediated autophagy (CMA) 
contain a peptide sequence related to the motif KFERQ.131,132 These motifs 
may be a directly encoded part of a protein’s sequence or the result of a 
post-translational modification. For example, oxidation and deamidation 
events that may occur as “wear and tear” during a protein’s functions can 
contribute to creating these motifs.133 
The constitutively expressed 70kDa heat shock protein hsc70 
recognises a range of peptide motifs including the KFERQ motif and can 
stimulate protein translocation across membranes. However, hsc70 must 
first be activated by cochaperone molecules such as hsc40, which stimulates 
the necessary ATPase activity of hsc70. hsc70 and other cochaperones form 
a complex with a target protein in a reaction with hsc70 interacting protein 
(hip). hsp90, responsible for preventing unfolded proteins from forming 
aggregates in the cytosol,  may also associate with this complex via the 
mediation of hsc70-hsp90 organiser protein (hop).131 
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The complexed target protein and chaperone proteins become 
associated with lysosome associated membrane protein 2A (LAMP-2A; 
CD107a)) at the lysosomal membrane. The unfolded protein is transported 
across the membrane into the lysosome in a process that requires ly-hsc70 
(an acidic isoform of hsc70) to be present in the lysosome.131,134 
Chaperone mediated autophagy is commonly upregulated under 
conditions of nutrient starvation and oxidative stress; loss of the pathway 
leads to the accumulation of damaged proteins and organelles, and to 
impaired homeostasis. 
1.2.4 Macroautophagy 
Macroautophagy is similar to microautophagy in that proteins or 
organelles are engulfed and eventually catabolised, often yielding amino 
acids and energy sources for the cell. However, where microautophagy 
begins with targets being taken up directly by lysosomes, macroautophagy 
begins with the formation of dedicated double-layered enclosures called 
“autophagosomes”. These autophagosomes later fuse with lysosomes to 
become “autolysosomes” or receive input from the endosome pathway to 
become amphisomes.135 In either case, the decreased pH and degradative 
enzymes released into the compartment degrade the contents to their 
constitutive parts. These amino acids, fatty acids, etc. are then typically 
released to the cytosol where they become available to the cell for use as 
metabolic components and energy sources. Alternatively, a proportion of 
the peptides from autophagosomes are displayed to the adaptive immune 
system to help surveillance of the intracellular environment. Both of these 
pathways will be discussed below. 
 
1.2.4.1 Autophagosome Formation 
Autophagosome formation begins at the phagophore assembly site 
(PAS). This site has been described as “a hybrid of the forming vesicle… 
and the core machinery proteins, the exact machinery of which depends on 
the stage of autophagosome formation.”136 A typical autophagosome has a 
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diameter of 0.4µm and can capture approx 0.1% of the cytosol.137 A 
growing list of proteins are known to be involved in the formation and 
maturation of the autophagosome. First isolated in yeast and extensively 
conserved in mammals, these are known as the autophagy related genes 
(ATGs). A summary of their functions is listed in Table 2. 
In yeast this PAS is a perivacuolar site, while in mammalian cells 
phagophore assembly does not appear to be restricted to a single location. 
The first stages of autophagosome formation in mammalian cells are known 
to require phosphatidylinositol 3-phosphate (PI(3)P) and to occur near the 
endoplasmic reticulum.138,139 The role of the PI 3-kinases in maintaining the 
pool of PI(3)P is complex and not entirely understood. While class III PI 3-
Kinases are required for the induction of autophagy, class I PI 3-Kinases are 
able to block induction of autophagy.138  
Although the exact origin of developing autophagosomes has not been 
widely agreed upon, evidence has been published recently supporting the 
hypothesis that the membrane originates from the endoplasmic reticulum. 
During the early stages of autophagy, a PI(3)P-enriched compartment is 
formed; this compartment is dynamically connected to the ER.139 The 
FYVE domain-containing protein 1 (DFCP1) was isolated based on its 
ability to bind PI(3)P in vitro.140 During the formation of the PI(3)P-
enriched compartment, DFCP1 translocates from the ER to this 
compartment, apparently via a contiguous membrane bridge, supporting the 
ER as the source of the forming autophagosome’s membrane.139 
Expansion of the autophagosome membrane then continues, elongating 
the structure before eventually closing the end and budding from the PAS. 
The forming autophagosome is structurally supported by ATG9, which may 
also be involved in trafficking new membrane to the developing structure.141  
ATG8 (also commonly called LC3) is recruited to the membrane at 
high levels.142,143 ATG8/LC3 is constitutively expressed and present in the 
cytosol of most cells in, until modified from this form (LC3I) to the lipid-
conjugated LC3II by a complex of ATG3 and ATG5, after which it 
becomes embedded in the developing autophagosome membrane. LC3II 
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may play a structural role in the developing autophagosome, although its 
best-characterised function is recognising targets marked for degradation via 
its ubiquitin-like domain.144,145,146  
 
Table 2 - Summary of known functions of autophagy genes in mammals 
 
Gene Protein Function 
ATG1, ULK1 A Ser/Thr protein kinase found complexed with its 
substrate ATG13. Essential for mTOR-mediated 
autophagy induction.147 
ATG3 A ubiquitin conjugating-like enzyme that attaches 
ATG8/LC3 to phosphatidylethanolamine 
ATG4 Cleaves ATG8/LC3 ready for its interaction with 
ATG3 
ATG5 Covalently attached to ATG12; this dimer binds 
ATG16 to form a trimer of unknown function 
ATG6 / Beclin 1 A component of the class III PI 3-kcomplex required 
for initiation of autophagy 
ATG7 A homologue of the ubiquitin-activating enzyme; it 
activates both LC3 and ATG12 before conjugation 
ATG8 / LC3 After covalent attachment to a lipid by ATG3, LC3 is 
embedded into the forming autophagic membrane and 
assists in targeting proteins for degradation 
ATG9 A transmembrane protein involved in delivering 
membrane to the forming autophagosome 
ATG10 A ubiquitin-conjugating-like enzyme that covalently 
attaches to ATG12 and ATG5 
ATG12 Structurally similar to ubiquitin; attaches to ATG5 and 
ATG16 
NB: Information mostly from Rubinsztein et al. 2007.148 
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Figure 7 - Phagophore Assembly Site (PAS); figure excerpted from Xie and 
Klionsky 2007.136 
 
1.2.4.2 Selection of autophagosome targets 
At first it was assumed that uptake of cytosolic components to these 
autophagosomes was an entirely non-specific bulk degradation 
pathway.149,150 However, more recent work has shown that it can be a 
precisely targeted process. In yeast, even during bulk autophagy certain 
proteins (e.g. catalase, Ald6, Lap3) are selectively targeted for autophagy.151  
In higher eukaryotes, several distinct targeting systems have been 
identified and appear to show distinct functions.  
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Large aggregates of proteins can form within a cell as a result of protein 
misfolding, or simple over-abundance. This misfolding may be due to a 
transient problem with the synthesis pathways, or part of a more serious 
condition such as Parkinson’s disease or Huntington’s disease.  
The formation of these inclusion bodies generally requires the 
multifunctional protein p62 (also known as A170/SQSTM1/sequestrome 1). 
p62 is able to directly bind LC3 and GABARAP family proteins along with 
K63-polyubiquitin chains. The structural basis of the binding of p62 to LC3 
is well understood, having been solved by a combination of NMR 
spectroscopy, X-Ray crystallography and other biochemical techniques.146 
Its binding to these targets may serve dual purposes, facilitating the 
extension of the polyubiquitin chains and shuttling polyubiquitinated 
proteins for degradation. The degradation of these proteins was originally 
thought to be via the proteosome,152 although it now seems more likely that 
p62 specifically targets K63-ubiquitinated proteins for autophagic 
degradation. Upon binding its targets, p62 is also able to polymerise to form 
large aggregates, which become inclusion bodies. Inclusion bodies 
containing p62 accumulate in autophagy-deficient cells and are reduced 
following the induction of autophagy.153,154 This autophagic degradation of 
protein aggregates also appears to be necessary for clearance of plaques of 
α-synuclein and huntingtin in Parkinson’s and Huntington’s diseases, 
respectively.148 This may have a protective effect, as deliberate induction of 
autophagy reduced the toxicity of mutant huntingtin in fly and mouse 
models of Huntington’s disease.155 
As an example of larger structures being selectively targeted by 
macroautophagy, yeast (Saccharomyces cerevisiae) under starvation 
conditions selectively degrades mature ribosomes.156,157 Although some of 
this degradation may be part of a less specific bulk catabolic pathway, it 
seems that ribosomal subunits are specifically recognised and incorporated 
into the autophagosome for degradation, following target-specific 
ubiquitination and subsequent de-ubiquitination steps. Interestingly this 
process (referred to as “ribophagy”) targets the ribosomal subunits at 
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different rates, leading to an imbalance. The consequences of – or a possible 
purpose for – this imbalance are currently unclear. 
The increase in understanding of targeting during bulk 
macroautophagic degradation has led some to suggest that all 
macroautophagy might be specifically targeted.151 At present, the evidence 
published does not seem sufficient to support that claim. It seems likely that 
at least some proportion of macroautophagy is bulk catabolism or, as will be 
discussed later, non-specific collection of cytosolic proteins for other uses 
such as immune surveillance.  
1.2.4.3 Autophagy and Starvation 
One of macroautophagy’s best-characterised functions is as a catabolic 
pathway used to recycle cytosolic components for use as a source of 
metabolic precursors. Under nutrient-poor conditions, proteins and 
organelles are engulfed by autophagosomes and degraded. The breakdown 
products are then released to the cytoplasm.158 This behaviour is strongly 
conserved across eukaryotes, having been observed in yeast (e.g. 
Saccharomyces cerevisiae), plants (e.g. Acer pseudoplantanus) and 
mulicellular animals. For example, Caenorhabditis elegans requires a 
functional macroautophagy pathway to enter the dauer diapause, a 
reversible developmental arrest brought on by limiting nutrient 
availability.159 In mammals, autophagy is required to survive the early 
neonatal starvation period. This is the period between the sudden 
interruption of trans-placental nutrient supply at birth and the resumption of 
supply from milk. During this period, neonatal mice strongly upregulate 
autophagy in many tissues; knockout mice unable to induce autophagy 
starve within one day of delivery unless force-fed milk.160,161 
In cells lacking the pro-apoptotic proteins Bak and Bax, withdrawal of 
growth factors lead to an inability to use extracellular glucose. In order to 
survive, cells upregulated macroautophagy and relied on the catabolism of 
cytosol components to maintain ATP production. Suppression of autophagy 
by RNAi or drug treatment lead to rapid cell death, confirming that 
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autophagy is essential for cell survival after growth factor withdrawal.162  
In mammals this regulation of autophagy in response to starvation is largely 
controlled by the mammalian target of rapamycin (mTOR) and its 
activators, notably the class I PI 3-kinase and Akt pathway. 
1.2.4.4 Regulation of autophagy by mTOR 
TOR kinase homologues function in a signal transduction pathway that 
is conserved from yeast to mammals.163 This pathway integrates signals 
from the detection of nutrient and growth factor availability, calcium 
signalling within the cell and levels of energy (in the form of ATP) 
available to the cell. 
In yeast, the proteins TOR1 and TOR2 are essential for progression 
through the G1 phase of the cell cycle.164 These proteins are around 289kDa 
in size and highly homologous, at around 70% identical. Mammals share a 
single protein, mTOR, which is conserved up to 60% across the species 
studied to date.165 TOR1, TOR2 and mTOR all contain a c-terminal kinase 
domain similar to Phosphatidylinositol 3-kinase and are, therefore, 
sometimes referred to as PI kinase-related kinases (PIKK). The target of this 
kinase is a (Ser/Thr)-Pro motif or a threonine flanked by large hydrophobic 
residues.166  
Inhibition of the TOR proteins leads to accumulation of glycogen, 
repression of genes associated with growing cells and stimulation of genes 
associated with starvation, even under nutrient rich conditions. Inhibition of 
the TOR proteins also leads to the induction of autophagy.167 
mTOR is found in two distinct complexes: mTORC1 and mTORC2. 
mTORC1 is composed of mTOR, raptor (regulatory associated protein of 
mTOR), PRAS40 and mLST8/GbL. mTORC2 is composed of mTOR, rictor 
(rapamycin-insensitive companion of mTOR), mSIN1, protor-1, 
mLST8/GbL and PRR5.165 
mTORC2 is primarily involved in actin cytoskeleton  organisation and 
cell survival. mTORC1 is primarily involved in regulating mRNA 
translation, cell cycle progression and autophagy.168 Disrupting mTORC1 
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leads to the formation of new autophagosomes, and allows their elongation 
and maturation. 
TOR and mTOR inhibit the formation of the Ser/Thr protein kinase 
complex composed of Atg1 Atg13 and Atg17. This effect is due to 
(m)TOR-dependent phosphorylation of Atg13, which prevents this complex 
from assembling169 and prevents the recruitment of class III PI 3-kinase 
Vps34 to autophagic membranes. Atg1:Atg13 and Vps34 are required for 
the early stages of autophagosome creation and expansion.169 
1.2.4.5 Autophagy in viral infections 
The role of autophagy in immunity against intracellular pathogens has 
been discussed previously. Sections 1.1.5.7 (page 22) and 1.1.5.8 (page 23) 
discuss autophagy’s role in intracellular and adaptive responses to 
pathogens, respectively. 
Briefly, several systems exist within the cell to detect intracellular 
infections, such as the Toll-like receptors and dsRNA-activated kinases (see 
Figure 3, page 15). 
Upon activation, the stress signals produced may lead to upregulation 
of macroautophagy. An example of this is the activation of dsRNA activated 
kinase PKR, resulting in phosphorylation of its target, eIF2α, and 
subsequent induction of macroautophagy.75 Many viruses have evolved to 
prevent activation of this pathway. In Herpes Simplex Virus, deleting the 
protein ICP34.5 allows this induction of autophagy to proceed, resulting in 
the degradation of viral proteins within autophagosomes and marked 
reduction in neurovirulence.74 In contrast, several RNA viruses – poliovirus, 
equine arterivirus and mouse hepatitis virus – appear to require the 
formation of autophagosomes (or autophagosome-like structures) for 
successful formation of replication complexes and therefore successful 
completion of replication.77 Further examples and a more detailed 
discussion can be found in section 1.1.5.7, page 22. 
Proteins from within autophagosomes can be passed to an endosome-
like compartment known as the MHC Class II Compartment (MIIC or 
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CIIV). Within these compartments they can be processed for binding to 
MHCII, and thus presented on the cell surface to cells of the adaptive 
immune system. For a more detailed description of the molecular pathways 
and consequences of this activity, see section 1.1.5.8, page 23. 
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1.2.5 Autophagy and Cancer 
1.2.5.1 Autophagy and tumour suppression 
Beclin 1 is a key autophagy gene involved in the early stages of 
autophagosome formation. While it has no enzymatic activity of its own, it 
is able to bind the class III PI 3-kinase Vps34 and two regulatory proteins, 
pro-autophagic UVRAG and anti-autophagic Bcl-2.168 
Beclin 1 is also a haploinsufficient tumour suppressor gene. It was 
found to be hemiallelically deleted in 40-75% of spontaneous human 
tumours from breast, ovary and prostate. In experiments in mice, 
homozygous deletion of the encoding gene BECN1 was embryonic lethal. 
Heterozygous mice showed reduced ability to induce autophagy and a 
higher incidence of spontaneous tumours.170,171 Additionally, the anti-
apoptotic oncogene Bcl-2 is known to bind Beclin 1 and inhibit its role in 
initiating autophagy, providing a possible mechanism for partial 
downregulation of Beclin 1 activity in some cancers.172 
Further negative correlations between autophagy induction and cancer 
have been pointed out. For example, the importance of mTOR control in 
regulating the growth of cancer cells is well established and cellular proteins 
known to suppress mTOR (and therefore upregulate autophagy) such as 
PTEN and TSC are well known as tumour suppressors. Conversely, 
molecules involved in the activation of mTOR (and therefore 
downregulation of autophagy) such as class I PI 3-kinases and Akt are 
commonly upregulated in cancers.171 
The relationship between autophagy and tumourigenesis is not firmly 
established. It can be expected that cells lacking efficient autophagy 
pathways will suffer more damage from various stresses, whether 
metabolic, chemical or from other sources, e.g. UV light exposure. 
Additionally, the basal level of autophagy is required for quality control of 
newly synthesised proteins and for homeostasis. Finally, an accumulation of 
exhausted mitochondria could lead to a build-up of reactive oxygen species 
within the cell. It has therefore been suggested that cells lacking an efficient 
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autophagic pathway would be more susceptible to accumulating the DNA 
damage that eventually leads to tumourigenesis. 173 
However, it has been extensively shown that cells defective for 
apoptosis or lacking growth signals are able to survive in environments with 
low nutrient or growth signal availability by relying on autophagy as a 
source of nutrients. These conditions are typical of those in solid tumours 
before the development of an adequate vascular structure.158,160,161,162,171,173  
Additionally, some cancer cell lines are known to rely on autophagic 
mechanisms to survive challenge with certain chemotherapeutic drugs. It 
seems possible that selective pressure favours a loss or impairment of 
autophagy at early stages of tumourigenesis, but a recovery of these abilities 
in established tumours, although there is currently insufficient evidence to 
make a strong claim to this effect. 
1.2.5.2 Autophagy protects cancer cells from starvation 
Due to the increased replication and synthesis activities typical of 
tumour cells, their need for oxygen and nutrients is often higher than that of 
normal cells. Additionally, dysplastic development of the tumour tissue 
often creates an environment through which these metabolic components 
cannot diffuse efficiently. Developed tumours overcome this challenge by 
encouraging vascularisation around and sometimes within the tumour. 
Before this process has completed the tumour is often hypoxic and nutrient-
poor, a challenging environment for rapidly dividing cells. Even once an 
adequate vasculature has been established throughout a tumour, it is still 
possible that dysregulated cell growth will disrupt the blood supply, again 
depriving of the tumour of sufficient nutrients and oxygen.171,174 
The upregulation of autophagy in response to starvation has already 
been described above. While normal cells without specific growth signals 
would typically undergo apoptotic death in these conditions, this cell death 
pathway is frequently disabled in tumour cells. Instead, autophagy has been 
observed to be upregulated in starved cancer cells from several sources, and 
these cells survive considerably longer than normal cells when starved of 
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carbon and nitrogen sources. Inhibition of autophagy by RNAi knockdown 
of ATG genes or constitutive activation of class I PI 3-K removes this 
survival ability.171 
1.2.5.3 Autophagy and chemotherapeutic drugs 
Being involved in management of cellular stresses, autophagy plays a 
role in the reaction of several cancers to challenge with various drugs. As 
mentioned above, inhibiting autophagy in a mouse lymphoma model 
sensitised the cancer to transient induction of p53 or alkylating drug 
therapy.175 A selection of the drugs known to induce autophagy in cancer 
cells is shown in Table 3, excerpted from Kondo et al. 2006.176 
 
Table 3 - Cancer therapies linked to autophagy  
Therapy (mechanism) Cancer Cell Type 
Tamoxifen (anti-oestrogen) Breast 
Ionising Radiation (DNA damage) Breast, prostate, colon, malignant 
glioma 
Arsenic trioxide Malignant glioma 
Temozolomide (DNA alkylation) Malignant glioma 
Resveratrol Ovarian 
Soybean B-group triterpenoid 
saponins 
Colon 
Vitamin D analogue Breast 
Rapamycin (mTOR inhibito) Malignant glioma 
Butyrate and suberoylanilide 
hydroxamic adic (HDAC Inhibitors) 
Cervical, with Bcl-XL 
overexpression 
 
HDAC, Histone deacetylase; mTOR, mammalian target of rapamycin 
 
Table data from Kondo et al. 2006176 
 
 
 
Although autophagy is observed in dying cells during treatment, it is 
not clear in all cases whether this is a route to cell death or a cell survival 
mechanism. For example, using 3-methyladenine to inhibit formation of 
new autophagosomes protected malignant glioma cells from treatment with 
Temozolomide (TMZ). Interestingly, treatment with bafilomycin A1, which 
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allows autophaghosomes to form but blocks their eventual fusion with 
lysosomes, increased the toxicity of TMZ in the same cell line.176 This 
suggests a complex relationship between autophagy and TMZ in this 
particular cancer. Inhibition of autophagy by RNAi knockdown of ATG5, 
Beclin 1 and ATG7 restored the vulnerability of tamoxifen-resistant breast 
cancer cell lines to tamoxifen treatment.171 
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1.2.6 Inhibiting Autophagy 
1.2.6.1 3-Methyladenine 
As described previously, the induction of autophagy is dependent on 
the creation of a compartment enriched with Phosphatidylinositol 3-
phosphate (PI(3)P) which recruits PX(Phox Homology) and FYVE-domain 
containing proteins to membrane compartments. 3-Methyladenine inhibits 
the activity of Class III PI 3-Kinase Vps34, thus blocking the creation of 
PI(3)P. This, in turn, blocks the formation of new autophagosomes, 
inhibiting the macroautophagy pathway.169 
1.2.6.2 Chloroquinine 
Chloroquinine is a lysosomotropic drug which appears to function by 
raising the lysosomal pH and thus reducing the efficiency of the lysosome’s 
degradative enzymes. A consequence of this is the failure to degrade the 
contents of targeted autophagosomes efficiently. Blocking this final step in 
the autophagic pathway leads to an accumulation of defective 
autophagosomes. More importantly, it can lead to the death of cells reliant 
on autophagy for survival, e.g. cancer cells in nutrient-poor or ischemic 
tumour environments.175 Mice carrying lymphoma rendered resistant to 
apoptosis by inactivating p53 were treated with Chloroquinine. This 
treatment significantly inhibited tumour growth, supporting the idea of 
autophagy being an important survival pathway for some tumour cells. In 
the same model, Chloroquine treatment also enhanced apoptotic tumour 
regression induced by transient reactivation of p53 and suppressed 
subsequent tumour recurrence.175 
1.2.6.3 Amino Acids 
One of the chief products of autophagy, amino acids, act to suppress 
further formation of autophagosomes.177,178 
 The presence of amino acids – particularly leucine or histidine179 – 
stimulates the class III PI 3-kinase Vsp34. Activated Vsp34 upregulates the 
activity of mTOR, thus downregulating the creation of new 
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autophagosomes.92,168 
Additionally, it is clear that at amino acids can inhibit autophagy in an 
mTOR-independent manner. In CRC12 myotubes, induction of autophagy 
appeared to be dependent on the production of PI(3)P and its interaction 
with Beclin-1; this activity was not stopped when mTOR was disrupted 
using rapamycin. In human colon cancer HK-29 cells, a further pathway 
was found: amino acids stimulated the inactivation by phosphorylation of 
the Erk1/2 mitogen-activated protein kinase (MAPK). This inactivation 
prevents MAPK from stimulating the GTPase-activating protein G alpha 
interacting protein (GAIP), thus leaving intact the inhibitory effect of 
trimeric Gi3 protein on autophagy.92 
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1.3 Detecting Autophagy 
As a complex, multi-staged process controlled by several distinct 
pathways, monitoring the overall progression of a cell through autophagy is 
not a simple task. Many steps of the induction process have been considered 
as potential targets for an assay of autophagy induction. A recent review by 
Klionsky et al.180 of targets attempted for use in an assay is reproduced in 
Table 4. 
Many of these events have proven to be too challenging to monitor, to 
vary between cell lines and the means by which autophagy has been 
induced, or to lack specificity for the autophagic pathway. Therefore it has 
become common for groups showing induction or modification of 
autophagy to utilise several different assays to confirm the extent of 
autophagic induction and progression.181,182,183 The more commonly used 
techniques in recent literature are discussed below. 
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Table 4 - A selection of assays used to detect autophagy.  
Step of 
Autophagy 
 
Assay Represents / Requires 
Atg8 synthesis Signalling 
Atg13 dephosphorylation Tor inactivation 
GFP-LC3 Signalling 
LCI conversion to LC3II Signalling 
LysoTracker Red Acidified compartments 
1. Induction 
Monodansylcadaverine Acidified compartments 
 
Ams1 activity Atg19, Atg11, Cytoskeleton 
Ape1 processing / activity Atg19, Atg11, Cytoskeleton 
2. Cargo 
Recognition / 
packaging Precursor Ape1 localisation Atg19, Atg11, Cytoskeleton 
 
Acridine orange Vesicle formation machinery 
Active site CtoS Atg7 activation, Atg3- Atg10 
conjugation 
Atg1 kinase activity Atg1, Atg11, Atg13, Atg17 
function 
Atg8-GFP processing Atg4 cleavage 
Atg12-Atg5 conjugation Atg7-Atg10 conjugation 
Atg8-PE formation Atg3 conjugation, Atg4, 
Atg7 
ATG8-PE membrane 
association 
Atg3 conjugation, Atg4, 
Atg7 
AP formation / 
accumulation 
Vesicle formation machinery 
Electron microscopy Vesicle formation machinery 
GFP-Atg8 localisation Atg3 conjugation, Atg4, 
Atg7 
GFP-LC3 Vesicle formation machinery 
LC3 C-terminal processing Atg4 cleavage 
LysoTracker Red Vesicle formation machinery 
Monodansylcadaverine Vesicle formation machinery 
Protease-protection AP/Cvt vesicle completion 
3. Vesicle 
formation 
Sequestration of cytosolic 
markers 
 
AP formation 
4. Retrieval TAKA assay Atg1, Atg2, Atg13, Atg18, 
Atg23. Atg27, cytoskeleton 
 
AB/AP formation and 
accumulation 
Atg15, Pep4, Prb1, Fusion 
machinery, Vacuolar pH 
Electron microscopy Atg15, Pep4, Prb1, Fusion 
machinery, Vacuolar pH 
Fox3 degradation Pexophagy 
5. Fusion / 
Breakdown 
GFP-Atg8 localisation Atg15, Pep4, Prb1, Fusion 
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machinery, Vacuolar pH 
GFP-Atg8/LC3 processing Membrane delivery, AB lysis 
LC3II turnover Complete autophagy 
Peroxisomal enzyme 
inactivation 
Pexophagy 
Pex14-GFP processing Pexophagy 
Pho8Δ60 activity Bulk delivery 
 
Protein degradation Bulk delivery 
 
6. Efflux Ape1 (or other protein) 
synthesis 
Permease function 
 
Table data from Klionsky et al. 2007180 
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1.3.1 LC3 modification and localisation 
As discussed above, the modification of LC3I to LC3II is an essential 
step in the formation of autophagosomes in mammalian cells. During the 
extension of the membrane that will become the autophagosome, the 
modified form – LC3II – becomes embedded in the internal and external 
surfaces of the autophagic membrane.136,142,144,145,184 This therefore makes 
LC3 an appealing target for measuring the formation and accumulation of 
autophagosomes. Of the homologues available in mammals, LC3B is the 
most commonly targeted.185 The two major techniques for measuring the 
incorporation of LC3 into autophagosomes are Western blotting and 
confocal microscopy. 
The principles of western blotting for conversion of LCI to LCII were 
recently reviewed by Mizushima and Yoshimori, 2007.185 Probing a western 
blot membrane for LC3B yields two bands, at approximately 17 and 15 
kDa, representing LC3I and LC3II respectively. This is represented in 
Figure 8.  
 
 
Figure 8 - Diagram of a typical Western blot result for LC3B.  
 
 
The proportion of LC3I to LC3II in a resting cell varies between cell 
types; additionally, LC3II within an autophagosome is degraded when 
fusion with a lysosome converts the autophagosome to an autolysosome.186 
LC3II on the outer surface of the autophagosome may be recycled to LC3I. 
To further complicate the interpretation of this technique, LC3II may be 
more sensitive to immunoblotting than LC3I.145 
Therefore the intensity of the lower band on the Western blot does not 
directly reflect the extent of autophagy induction in those cells. Rather, the 
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ratio of LC3I to LC3II in treated cells must be compared to the same ratio in 
resting cells. This comparison gives an indication of the increase in 
modification of LC3I to LC3II. This is often taken to be indicative of an 
increase in the rate of autophagosome formation. However, it is important to 
note that the same effect could be seen at endogenous levels of autophagy 
induction if the maturation and subsequent degradation steps are inhibited.   
A possible solution to this problem is the inclusion of controls treated 
with bafilomycin or other agents that block the final stages of autophagy. 
This allows the effect of a block in autophagosome clearance to be observed 
and compared with the effect of the experimental conditions. For example, 
when autophagy is upregulated, a higher LC3II:LC3I ratio would be 
expected in cells exposed to the treatment and bafilomycin than in the cells 
treated with bafilomycin alone. Equal LC3II:LC3I ratios between these two 
samples would suggest that the increase is not due to induction of 
autophagy, but due to the failure to clear autophagosomes that are being 
formed at the usual rate. 
Confocal microscopy had been used extensively to detect changes in 
the localisation of LC3. During the construction of an autophagosome, LC3 
is recruited from its diffuse distribution in the cytoplasm to be packed 
relatively densely in the newly formed membrane.145 Several groups have 
published work using cells transiently or stably transfected with a plasmid 
expressing a GFP-LC3 fusion protein under the control of a CMV 
promoter.144,187 
This technique must be used with caution, however, as under some 
conditions over-expressed GFP-LC3 protein has been shown to form 
aggregates in the cytoplasm. This behaviour is not entirely unexpected, as 
many other proteins have been shown to form aggregates when 
overexpressed under various conditions.188 These aggregates of GFP-LC3 
can resemble small autophagosomes under confocal microscopy, but occur 
independently of autophagy induction.187 Similar puncta may be formed or 
enhanced in fixed cells when treated with various detergents to permeabilise 
membranes in preparation for immunoblotting.189 Additionally, GFP-LC3 
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has been shown to associate with organised smooth endoplasmic reticulum 
membranes independent of autophagy induction; by contrast, unmodified 
LC3 does not associate with this type of membrane at any stage.190 
Several antibodies specific to LC3 and suitable for confocal microscopy 
have recently become commercially available, and have now been used by 
several groups to visualise endogenous LC3 expression and localisation. An 
example of this staining, taken from my own data, is shown in Figure 9. As 
expected from the varying levels of LC3II shown by Western blots, 
different cell types display differences in LC3 distribution at rest and after 
induction of autophagy. 
 
Figure 9 - LC3 immunofluorescence to visualise autophagosomes. Cells in the 
right column were infected with dl331 and fixed after 28 hours.  
 
It should be noted that, as this method visualises the accumulation of 
autophagosomes based on detecting LC3, it might be expected to lose 
efficacy in detecting autolysosomes, whose internal LC3 is subject to rapid 
degradation. Additionally, the number and size of autophagosomes present 
in a cell do not necessarily reflect the rate of autophagic degradation. It is 
possible that a cell containing a large number of autophagosomes is forming 
them at its normal background rate, but the clearance of the 
autophagosomes is being somehow inhibited. 
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1.3.2 p62 accumulation 
A common fate for misfolded or denatured proteins within the cell is to 
become insoluble and form aggregates, which may grow to form large 
inclusion bodies. This is especially true for ubiquitinated proteins and 
LC3.188,191 This behaviour is exemplified by the tendency of overexpressed 
GFP-LC3 to form large punctate structures, as described in the previous 
section. 
The formation of these inclusion bodies requires the multifunctional 
protein p62 (also known as A170/SQSTM1/sequestrome 1). p62 is able to 
directly bind LC3 and GABARAP family proteins along with K63-
polyubiquitin chains. Its binding to these targets may serve dual purposes, 
facilitating the extension of the polyubiquitin chains and shuttling 
polyubiquitinated proteins for degradation. The degradation of these 
proteins was originally thought to be via the proteosome,152 although it now 
seems more likely that p62 specifically targets K63-ubiquitinated proteins 
for autophagic degradation. Upon binding its targets, p63 is also able to 
polymerise to form large aggregates, which become inclusion bodies. 
Inclusion bodies containing p62 accumulate in autophagy-deficient cells and 
are reduced following the induction of autophagy.153,154 
 Accumulation of p62 has therefore been used as an indicator of 
inhibited autophagy, although measuring the half-life of p62 after treatment 
may give more meaningful results. Live-cell imaging of p62 to detect 
formation, trafficking and degradation of inclusion bodies is also possible; a 
thorough review of these methods has been published recently.192 
Similar to p62 is the recently described protein NBR1 (neighbour of 
BRCA1 gene 1). NBR1 carries LC3- and Ubiquitin-binding domains and is 
found recruited to inclusion bodies, which are eventually targeted for 
degradation by autophagy. This behaviour can occur in co-operation with 
p62, with which it can form oligomers, although p62 is not required for 
NBR1 to function.193 This makes NBR1 an appealing target to measure 
autophagy using similar techniques to p62. However, at the time of writing 
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no groups have published evidence confirming its utility as a marker of 
autophagic degradation. 
1.3.3 Acridine Orange  
When applied to cells, Acridine Orange fluoresces green when in 
contact with dsDNA, dim orange when bound to ssRNA or bright red when 
in acidic compartments such as lysosomes or late stage autophagosomes 
(autolysosomes).193 The upregulation of autophagy correlates with the 
appearance within the cells of acidic vesicular organelles (AVOs), 
presumably lysosomes prepared in readiness for fusion with 
autophagosomes to form autolysosomes.180 Several groups have therefore 
used Acridine Orange staining as a measurement of autophagy 
upregulation.182,183,194  
No consensus seems to have been reached on the best application of 
this technique. Confocal microscopy has been used to count the mean 
number of AVOs per cell, or to count cells containing more than a threshold 
level of AVOs. Alternatively, flow cytometry has been used to detect the 
overall intensity of red signal emitted by each stained cell. These data are 
then analysed by either counting the number of cells whose signal exceed a 
given threshold, or by comparing the ratio DNA:AVO (green signal:red 
signal) of cell populations.  
It must be noted that, as early autophagosomes are generally not acidic, 
this staining is not specific to autophagosomes. While autophagy 
upregulation does entail the productions of AVOs, these methods are best 
used in conjunction with a more specific assay for autophagic flux, such as 
LC3 localisation or processing. 
1.3.4 Monodasylcadaverine (MDC) staining 
The autofluorescent compound monodasylcadaverine (MDC) was 
originally suggested as a specific stain for autophagic components in 1995 
by Biederbick et al.195 Later work in Chinese hamster ovary (CHO) cells 
demonstrated that many MDC-stained vesicles are acidic and that MDC 
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staining typically accumulates in vesicles labelled with GFP-LC3, 
presumably autophagosomes.196 
Numerous investigators have since used MDC staining to detect 
autophagy and reported good specificity and selectivity for this dye in 
animal197 and plant198 cells. 
 This accumulation is reliant on two separate mechanisms. Firstly, 
MDC’s negative charge causes it to become trapped in acidic vesicles; the 
resulting change in charge may alter its fluorescence slightly through a pH-
dependent Stokes shift. Secondly, MDC shows increased fluorescence in a 
hydrophobic environment typical of the lipid-rich autophagosome 
environment. Together, these characteristics cause MDC to localise to, and 
fluoresce most brightly from, autophagosomes.199  
However, others have reported problems with MDC’s specificity. 
Bampton et al. showed that MDC stains double-membraned acidic 
lysosomes and endosomes, including but not exclusively autolysosomes. 
This staining was still visible where autophagy had been inhibited by 
homozygous ATG5 deletion; additionally, MDC staining did not always co-
localise with LC3-positive enclosures in mouse embryonic fibroblasts 
(MEFs).200 It is worth noting that this lack of specificity was observed only 
in living cells, and is presumably due to MDC accumulating in lysosomes 
and late endosomes due to ion trapping of MDC in the low-pH 
environments. In fixed cells the pH gradient should no longer be present, 
causing the MDC to accumulate only in lipid-rich structures such as 
autophagosomes and other lamellar bodies. Comparison of live and fixed 
staining of the same field on a coverslip appears to support this, showing 
that some vesicles stained in living cells are not stained when the same cells 
are fixed and re-treated with MDC.201 
Replacing the primary amino group of MDC with the non-polar 
dansylamylamine to create monodansylamylamine (MDH) removes MDC’s 
tendency to accumulate in low-pH environments, improving its specificity 
for lipid-rich structures such as autophagic vesicles.201 
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1.3.5 Radiolabelled protein degradation 
Autophagy is just one of several distinct pathways responsible for 
degradation of cellular proteins. However, while the proteosome and 
various proteases seem to target short-lived proteins, autophagy is generally 
used to degrade relatively long-lived proteins. This distinction makes it 
possible to use long-lived protein degradation as a proxy measurement of 
the overall functioning of the autophagy pathway.180,202 
The typical approach is to grow cells in media containing one or more 
radiolabelled amino acid(s), such as [14C]Valine or [3H]Leucine. After an 
incubation of 10-16 hours, cells are restored to normal growth media and 
incubated for a suitable time to allow turnover of short-lived proteins. Once 
the short lived proteins have been degraded and excreted from the cells, the 
slower degradation of labelled long-lived proteins can be monitored by 
measuring the change in radioactivity of washed cell pellets.180,202 
With this technique it is important to note that high amino acid 
concentrations in growth medium have been shown to inhibit autophagy 
induction. Of the labelled amino acids commonly used in this technique, 
[14C]Valine is likely to be the preferable choice, as high Leucine 
concentrations may be a more powerful inhibitor of autophagy 
induction.178,180,202 
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2 Materials and Methods 
 
2.1  Cells and media 
2.1.1 Tumour cell lines 
Cell line Tissue type Cultured in 
HCT116 Colorectal E4 + 10% FCS 
MiaPaCa-2 Pancreatic E4 + 10% FCS 
Suit-2 Pancreatic E4 + 10% FCS 
PANC-1 Pancreatic E4 + 10% FCS 
A549 Alveolar epithelial E4 + 10% FCS 
2.1.2 Normal cells 
Normal Human Bronchial Epithelial (NHBE) cells were bought from Cambrex 
Biosciences. They were cultured following manufacturer’s instructions, and fed with 
BEGM every other day.  
Prostate Epithelial Cells (PrEC) were bought from Cambrex Biosciences. They 
were cultured following manufacturer’s instructions, and fed with PrEGM every other 
day.  
2.2  Viruses 
Ad5 – Wild-type class C adenovirus 
dl309 – Based on Ad5, partial E3 deletion, specifically E3 10.4kDa, 14.5kDa and 
14.7kDa are deleted; E3 6.7kDa lacks two internal amino acids.203 
dl331 – Originally constructed from dl327, an Ad5-based virus with a large deletion 
having removed the E3 region. In addition to this E3 deletion, dl331 has a 29bp 
deletion in the intragenic promoter of VA-RNAI.121 
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2.3  Virus Production 
2.3.1 Acknowledgement 
The viruses used in this work – Ad5, dl331 and dl309 – were bulked up from pre-
existing laboratory stocks by Jennelle Francis and Katrina Sweeney, who were also 
responsible for their purification and initial titres. The following, up to and including 
the measurement of infectious titre, is a description of their methods. 
2.3.2 Initial expansion 
For production of Ad5 and dl331, A549 cells were grown in E4 + 10% FCS to a 
confluence of 90%. When producing dl309, 293 cells were used instead. Infection 
medium was made by adding 30µl of purified virus stock to 30ml E4 + 2% FCS. 
Medium was aspirated from the A549 cells and replaced with the infection medium. 
After 48 hours of incubation at 37°C, cells are checked for cytopathic effect (CPE). If 
CPE is not visible, cells were incubated for a further 24 hours. 
Once cells have detached, they are harvested. The cell suspension was transferred 
to a 50ml centrifuge tube and freeze-thawed three times using liquid nitrogen and a 
water bath at 37°C. 
2.3.3 Second expansion 
When producing Ad5 and dl331, four T-175 flasks of A549 cells were used to 
seed a CF-10TM. When producing dl309, 293 cells were used instead. A parallel 
culture in a single T-175 flask was seeded at the same cell density as the CF-10 and 
kept under identical conditions. Both cultures were incubated at 37°C for 48 hours. 
Once the cells in the parallel culture reached 90% confluence, the CF-10TM was 
infected with the freeze-thawed cell suspension. The infected CF-10 was incubated 
for 48-72 hours, until extensive cytopathic effect (CPE) was visible and cells were 
floating. The suspended cells were then collected, pelleted by centrifugation at 2000 
rpm and re-suspended in 15ml cold PBS. The cells were pelleted again, then re-
suspended in 12ml of cold 10mM Tris.HCl at pH 8.0. 
2.3.4 Purification 
The concentrated cell suspension was freeze-thawed three times using liquid 
nitrogen and a 37°C water bath. This lysate was then spun at 6000rpm for 10 minutes 
to remove cellular debris. The supernatant was layered onto a CsCl concentration 
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gradient (upper layer at 1.25g/ml, lower layer at 1.4g/ml). Centrifuging this at 
25,000rpm for 2 hours banded the purified virus particles between the two CsCl 
layers.  
This purified virus was extracted from the tube and layered onto 4ml of 1.35g/ml 
CsCl solution. This was then centrifuged at 40,000rpm for 15 hours and the resulting 
band collected. This purified virus was diluted with TSG buffer (Table 5) to 12ml and 
injected into a slide-a-lyzer dialysis chamber. This is then stirred in 2 litres of dialysis 
solution (Table 6) for 24 hours to remove CsCl from the virus stock. The 
concentrated, purified virus stock is stored at -80°C. 
 
 
Table 5 - TSG Buffer: Combine 700ml of solution A with 3.5ml of solution B and 
300ml Glycerol. Heat together and filter to sterilise. 
Solution A Solution B 
Stock Solution Final Concentration Stock Solution Final Concentration 
Distilled Water --- Distilled Water --- 
NaCl 137mM MgCl2 98mM 
NaHPO4 
(dibasic) 
0.7mM CaCl2 136mM 
0.3g KCl 4mM   
 
Table 6 - Dialysis solution to remove CsCl from purified virus stock 
Stock Solution Final Concentration 
1M Tris.HCl pH7.4 10mM 
1M MgCl2 1mM 
5M NaCl 150mM 
Glycerol 10% 
Sterile Distilled 
Water 
--- 
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2.4  Determination of viral titre 
 Purified virus stocks were titrated using two methods, to determine particle 
count and concentration of viable particles. 
2.4.1 Particle count 
Two dilutions of virus in a lysis buffer were prepared along with a virus-free “blank” 
solution (Table 7). 
 
Table 7 - Viral solutions used for measurement of particle counts by 
spectrophotometry 
 Blank A B 
Virus - 100µ l 200µ l 
Dialysis Buffer 200µ l  100µ l - 
Lysis Buffer 200µ l  200µ l  200µ l 
Water 600µ l  600µ l  600µ l  
 
These samples were heated to 56°C for 10 minutes then allowed to cool to room 
temperature. Using the blank sample as a reference, the absorbance of each sample 
was measured at 260nm and the particle count determined by the formula: 
OD260 x dilution factor x 1.12x1012 = number of particles per millilitre. 
NB: 
1.2x1012 is the extinction coefficient. 
Samples A and B have dilution factors of 10 and 5 respectively. 
2.4.2 Infectious Titre 
The number of plaque-forming units (pfu) per millilitre was measured by a limiting 
dilution assay. 293 cells (or A549 cells for dl309) were plated into triplicate 96-well 
plates at 10,000 cells/well. After overnight incubation, the viral sample was serially 
diluted down these plates in steps of 10-fold dilution. After 11 days of incubation, 
wells were examined microscopically for evidence of cytopathic effect (CPE). This 
includes swollen, detached and dead cells. The number of wells showing CPE at each 
dilution was entered into the TCID50 calculation to determine pfu/ml.204 
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2.5  Virus Replication Assay 
2.5.1 Infecting cells and collecting viral lysates 
Cells to be assayed were grown to 80% confluence in tissue culture-treated 
flasks. Cells were then trypsinised and plated in 6-well plates at 3x105 cells per well. 
Only three wells on each plate were seeded, to minimise risk of splashing medium 
between wells when harvesting. Three wells were seeded for each combination of 
virus and timepoint; and additional three wells were seeded for cell number controls. 
After incubating for 24 hours in standard conditions, cells from three wells were 
trypsinised and counted. Based on this cell count, the remaining wells were infected 
with virus at 100 pt/cell, diluted into 1ml of serum-free medium per well. 
Cells were incubated at 37°C in this infection medium for two hours. After this 
time, the medium was removed, and cell monolayers rinsed with warm PBS. Cells 
were then covered with 2ml of E4 + 5% FCS and returned to the incubator. 
Cells and medium were harvested at 24-hour timepoints, by scraping into 
cryogenic tubes. These were stored at -80°c until all samples were collected. 
2.5.2 Measuring viral yield by TCID50 assay 
A549 cells were grown to 80% confluence, then trypsinised and re-plated into 96-
well plates at 10,000 cells/well. Each well contained 190µl medium. Viral lysates 
were recovered from storage at -80°C, then freeze-thawed three times using liquid 
nitrogen and a 37°C water bath. Each sample was diluted 1/100 into 5ml serum-free 
E4. Each of these diluted viral lysates was then serially diluted in 1/10 steps down 
three of the replicate 96 well plates (Figure 10).  
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Figure 10 – Plate layout for serial dilution down TCID50 plates. 
 
 
These plates were then incubated for ten days. On the 11th day post-infection, 
each well was examined for CPE. The total of wells showing CPE in each row was 
used to calculate the viral yield. The method used was to calculate the dilution at 
which 50% of wells showed cytopathic effect (CPE). This is the tissue-culture 50% 
infectious dose, TCID50..204 
2.6  Virus Cytotoxicity Assay 
Cells to be assayed were grown to 80% confluence, then trypsinised and re-plated 
into 96-well plates. Cells were typically seeded at 10,000 cells/well in 90µl of E4 + 
5% FCS. Fast-growing cells were seeded at lower densities, chosen so uninfected 
wells will reach confluence 5 days post-infection.  
One edge column of wells contained medium but no cells, to act as a blank for 
the spectrophotometer. The other edge wells were filled with PBS to prevent 
evaporation from the sample wells. Triplicate plates were infected with serially 
diluted virus, leaving a row of uninfected cells to act as a negative control. See Figure 
11 for layout. 
Six days post-infection, 20µl of MTS was added to each well. Plates were then 
incubated at 37°C for 2 hours. The optical density of each well was then measured at 
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490nm using a 96-well plate reader. This was then analysed using a customised Excel 
spreadsheet and Prism statistical software to calculate the EC50 for each virus. 
 
 
Figure 11 – Viral Toxicity assay plate layout. Green numbers refer to 
concentration of virus in particles / cell. 
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2.7  Protein Expression Assay (Western Blotting) 
2.7.1 Preparation of whole cell extract 
Cells were grown to 80% confluence in 6cm circular dishes, then infected with 
virus at 100 pt/cell. Cells were harvested by trypsinisation, then re-suspended in E4, 
10% FCS  to deactivate the trypsin. Cells were then rinsed with PBS, pelleted and the 
pellets lysed with 200µl of ice-cold RIPA (RadioImmunoPrecipitation Assay) buffer 
(Table 8), prepared by dissolving one protease inhibitor tablet into 10ml of buffer. 
Lysed cells were incubated on ice for 30 minutes with occasional agitation, then 
centrifuged at 12000rpm for 15 minutes at 4°C to pellet cell debris. The supernatant 
was then stored at -80°C before assaying for concentration and immunoblotting. 
 
 
Table 8 - 5x RIPA reducing cell lysis buffer. This must be diluted 1/5 in water, and one 
protease inhibitor tablet added to 15ml 
Reagent Final concentration 
NaCl 0.75M 
NP40 5% 
Deoxycholic Acid 2.5% 
SDS 0.5% 
Tris pH 8 0.25M 
Distilled Water - 
 
2.7.2 Preparation of nuclear and cytoplasmic extracts 
Nuclear and cytoplasmic protein lysates were extracted using the NuCLEAR 
Extraction Kit (Sigma UK). Cells were grown in 6cm dishes to 80% confluence, then 
infected at 100 pt/cell as described above. The manufacturer’s protocol was followed 
to lyse cell membranes, extract nuclei then treat each fraction in preparation for 
analysis by western blotting. 
2.7.3 Concentration of proteins from culture medium 
Cells were grown and infected as described in “Preparation of whole cell 
extract”, above. 5ml of medium was collected at each timepoint and stored at -80°C. 
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When all samples had been collected, medium was filtered by centrifugation through 
Centricon 10,000D filters. Centrifugation was at 5000g for approximately 80 minutes 
at 4°c. Filtered medium was discarded; the remaining medium (approx. 1/10th of 
original volume) was treated as a cell suspension. RIPA buffer carrying protease 
inhibitors was added to ensure ideal conditions for subsequent electrophoresis. 
2.7.4 Bradford Assay 
Protein concentration of lysates was assessed using the Bradford Assay. 30µl of 
each lysates was pipetted into a separate cuvette. Pre-made Bradford Reagent (Bio-
Rad) was diluted to 1x concentration. 1ml of this was added to each cuvette, and 
incubated at room temperature for 5 minutes. After this incubation, absorbance was 
measured at 595nm. These values were compared to a standard curve of 0, 1, 2, 5, 10 
& 20µg of bovine serum albumin (e.g. Figure 12). Protein lysates were then diluted to 
give a standard protein concentration for every well on a gel. 
 
 
 
Figure 12 - Typical standard curve from Bradford protein concentration assay. 
 
2.7.5 PAGE and Immunoblotting 
Samples were mixed with 5x loading buffer  
Table 9) and heated to 100°C for 5 minutes. Poly-acrylamide gels were poured 
using the mixtures listed in  
Table 10. When both layers were set, samples mixed with loading buffer were 
loaded into wells. Gels were run at 0.2A per gel. Amersham’s Rainbow Molecular 
Weight Marker was used to monitor progress through the gel and to estimate protein 
sizes. 
 
72 
 
Table 9 – 5x Loading buffer for PAGE 
Reagent Final concentration 
Tris.HCl pH 8 225mM 
Glycerol 50% 
SDS 5% 
Bromophenol Blue 0.05% 
DTT 250mM 
Water - 
 
 
 
 
Table 10 – Poly-acrylamide Gel mixtures 
Running Gel Stacking Gel 
Reagent Volume Reagent Volume 
Protogel 8 (National 
Diagnostics) 
2.3ml Protogel 8 (National 
Diagnostics) 
0.39ml 
4x Resolving Gel 
(National Diagnostics) 
1.75ml Stacking Buffer (National 
Diagnostics) 
0.75ml 
Distilled Water 2.842ml Water 1.83ml 
TEMED 7µ l TEMED 3µ l 
10% Ammonium 
Persulphate 
70µ l 10% Ammonium 
persulphate 
15µ l 
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After separation by mass, proteins were transferred from gel to PVDF 
membranes by semi-dry electroblotting. Damp membrane was laid over the gel, and 
this was then covered with filter paper soaked in transfer buffer. A potential of 50v 
was then applied for 45 minutes, causing the protein to migrate out of the gel onto the 
membrane. The membrane was then covered in 5% milk powder in TBS-T for 30 
minutes at room temperature or overnight at 4°C to block. 
Blocked membrane was then transferred to a falcon tube with 10ml of primary 
antibody solution (see Table 11) and gently agitated for 1.5 hours. The membrane was 
then rinsed twice in TBS-T before two longer washing steps of 5 minutes’ agitation in 
TBS-T. Secondary antibody was then washed over the membrane for 45 minutes, 
followed by another wash as before. 
Bound antibody was visualised using an ECL biotin detection kit. The two kit 
solutions were mixed in equal proportion and used to cover the membrane surface. 
After one minute, excess solution was shaken off. Photographic film was then 
exposed to the membrane in a film cassette. After exposure (varying from 30 seconds 
to 5 minutes), membranes were developed using a Fuji automated developer. 
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2.7.6 Antibodies 
Table 11 - Antibodies used in immunoblotting 
Antigen Raised in Source Lot Number 
RIG-i Rabbit Tadaatsu Imaizumi’s lab* -- 
IFNβ   Rabbit Santa Cruz Biotechnology A0203 
IFNβ   Rabbit Abcam 199168 
PKR Rabbit Santa Cruz Biotechnology G3103 
PKR[pT451] Rabbit Abcam 257820 
IRF-3 Rabbit Abcam 203324 
eIF2α[pS52]  Rabbit Invitrogen AHO0802 
*NB: anti-RIG-i antibody was a generous gift from Tadaatsu Imaizumi at the 
Hirosaki University School of Medicine, Japan. 
 
2.7.7 Membrane Stripping 
Stored membranes were stripped of antibody using the membrane stripping 
buffer described in Table 12. Membranes to be stripped were washed in TBS-T for 10 
minutes. Membranes were then submerged in stripping buffer and incubated at 50°C 
for 30 minutes. After stripping, membranes were washed twice in TBS-T before 
blocking in 5% powdered milk in TBS-T. 
 
Table 12 - Membrane Stripping Buffer 
Reagent Final Concentration 
β-mercaptoethanol  100 mM 
SDS 2% 
Tris-HCL pH 6.7 62.5mM 
Distilled Water - 
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2.8  mRNA expression assays 
2.8.1 RNA extraction 
Whole RNA was extracted from cells using TriZOL reagent (Invitrogen). As 
described above, 3x105 cells were seeded into 6-well plates, incubated overnight and 
infected at 100 pt/cell. Two wells were seeded and infected for each sample. At 
appropriate timepoints, medium was aspirated from both wells and 0.75ml of TriZOL 
pipetted onto each monolayer. These samples were combined and stored at -80°C 
until all samples had been collected. After thawing to room temperature, 
manufacturer’s instructions were followed to extract and ethanol-precipitate 
nucleotides from the sample. 
2.8.2 Assessment of RNA purity 
The yield and purity of extracted nucleotides were assessed using the Nanodrop 
spectrophotometer. 1.5µl of each sample was used for the measurement; DEPC-
treated water was used to blank the device. 
The information returned was: 
• Absorbance at 260nm (A260) 
• Concentration in ng/µl  (Calculated from A260) 
• A260/230, an indication of phenol or similar compound contamination 
• A260/A280, an indication of protein contamination 
Generally, an A260/230 of over 1.9 was considered to be pure. Similarly, an 
A260/A280 over 1.8 was considered pure. 
2.8.3 Assessment of RNA integrity 
Purified nucleotides (from RNA extractions or PCR products) were visualised 
using RNAse- free agarose gel electrophoresis, stained with ethidium bromide. Whole 
RNA was assessed for integrity by running a small sample (3-4µl) in a 1% TBE gel, 
made with DEPC-treated water. The expected result for intact RNA was two sharp 
bands representing 28s and 18s rRNAs. Degradation of the RNA sample results in 
smearing of these bands. 
2.8.4 RT-PCR 
DNA was digested using RNAse H and buffers supplied by QIAGEN. After 
inactivation of RNAse, reverse transcription was performed using the Superscript II 
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enzyme and buffers kit, also supplied by QIAGEN. Random primers were used, to 
allow transcription of rRNA and VA-RNAI. Reactions were based on a starting 
template of 2µg total RNA. 
PCR to detect IFNβ mRNA was based on the primers listed in Table 11. GAP-
DH was used as an endogenous control. The PCR was performed using Taq 
polymerase and buffers from QIAGEN. Concentrations of reagents used are listed in 
Table 13; Primer sequences and melting temperatures are listed in Table 14. PCR 
products were visualised on 2% agarose TBE gels. 
 
Table 13 - Reagent concentrations for PCR 
Reagent Volume for IFNβ  PCR Volume for GAP-DH PCR 
10x PCR Buffer (2.5mM 
MgCl2) 
5 µ l  5 µ l  
10mM dNTPs 1 µ l  1 µ l  
Primers mix 5 µ l (to 3 µM each) 5 µ l (to 3 µM each) 
Taq 0.25 µ l 0.25 µ l 
H2O 28.75 µ l 28.75 µ l 
Template (product of RT 
reaction) 
5 µ l 5 µ l 
Total volume 50 µ l  50 µ l  
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Table 14 - Primers for PCR to detect IFNβ mRNA 
Gene Forward Primer Reverse Primer Melting temperatures (°c) 
IFNβ  CACGACAGCTCTTTC
CATGA 
AGCCAGTGATCGAT
GAATCT 
64.4; 63.9 
GAP-
DH 
GTGAAGGTCGGAGT
CAAC 
TGGAATTTGCCATG
GTG 
58.0; 65.5 
 
 
Table 15 - Thermal cycler programme for IFNβ and GAP-DH PCR 
Initial denaturing step 95°c 5 minutes Once 
Denature 95°c  2 minutes  
Annealing 56.5°c  45 seconds 30 cycles 
Extension 72°c  45 seconds  
Final extension 72°c  10 minutes Once 
 
2.8.5 qPCR 
Taqman primers and probes for qPCR were ordered from Applied Biosystems 
after being designed with Applied Biosystems’ Primer Express 3 software. Primers 
and probe for E1A and Hexon were created automatically. VA-RNAI is too short for 
the oligos to be automatically designed, so primers and probes were manually 
designed. Melting temperatures and lengths were kept as close as possible to the 
program’s default settings. 18s rRNA was used as an endogenous control, using 
Taqman Ribosomal RNA Control Reagents. See Table 16 for the sequences and other 
properties of primers and probes. 
Infected cells were harvested by TRIzol extraction, and their nucleotides purified. 
DNA was digested using Ambion’s DNA-free DNAse and deactivator system. Using 
this purified RNA as template, cDNA was produced using Applied Biosystems’ High 
Capacity cDNA Reverse Transcription Kit. Random primers were used to initiate 
reverse transcription of 2µg RNA. 
78 
The purity, concentration and integrity of RNA were confirmed as described 
above. Pure samples were then used as template for real-time PCR (qPCR). These 
reactions used Taqman PCR Master Mix, with primer/probe sets and the 18s rRNA 
detector as an endogenous control (Table 17). 
Reaction mixtures were assembled in triplicate, in 96-well optical reaction plates 
set up in a sterile tissue culture class II safety cabinet. The PCR was run in a 7500 
Real-Time PCR unit from Applied Biosystems using the standard cycler settings. 
 
Table 16 - Primers designed for qPCR.  
Primer Sequence Melting 
temp. 
Secondary 
Structure 
Self-Dimer 
E1A Forward CCAACGAGGAGGCG
GTTT 
67.4 Very Weak No 
E1A Reverse TCCTGCACCGCCAAC
AT 
66.8 None No 
Hexon 
Forward 
GAAGACGAAGTAGA
CGAGCAAGCT 
65.9 None Yes 
Hexon Reverse GCGCCTGCCAAATAC
G 
67.7 None No 
VAI Reverse CCGTTGTCTGACGTC
GCAC 
68.2 Weak No 
VAI Reverse GGGCACTCTTCCGTG
GTCT 
66.6 Weak No 
These data were reproduced from the manufacturer’s Quality Control Sheet. 
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Table 17 - Reagent volumes for real-time PCR using Taqman primers and probes. 
Reagent Volume in each well Volume in Master Mix 
2x Taqman PCR Master 
Mix 
12.5µ l 1000µ l 
Forward primer 
(900nM) 
2.5µ l 200µ l 
Reverse (900nM) 2.5µ l 200µ l 
Probe (2.5µM) 2.5µ l 200µ l 
20x 18s rRNA detector 1.25µ l 100µ l 
Water 1.5µ l 220µ l 
Template 1µ l - 
Total Volume 25µ l 1.92ml  
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2.9  Microarray sample preparation 
NHBE cells were grown according to manufacturer’s instructions then seeded at 
3x105 cells per well in 6-well dishes. After 24 hours, these were infected with dl309, 
dl331 or mock-infected at 100 pt/cell. After two hours, the infection media were 
aspirated and then the monolayers were rinsed with warm HEPES-buffered saline and 
re-fed with 1.5ml of medium. RNA was harvested from the cells using TRIzol 
(Invitrogen) at 6, 12, 18, 24, 28 & 32h after infection. Two wells were seeded and 
infected for each combination of timepoint and virus. RNA from these pairs was 
pooled into a single sample. Three biological replicates of the experiment were 
performed at different times. The same lots of cells and viruses were used for all 
replicates, and cells were grown for the same number of passages before infection. 
Total RNA was extracted from the TRIzol following the manufacturer’s 
instructions. The resulting RNA was cleaned using an additional purification step. 
1/10 volume of NaOAc (pH 5.2) and 2.5 volumes of ethanol were added to each 
sample. RNA was precipitated by incubating this sample at -20°C for two hours. The 
precipitate was pelleted by centrifugation at 15,000g for 20 minutes at 4°C.  This 
pellet was then washed twice with 80% ethanol in DEPC-treated water before drying 
and re-suspending in 30µl DEPC-treated water. This cleaned RNA was assessed for 
concentration, purity and integrity as described above. 
Preparation of samples for the microarray analysis proceeded following the 
protocol supplied by Affymetrix. The chips used were Affymetrix’s U133 plus 2.0 
expression analysis arrays. For each sample, the protocol was begun with 5µg RNA; 
all proceeding measurements and calculations were based on this quantity. Surplus 
RNA samples were stored at -80°C. The procedure is outlined in Figure 13.  
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Figure 13 - Outline of microarray sample protocol. 
 
Briefly, the protocol involves the reverse transcription of total RNA using poly-A 
primers. A second strand of DNA is then synthesised, giving double-stranded cDNA. 
After cleaning, this cDNA is used as a template for the synthesis of “cRNA” 
incorporating biotin-labelled nucleotide analogues. After cleaning, the labelled cRNA 
is hybridised to “probe” DNA sequences embedded on a microchip. The level of 
hybridisation to each probe is measured by scanning the chip for fluorescence 
produced by the biotin labels. 
These fluorescence data are recorded as an image file, which is then processed to 
quantify the level of binding to each probe. The final check for hybridisation 
efficiency and integrity of the sample is by comparison of binding intensities of 3’ 
and 5’ ends of control RNAs. 
2.9.1 Analysis of Microarray Data 
The data analysis and bioinformatics protocol described between this statement 
and the end of the section “Unsupervised hierarchical clustering” was designed and 
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carried out by Dr Claude Chelala, who very kindly gave her time and expertise to this 
section of the project. 
Data analysis was performed in the ‘R’ platform using the Bioconductor software 
packages (http://www.bioconductor.org). Bioconductor is an open source 
environment for statistical analysis of genomic data.205 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9.2 Quality control assessment 
The expression data were read from the .CEL files using the ‘affy’ package. As 
quality control is a crucial step for successful microarray data analysis, scanned 
images were first analysed using Simpleaffy, a Bioconductor package dedicated for 
Affymetrix quality control. It uses a number of assessments including: scaling factor, 
the percentage of probe sets declared ‘present’ (% P) by the detection call algorithm, 
and the 3'/5' ratios of the signal intensity values for two housekeeping genes, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin (ACTB).  
 
Quality control (Simpleaffy) 
 
Normalization (RMA) 
 
Statistical analysis (LIMMA) 
Identification of differentially 
expressed genes 
 
Annotations (Affymetrix) 
            ‘R’ packages 
Figure 14 - Four different steps in the Affymetrix data analysis. 
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2.9.3 Normalization 
Gene expression data were normalized by computing the Robust Multichip 
Average (RMA) directly from the Affymetrix .CEL files. RMA consists of three 
steps: a background adjustment, quantile normalization and finally summarization. 
After background correction, normalization and summarization by the median 
polishing, we applied a filter using the standard deviation of gene expression values to 
select the top 5,000 and top 1,000 genes.  
2.9.4 Identification of differentially expressed genes using LIMMA 
To identify differentially expressed genes we used LIMMA, a Bioconductor 
package designed for the differential expression analysis of microarray data.206 
LIMMA fits a linear model to the expression data for each gene and uses an empirical 
Bayes method to moderate the standard errors of the estimated log-fold changes.  It 
has been shown that LIMMA is particularly useful for analysis of experiments with 
small number of samples.207 Gene annotations were obtained from R packages called 
‘hgu133a’ and ‘hgu133b’. A double cutoff of False Discovery Rate (FDR) < 0.01 and 
a fold change ≥ 2 was selected. 
2.9.5 Unsupervised Hierarchical Clustering 
In order to reveal the relationship between the specimens analyzed, unsupervised 
hierarchical clustering of samples and gene expression values was performed using 
the average linkage method and Euclidean distance measurements in R ‘hclust’ 
package. Average linkage clustering uses the average similarity of observations 
between two groups as the measure. This is a multivariate technique that puts samples 
into unknown groups or clusters suggested by the data itself (and not defined a 
priori). The samples in a given cluster tend to be more similar then samples in 
different clusters. 
2.9.6 qPCR of Genes Selected from Microarray 
Cells were grown in 6-well plates and infected with dl309 or dl331 to 100pt/cell 
as described previously, and their RNA extracted using the TriZol method, also 
described previously. After purification and integrity of RNA were checked by 
Nanodrop and running samples on a nuclease-free agarose gel, samples were reverse-
transcribed and this cDNA used as template for qPCR reactions with the following 
primers: 
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Table 18 - Affymetrix Gene Validation Primer Sequences 
Gene Primer Sequence Tm Produ
ct size 
E2F1 AGGACGTTGGTGATGTCATAGATG 59°c  78bp 
 CGGTGTCGTCGACCTGAACT 60°c   
E2F8 TTCAAGGTGCCAAGGGTTTT 58°c  71bp 
 AGCCGCCTCGCCAAA 58°c   
Zinc Finger 239 TCTTCTTGTGTCATTGCTGAGTTG 58°c  78bp 
 TTCCTGCGAGTGTTAAGGTTGTC 59°c   
ID2 CTGCTTAGATTGGGCAATTCCT 58°c  86bp 
 TGCAGTTGGAAGGTTTTCTTTATATACT 58°c   
DUSP6 AGCCAAGCAATGTACCAAGACA 58°c  66bp 
 CGGGCGTTCTACCTGGAA 58°c   
H2al TTGGCGCGAGCTTTGC 59°c  61bp 
 CCATTTATCGTTTCTTCGTCATGT 58°c   
DMRT2 GGACTCGTGCTCCCTTCAAGT 57°c 67bp 
 AATGCCACCACCTCAGTTCAA 59°c   
RRAD TGGGCACATCATCTGTTTGC 59°c  64bp 
 TTCGAGAAGGCCTCAGAACTG 58°c   
KRT53 TCCCAGCACACCTCAAAACC 60°c  89bp 
 GGCTGCTAACAACGGCTACAT 58°c   
CCNE2 GGTTATTACCAAGCAACCTACATGTC 58°c  117bp 
 ATGGTGTTCAACCTGTGCTCTAAA 58°c   
18s CGCCGCTAGAGGTGAAATTC 58°c   
 CATTCTTGGCAAATGCTTTCG 58°c  
Results of these reactions were normalised against those from commercial 18s 
rRNA primers. 
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2.10 Confocal Microscopy 
Confocal microscopy was used to detect autophagy in cells, based on visualising 
the protein LC3 as it is incorporated into autophagosomes. 
2.10.1 Transfected cells 
U20S cells stably transfected with a plasmid expressing GFP-LC3 fusion protein 
under control of a CMV promoter were a gift from Dr Claire Barra. These transfected 
cells were grown on sterile coverslips in the bottom of cell culture plates, then 
infected with virus at 100pt/cell as described above. At 28 or 48 hours after infection, 
cells were fixed with 2% paraformaldehyde in PBS for 15 minutes at room 
temperature. Coverslips with fixed cells attached were then rinsed briefly with PBS 
before mounting on slides using Invitrogen’s “ProLong Gold” with DAPI mounting 
reagent. The reagent was allowed to set overnight at room temperature, and the 
mounted slides stored at 4°C in the dark before visualisation by microscope. 
2.10.2 Antibody Probing 
After fixing with paraformaldehyde as described above, cells were permeabilised 
with 0.5% Triton X-100 in PBS for 5 minutes at 4°C. This was then removed by 
briefly rinsing with cold PBS. 
Coverslips were immersed in blocking solution (10% FCS in IF Buffer [Table 
19]) at room temperature for 1 hour to block non-specific binding of antibodies. This 
was replaced with primary antibody solution, consisting of primary antibody 
dissolved in IF Buffer, for 1 hour at room temperature. Coverslips were then washed 
three times, each for 5 minutes in IF Buffer. Secondary antibodies were dissolved in 
IF Buffer and used to probe slides for 45 minutes at room temperature, before 
washing the slides a further three times. Finally, the coverslips were briefly rinsed 
(approx 1 second immersion) in sterile water to remove excess salts before mounting 
with ProLong Gold with DAPI, then set overnight and stored at 4°C in the dark. 
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Table 19 - IF Buffer for preparing slides for immunofluorescent microscopy 
NaN3 7.7mM 
BSA 1% 
Triton X-100 0.2% 
Tween-20 0.05% 
PBS - 
 
2.10.3 Acridine Orange Staining 
Cells were grown on coverslips as described above. After allowing attachment, 
cells were either re-fed with E4, 10% FCS or starved by replacing growth medium 
with Hank’s Buffered Salts Solution for approx. 12 hours. Growth medium or HBSS 
was removed and the coverslips rinsed twice with PBS to remove traces of phenol 
red. The coverslips were then immersed in either 1.0µg/ml or 0.1µg/ml acridine 
orange in PBS for 15 minutes at room temperature. They were then rinsed twice with 
PBS to remove excess dye, then fixed, mounted and stored as described above. 
2.11 Flow Cytometry 
2.11.1 For Cell Cycle Analysis 
Cells grown in 6-well plates were arrested at the G1/S phase transition by treating 
with 5µg/ml aphidicolin added to E4, 10% FCS for 16 hours. This arrest was released 
by removing the treated medium and washing cells twice with warm PBS before 
infecting the cells with 100pt/cell of dl331, dl309 or mock-infection, as described 
above. For each virus, two wells (approx. 6x105 cells total) were treated in parallel 
and later combined for reading by flow cytometry. 
At 24 and 28 hours after infection, medium and any floating cells were removed 
from each well and saved in labelled FACS tubes. Adherent cells were trypsinised, 
and the trypsin in each well neutralised using the medium originally taken from that 
well. These cell suspensions were then pelleted and the medium discarded, thus 
saving both adherent and floating cells from each well. 
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Pelleted cells were washed twice with PBS, then fixed in ice-cold 75% Ethanol in 
water. When adding the ethanol, pellets were constantly agitated to avoid formation 
of cell clumps. After 30 minutes at 4°C, cells were pelleted again, ethanol decanted 
and discarded, and the remaining ethanol washed away with PBS. Finally, each 
sample (estimated as approx. 5x105 fixed cells per sample) was treated with 50µl 
RNAse A at 0.5µg/ml in PBS and 250µl phosphatidyl inositol (PI) at 2.5 µg/ml in 
PBS. 
2.11.2 For Detection of Autophagy 
Cells growing in 6-well plates were infected with virus at 200 pt/cell (infections 
carried out as described previously), starved in Hank’s Buffered Salts Solution for 12 
hours or mock-infected and re-fed with E4, 5% FCS. Two wells (approx.  6x105 cells 
in total) were treated in parallel and combined for each sample.  When ready for 
harvesting, growth medium or HBSS was aspirated and the monoloayer rinsed twice 
with PBS before being overlaid with acridine orange at 0.1µg/ml, 1.0µg/ml or 
5.0µg/ml in PBS. After incubation for 15 minutes at room temperature, the stain was 
aspirated off and the cells trypsinised. Trypsin/Versene was neutralised with an equal 
volume of E4, 10% FCS before pelleting the cells. The pellet was then washed twice 
with PBS to remove traces of phenol red before resuspending the stained, washed 
cells in 0.5ml PBS ready to run immediately on the flow cytometer. 
 
2.12 Transfection 
2.12.1 Plasmids 
pAdVAntage plasmid was purchased from Promega. pGEM-7Zf(+) plasmid was 
a gift from Professor Hurst’s lab. It was originally purchased from Promega and has 
since been amplified, re-purified and checked by digestion. 
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2.12.2 Amplifying plasmids 
The plasmid pAdVAntage was bought from Promega and amplified in the lab 
using Top10 Chemically Competent E. coli (Invitrogen): 
One 50µl vial of cells was thawed on ice, half of which was transferred to a 
separate sterile tube for use, the other half re-frozen (-80°C) for future use. 0.5µl of 
plasmid in sterile water was added to the cells and mixed by flicking the tube. After 
keeping this mixture on ice for 30 minutes, the cells were heat shocked at 42°C for 30 
seconds, then immediately re-chilled on ice. Next, 250µl of pre-warmed SOC medium 
was added to the cells. The transformed cells in warmed medium were then 
transferred to a shaking 37°C incubator for 1 hour. The cells were then spread on a 
plate containing 100µg/ml ampicillin and placed in a dry 37°C incubator overnight. 
The following day, four colonies were picked and transferred to 15ml of LB agar 
with 50µg/ml ampicillin. After approx 16h incubation (overnight) at 37°C, each 
culture was pelleted and plasmid DNA extracted with a miniprep kit. 
Transient transfections were carried out using QIAGEN’s Effectene Transfection 
Reagent, following the manufacturer’s guidelines. Specifically, plasmid DNA was 
diluted in buffer EC then mixed with “Enhancer”. After 3 min incubation at room 
temperature, Effectene reagent was added, the mixture vortexed and then incubated 
for a further 5 min. This DNA/Effectene mixture was then mixed with a small volume 
of medium, and then added dropwise to fresh growth medium covering the cell layer. 
Transfections were typically performed in 6-well plates using the reagent volumes 
shown in Table 20. 
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Table 20 - Typical Effectene Transfection Protocol (volumes for 1 well) 
Plasmid DNA 0.4µg 
Volume of DNA (in Buffer EC) 100µl  
Effectene Reagent 10µl  
Enhancer 3.2µl  
Volume of medium mixed with above 600µl 
Final volume of medium in each well 1.6ml 
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Results 
3 VA-RNAI affects Adenovirus replication and 
cytotoxicity 
3.1  VA-RNAI-deleted virus dl331 replicates poorly in normal 
epithelial cell lines 
Our group has demonstrated that VA-RNAI-deleted adenovirus 
replicates poorly in normal human cells when compared to wild-type 
adenovirus. In order to confirm this in my project, replication of dl331 was 
compared to wild-type Ad5 in normal human prostate epithelial cells 
(PrEC). Similarly to our group’s previous findings, dl331 showed over a 
100-fold reduction in replication efficiency compared to wild-type virus 
(Figure 15). 
 
 
Figure 15 - Replication of dl331 and Ad5 in normal human prostate 
epithelial cells. 
 
dl331 was derived from a type 5 adenovirus mutant that had almost the 
entire E3 region deleted, with no genes remaining intact. As described in the 
introduction, the E3 region is predominantly responsible for regulation of 
the whole-body immune response to adenoviral infection. Therefore it is 
generally regarded as dispensable for infections in cultured cancer cells. 
However, for growth in normal cells the functions of E3 may become 
relevant, even in the absence of immune cells. For this reason, wild-type 
Ad5 is not an ideal control virus for investigating the properties of dl331. 
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Instead, dl309 was chosen for use as a control. Like dl331, dl309 was 
derived from Ad5 and has a deleted E3 region; the only major difference 
between dl331 and dl309 is the presence or absence of VA-RNAI. 
Therefore, dl309 is a more useful control for examining the effect of VA-
RNAI deletion.  
Bronchial epithelial cells are the first site of infection for Ad5 during 
the typical route of transmission by aerosol. In order to provide more 
biologically relevant data, replication of dl331 was measured in cultured 
normal human bronchial epithelial cells (NHBE). 
dl331 showed greatly reduced replication in NHBE cells when 
compared to dl309. The overall quantity of infectious virus produced in 
bronchial cells was much lower than that seen in prostate cells (Figure 16). 
Despite this, both cell lines show a very similar pattern of yields between 
VA-RNAI-positive and VA-RNAI-negative viruses. 
 
Figure 16 - Replication of dl331 and dl309 in normal human bronchial 
epithelial cells. 
 
3.2  VA-RNAI-deleted virus dl331 replication is rescued in 
some cancers 
In order to test the hypothesis that cells affected by K-ras mutations are 
able to support replication of VA-RNAI-deleted adenoviruses, two cancer 
cell lines with ras mutations were infected with dl331. The viral yield from 
each was measured by a limiting dilution assay. 
In colon cancer cell line HCT116, dl331 replicated with approximately 
80% of the efficiency of VA-RNAI-positive dl309 (Figure 17). In contrast 
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to these results, replication of dl331 in the metastatic pancreatic cancer cell 
line Suit-2 support of dl331 was more than 10-fold lower than dl309 after 
96 hours (Figure 18). After 72 hours, PANC-1 cells showed a similar 
difference in virus replication, dl331 reaching approximately 10-fold lower 
titre than dl309 (Figure 19). The highest replication for dl331 was seen in 
pancreatic cell line MiaPaCa2, in which the replication of dl331 was almost 
indistinguishable from dl309 at all timepoints (Figure 20). 
These results show that while some cancer cell lines support VA-
RNAI-deleted viral replication at levels equivalent to VA-RNAI-positive 
virus, exceptions do exist. All of the cell lines tested here carry a K-ras 
mutation, suggesting that K-ras mutation is not sufficient to rescue VA-
RNAI’s missing functions. 
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Figure 17 - Replication of dl331 and dl309 in colon cell line HCT116. 
 
 
 
 
 
 
 
 
 
Figure 18 - Replication of dl331 and dl309 in pancreatic cell line Suit-2. 
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Figure 19 - Replication of dl331 and dl309 in pancreatic cell line PANC-
1. 
 
 
 
 
 
Figure 20 - Replication of dl331 and dl309 in pancreatic cell line 
MiaPaCa2. 
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3.3  Viral toxicity - dl331 is less toxic to cancer cells than 
control dl309 
The toxicity of dl331 and dl309 was measured in the same cancer cell 
lines. Following the method for measuring viral toxicity described 
previously (page 69) The EC50 was calculated for each virus in each cell 
line (Figure 21).  
In HCT116, Suit2 and PANC1 cells, the toxicity of dl331 was 
significantly lower than that of dl309. In MiaPaCa2 cells, there was no 
significant difference between the two viruses; indeed, dl331 was actually 
slightly more toxic than dl309. This fits with the replication data observed 
previously. Understanding the root of MiaPaCa2’s support for the 
replication of dl331 could provide a valuable insight into the function of 
VA-RNAI and exploitation of deletion mutants in cancer cells. 
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Figure 21 – EC50 of dl331 and dl309 in four cell lines; cells were seeded 
into 96 well plates and infected with serial dilutions of virus. 
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Cytotoxicity was measured by MTS assay (top panel), and EC50 values 
calculated using Prism (bottom panel). 
 
 
 
4 Known molecular pathways interacting with VA-
RNAI  
In an effort to identify the molecular basis of dl331’s selectivity, several 
key pathways of the antiviral response were analysed. 
4.1  PKR is differentially upregulated in response to infection 
in Suit-2 cells 
HCT116, MiaPaCa2 and Suit-2 cells were infected with dl309, dl331, 
Mock-infected or untreated. After 28 hours, protein lysates were harvested, 
and probed for regulation of Protein Kinase R, PKR. As described earlier, 
PKR is one of the key regulators of the cellular response to viral infection, 
and a known target of VA-RNAI. 
In Suit-2 cells, infection with dl309 and dl331 resulted in a small 
upregulation of PKR when compared to mock or untreated cells. dl331 
infection induced a slightly higher level of PKR expression than dl309 
(Figure 22).  
MiaPaCa2 cells showed no difference between the two viruses in PKR 
upregulation, as expected from the two viruses’ near-identical replication 
and toxicity in this cell line. Unexpectedly, a slight decrease in PKR activity 
is visible after virus infection. 
HCT116 cells also show no increase in PKR expression in response to 
viral infection.  
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Figure 22 – Western blot for dsRNA-activated protein kinase (PKR) in 
HCT116, MiaPaCa2 and Suit-2 cells 28 hours after infection with dl331 
or dl309, mock infection or untreated. 
 
 
Figure 23 - Western blot loading control; Beta-actin levels in the cell 
lysates used for the Western blot for PKR (Figure 22) 
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4.2  PKR activation is differentially regulated by VA-RNAI  
As described in the introduction, PKR is upregulated in response to 
some viral infections but inactive as a kinase until phosphorylated. The 
lysates described above were re-probed for PKR that had been activated by 
phosphorylation.  
28 hours after infection, Suit-2 cells infected with dl331 showed higher 
levels of activated PKR than those infected with dl309 (Figure 24, right 
column). Unexpectedly, mock-infected Suit-2 cells showed a higher level of 
phosphorylated PKR than untreated cells and dl309-infected cells, 
suggesting that the infection protocol might stress the cells and that dl309 
plays an active role in suppressing this stress response. 
MiaPaCa2 cells (Figure 24, centre column) show a much smaller 
increase in PKR activation after infection with dl331 and do not show the 
stress response seen in Suit-2. 
HCT116 cells (Figure 24, left column) show a small increase in PKR 
activation in response to dl331 when compared to dl309, mock infection or 
untreated cells.  
In these cells the canonical function of VA-RNAI remains intact, as it is 
necessary to prevent the virus-induced activation of PKR. 
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Figure 24 - Western blot for phosphorylated PKR in HCT116, 
MiaPaCa2 and Suit-2 cells, 28 hours after infection with dl331 or dl309, 
mock infected or untreated. 
 
 
 
Figure 25 - Western blot loading control; Beta-actin levels in the cell 
lysates used in the Western blot for pPKR (Figure 24) 
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4.3  Phosphorylation of eIF2α  is affected by VA-RNAI 
The previous results confirmed that PKR expression is regulated by 
VA-RNAI. However, to influence the cell’s behaviour PKR must be 
activated by binding dsRNA. The best-characterised target of PKR is the 
initiation factor subunit eIF2α, therefore phosphorylation of eIF2α is a 
useful indicator of PKR activity. 
A phosphospecific antibody was used to detect phosphorylation of 
eIF2α in Suit-2, HCT116, PANC-1 and MiaPaCa2 cells (Figure 26) 28 
hours after infection with dl309 or dl331. 
In Suit-2 and HCT116 cells, much more phosphorylated eIF2α is 
present in response to dl331 infection than infection with dl309, suggesting 
that VA-RNAI-RNA is able to prevent PKR activation in these cell lines. 
In PANC-1 and MiaPaCa2 cells, no difference between dl309 and 
dl331 is discernable. This is as expected for MiaPaCa2 cells: similar levels 
of eIF2α should allow similar levels of virus replication to proceed. 
However, PANC-1 cells showed significant differences in virus replication 
and toxicity despite showing similar levels of eIF2α phosphorylation. 
Therefore the difference in PANC-1 cells’ support for virus replication 
cannot be accounted for by VA-RNAI’s best described function. 
 
 
Figure 26 - Western blot for phosphorylated eIF2α  in Suit-2, HCT116, 
PANC-1 and MiaPaCa2 cells, 28 hours after infection with dl331 or 
dl309. 
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4.4  VA-RNAI’s interaction with the interferon-β  pathway 
Several viruses encode proteins or structured RNA molecules that 
inhibit the activity of PKR, and also inhibit the interferon β response. 
Examples include HIV TAR RNA and its binding protein, Vaccinia virus’s 
K3L protein and Influenza virus’s protein NS1 (reviewed by Gale and 
Katze208). Due to similarities between these molecules and VA-RNAI, its 
interaction with the IFNβ pathway was investigated. Preliminary data from 
our group suggested that VA-RNAI might have a role in regulating IFNβ. 
Previously published work has associated VA-RNAI with both inducing and 
suppressing IFNβ expression (see Introduction for details). As the interferon 
response is such a crucial factor in the success of any viral infection, it is 
important to determine VA-RNAI’s actual effect on the pathway. In an 
attempt to resolve this contradiction, the next antiviral pathway examined 
was expression of IFN-β. 
4.5  VA-RNAI suppresses IFNβ  transcription in PANC1 
As phosphorylation of eIF2α could not explain the viruses’ different 
replication efficiencies and toxicities in PANC1 cells, the IFNβ secretion 
pathway was investigated for this cell line. PANC1 cells were infected with 
either dl331 or dl309. Total RNA was collected 24 hours later, and IFNβ 
levels assessed using RT-PCR (Figure 27). The reaction was normalised by 
controlling cDNA concentration and using constitutively expressed GAP-
DH as an endogenous control. The positive control for IFN-β (left column) 
was approx. 0.5ng of a plasmid encoding the human IFN-β gene. The 
dl331-infected cells showed higher levels of IFNβ expression than those 
infected with dl309. This suggests that the presence of VA-RNAI in dl309 
is suppressing transcription of IFNβ. 
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Figure 27 – RT-PCR for IFNβ expression in tumour cell line PANC-1, 
24 hours after infection with dl331 or dl309. 
 
4.6  VA-RNAI does not suppress IFNβ secretion from PANC-
1 cells 
Following the observation that VA-RNAI suppresses transcription of 
IFNβ in PANC-1 cells, levels of secreted IFNβ were examined by western 
blotting (Figure 28). As before, PANC-1 cells were infected with dl331 or 
dl309. At 12 or 24 hours after infection, medium was collected from the 
cells. The proteins were then concentrated by centrifugation through a 
filtration column. Concentrated media were treated like cell suspensions for 
PAGE and subsequent blotting for IFNβ. 
No difference in levels of secreted IFNβ is apparent. Unexpectedly, 
medium from mock-infected cells contained IFNβ at levels comparable to 
virally infected cells. This may be a reaction to some part of the infection 
protocol itself, although the exact cause has not yet been determined. 
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Figure 28 - Western blot for IFNβ secreted by PANC-1 cells 24 hours 
after infection with dl309 or dl331. 
 
4.7  VA-RNAI has very little influence on IFNβ  transcription 
in Suit-2 cells 
Following the same pattern as the experiment in PANC-1 cells, Suit-2 
cells were infected with dl331 or dl309. Total RNA was harvested at 12 and 
24 hours then tested for IFNβ mRNA by RT-PCR. 
A small difference in IFN β mRNA levels was visible at 12 hours after 
infection, with dl331 showing slightly higher levels. However, at 24 hours 
post-infection no difference in levels of IFNβ mRNA was visible by RT-
PCR (Figure 29).  The reduced replication of dl331 in Suit-2 cells cannot be 
attributed to increased IFNβ expression.  
 
 
 
Figure 29 – RT-PCR to detect IFNβ  mRNA in Suit-2 cells 12 and 24 
hours after infection with dl331 or dl309. 
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4.8  VA-RNAI expression leads to upregulation of RIG-I in 
PANC-1 
In preparation for studying RIG-i dimerisation and activation, PANC-1 
cells infected with either dl331 or dl309 were assayed for upregulation of 
RIG-i. Although constitutively expressed in most cells, RIG-i can be 
upregulated as an interferon-stimulated gene (ISG). Although not a standard 
marker, levels of this protein may indicate levels of other ISGs. 
Whole cell protein lysates collected 24 hours post-infection were 
analysed by denaturing PAGE and immunoblotting (Figure 30). 
As expected, mock-infected cells showed a basal level of RIG-i 
expression. Expression of RIG-i was highest in response to Ad5 infection, 
followed by dl309, which expressed RIG-i at approximately basal levels. 
Unexpectedly, dl331-infected cells showed expression levels lower than 
mock-infected cells. The cause of this is not immediately obvious, although 
it should be noted that the accumulation of RIG-i may not necessarily 
indicate its activity. 
 
 
Figure 30 - Western blot of RIG-I expression in PANC-1 cells, 24 hours 
after infection with dl309 or dl331 or mock infected. 
 
4.9  VA-RNAI does not influence IRF3 translocation to the 
nucleus in Suit-2 cells 
IRF3 is a key virus-induced inducer of IFNβ (see Introduction for 
detail). As IRF-3 is induced by signals including the Toll-like receptors and 
RIG-I, it seemed interesting to determine whether IRF3 activation is 
influenced by VA-RNAI expression. 
Suit-2 cells were infected with dl331 or dl309. Twenty-four hours later, 
cytoplasmic and nuclear protein fractions were separately harvested and 
analysed by PAGE followed by immunoblotting for IRF3 (Figure 31). 
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Figure 31 - Western blot for IRF3 in cytoplasmic (Cy) and nuclear (Nu) 
fractions of Suit-2 cells, 24 hours after infection with dl331 and dl309. 
 
No difference in levels of IRF-3 translocation was observed between 
the viruses. This suggests that VA-RNAI does not target the key activators 
of IFR3, including the Toll-like receptors and dsRNA-induced RNA 
helicase RIG-i. 
4.10 The interferon-β  pathway: summary of results 
After confirming that dl331 acts as a replication-selective oncolytic 
virus, replication assays confirmed that this activity is not dependent on K-
ras status as previously believed. VA-RNAI’s interaction with the IFNβ 
pathway appears to be at least partially cell line-dependent.  
The pathways believed to be involved in VA-RNAI’s activity are 
complex and frequently mutated or otherwise defective in cancers. In order 
to escape these complications, the focus of the project moved to work in 
normal cells. Results from these non-transformed cells can be expected to 
give a more realistic idea of VA-RNAI’s normal function. 
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5 VA-RNAI Protects Adenovirus From 
Macroautophagy 
 
5.1  eIF2α  phosphorylation is linked to induction of 
autophagy  
As shown previously, VA-RNAI is able to suppress the virus-induced 
phosphorylation of eIF2α in some cell lines. In yeast and in mammalian 
cells, phosphorylation of eIF2α in response to various cellular stresses can 
lead to induction of macroautophagy.74,75,209 As discussed previously, 
several other viruses are known to lead to induction of autophagy in 
mammalian cells. This may lead to degradation of the virus and inhibition 
of its replication (e.g. HSV1), or may be essential for the viral replication 
cycle (e.g. reovirus). At the time of writing, only very limited information 
about the interaction of adenovirus with the autophagic pathways is 
available. 
 In order to determine whether VA-RNAI has an effect on the 
induction of autophagy in response to adenovirus infection, the cell lines of 
interest were infected with dl331, dl309, Ad5 or mock-infected then assayed 
for signs of virus-induced autophagy. 
5.2  dl331 induces autophagy in U20S cells expressing an 
GFP-LC3 fusion protein 
As a preliminary experiment to detect the induction of autophagy in 
response to viral infection, U20S cells stably transfected with GFP-LC3 
were infected with dl309, dl331 or Ad5. At 28 hours after infection, the 
coverslips were fixed, stained with DAPI and mounted for visualisation on 
the confocal microscope. The GFP-LC3 fusion protein was visible in the 
cytoplasm under high gain as a diffuse cloud (green channel). In cells 
infected with dl309, a small number of small, brighter structures were 
visible in the cytoplasm. Cells infected with dl331 contained markedly more 
of these structures, often much larger than seen in dl309-infected cells 
(Figure 32).  These punctate structures strongly resemble the 
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autophagosomes described previously by other groups, as reviewed by 
Klionsky et al. 2007180 and described earlier in this thesis’s introduction. 
 
.  
Figure 32 - U20S cells stably transfected with a plasmid expressing 
GFP-LC3 (shown in green), mock-infected or infected with Ad5, dl309 
or dl331. 
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5.3  Autophagy in virus-infected U20S cells is associated with 
eIF2α  phosphorylation 
In order to confirm the link between phosphorylated eIF2α and virus-
induced autophagy, U20S cells expressing GFP-LC3 were again infected 
with dl309 or dl331, and then fixed after 28 hours. These cells were probed 
with an antibody against phosphorylated eIF2α before DAPI staining and 
mounting. As shown in Figure 33, large autophagic vesicles were seen in 
dl331-infected cells, but not in dl309-infected cells. Additionally, cells 
containing autophagosomes (green channel) also have high levels of 
phosphorylated eIF2α (red channel). 
 
Figure 33 - U20S cells stably transfected with a GFP-LC3 plasmid, 
infected with dl309 or dl331. GFP-LC3 is green, phosphorylated 
eIF2alpha is shown in red. 
 
 
5.4  The autophagy observed in dl331-infected U20S cells is 
not an artefact of overexpression 
Overexpression of GFP-LC3 has previously been shown to form 
aggregate structures resembling autophagosomes, independently of the 
autophagic pathway.187 To ensure that the structures detected by microscopy 
are autophagosomes rather than aggregates of GFP-LC3, this construct was 
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not used in subsequent experiments. Instead, endogenous LC3 was detected 
by immunofluorescent microscopy.  
Untransfected U20S cells growing on glass coverslips were starved in 
HBSS for 16 hours or grown in normal conditions, then fixed. After 
permeabilisation and blocking, the slides were probed with: rabbit anti-LC3 
antibody only; rabbit IgG followed by goat anti-rabbit secondary antibody; 
or both primary and secondary antibodies.  
As expected, no signal was seen in cells probed with primary antibody 
only, confirming that the cells and primary antibody do not autofluoresce 
under UV light (Figure 34, left panel). Cells probed with secondary 
antibody only showed minimal background signal, confirming that the 
secondary antibody does not target any endogenous cellular proteins (Figure 
34, middle panel). After probing with both antibodies, cells grown in normal 
conditions showed a few, small dots in the cytoplasm (Figure 34, right 
panel). Starved cells stained with both antibodies showed a high number of 
larger structures, presumably starvation-induced autophagosomes (Figure 
35, right panel). 
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Figure 34 - U20S cells grown in normal conditions, probed with 
primary (rabbit anti-LC3), secondary (fluorescent goat anti-rabbit) or 
primary and secondary antibodies. 
 
 
 
Figure 35- U20S cells starved in HBSS for 16 hours, probed with 
primary (rabbit anti-LC3), secondary (fluorescent goat anti-rabbit), or 
primary and secondary antibodies. 
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These experiments confirmed that infection with dl331 but not dl309 
could induce autophagy in transfected and normal U20S cells. They also 
showed that autophagy induction correlates with eIF2α phosphorylation. 
Therefore in this cell line, it seems that VA-RNAI is able to prevent virus-
induced autophagy via the eIF2α pathway.  
5.5  Viral induction of autophagy corresponds to eIF2α  
phosphorylation in cell lines 
Next, cells from the original panel of cell lines were infected with dl331 
or dl309, fixed after 28 hours and probed for LC3, following the same 
protocol as described above. 
For each combination of cell line and virus, ten fields were 
photographed using the confocal microscope’s 40x lens. Each set of ten 
fields contained a total of 250-350 cells. These cells were examined and 
visible autophagosomes counted to quantify the induction of autophagy in 
response to each infection (Figure 36).  
For Suit-2 cells, infection with dl309 led to a small but significant 
(p<0.0001) upregulation of autophagy when compared to mock-infected 
cells. Infection with dl331 increased autophagosome formation almost 
three-fold when compared to dl309 (p<0.0001), confirming that VA-RNAI 
is necessary to suppress induction of autophagy in this cell line. 
MiaPaCa2 cells infected with either dl309 or dl331 showed a 
significant increase in autophagosomes over mock-infected cells (P≤0.002). 
As expected, however, no significant difference was found between the two 
viruses. 
HCT116 cells infected with dl331 showed a slight increase in 
autophagosome formation over cells infected with dl309; however, this did 
not reach significance. Similarly, no significant difference was seen 
between dl309- and mock-infected cells.  
Representative images of infected cells probed for LC3 are shown in 
Figure 37. 
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Figure 36 - Induction of autophagy 28 hours after infection with dl331, 
dl309 or mock infection. Autophagosomes were detected using 
immunofluorescence with an antibody against LC3, as described above. 
Autophagosomes were counted in approximately 300 cells for each 
combination of cell line and infection. 
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Figure 37 – LC3 protein expression in Suit-2, MiaPaCa 2 and HCT116 
cells 28 hours after infection with dl331, dl309 or PBS (mock infection). 
As described earlier, autophagy was detected using 
immunofluorescence with an antibody targeting LC3 (shown in green). 
5.6  Infection with dl331 leads to more cells strongly 
expressing E1A than infection with dl309 
Even in Suit-2 cells, not all cells infected with dl331 showed induction 
of autophagy. This could be due to incomplete infection of cells on the 
slide, or due to a proportion of successfully infected cells failing to undergo 
autophagy. Suit-2 and MiaPaCa2 cell lines showed the most and least 
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induction of autophagy respectively, so were chosen to examine whether 
induction of autophagy correlates with infection. 
5.6.1 By confocal microscopy 
After fixation and permeabilisation, the cells were then probed with 
antibodies against both LC3 and adenovirus E1A. E1A was chosen as it is 
expected to be present at high levels in the cell very soon (typically within 
four hours) after infection. Representative images of these cells are shown 
in Figure 38. The pattern of autophagy induction matched that previously 
observed, with vesicles only induced at high levels by dl331 in Suit-2 cells. 
Unexpectedly, only a minority of cells stained positive for high levels of 
E1A in any combination of cell line and virus. In Suit-2 cells infected with 
dl331, those cells containing high levels of E1A uniformly contained high 
numbers of autophagic vesicles. 
 
Figure 38 - Suit-2 or MiaPaCa2 cells 28 hours after infection with 
dl331, dl309 or PBS (mock infection). Immunofluorescence was used 
with antibodies targeting LC3 (green), and adenovirus E1A (red). 
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Cells expressing markedly high levels of E1A compared to the majority 
were identified visually and counted. Unexpectedly, Suit-2 cells showed 
significantly more high-expressing cells after infection with dl331 than 
dl309 (p=0.0009). HCT116 and MiaPaCa2 cells also showed slight 
increases, although this did not reach significance in either cell line. 
 
 
Figure 39 - Proportion of cell population expressing high levels of E1A 
28 hours after infection. Ten fields totalling approximately 300 cells 
were counted for each combination of cell line and virus. “**” 
represents a significant difference, in this case p=0.0009. 
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5.6.2 By Western blotting 
Cell lysates harvested from infected cells confirm that E1A protein 
accumulates to higher levels in dl331-infected cells than in cells infected 
with dl309 (Figure 40). 
 
Figure 40 - Western blot for adenovirus E1A in HCT116, MiaPaCa2 
and Suit-2 cells, 28 hours after infection with dl331 or dl309, mock 
infected or untreated.  
 
 
Figure 41 - Western blot loading control; Beta-actin levels in the cell 
lysate used for the Western blot for E1A (Figure 40). 
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5.7  Adenovirus E1A co-localises with autophagosomes 
While only a minority of cell undergoing autophagy stained strongly for 
E1A, a weaker signal was still visible in almost all of them. In these cases, 
most of the detectable viral protein was co-localised with the 
autophagosomes (Figure 42).  
 
 
 
Figure 42 – Co-localisation of Adenovirus E1A with autophagosomes. 
Suit-2 cells infected with dl331, probed for LC3 (green) and E1A (red). 
 
As discussed earlier, several viruses are known to exploit 
autophagosomes during their replication cycle. However, given VA-RNAI’s 
function in blocking virus-induced autophagy, it seems more likely that this 
co-localisation indicates the degradation of viral proteins through the 
autophagic pathway. 
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5.8  VA-RNA expression from plasmid rescues dl331 from 
virus-induced autophagy 
5.8.1 Expression of VA-RNAs from plasmid 
In order to confirm that deletion of VA-RNAI is responsible for the 
difference in autophagy induction between dl331 and dl309, cells were 
transiently transfected with a plasmid expressing VA-RNAI (pAdVAntage) 
or a control plasmid (pGEM 5zf(+)) before infection. Quantitative RT-PCR 
was used to confirm continued expression of VA-RNAI in cells 48 hours 
after transfection (Figure 43). 
 
 
 
Figure 43 - Expression of VA-RNAI from cells transfected with 
pAdVAntage or the vector control pGEM 5zf(+), 48 hours after 
transfection.
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5.8.2 Using confocal microscopy to detect autophagy 
Suit-2 cells were transiently transfected with the VA-RNA expressing 
plasmid pAdVAntage or the vector control plasmid pGEM, then infected 
with dl309 or dl331. Twenty-eight hours after infection, cells were fixed 
and probed with antibodies against LC3 (green) and adenovirus E1A (red). 
As expected from previous results, cells transfected with the control 
plasmid showed higher levels of autophagy after infection with VA-RNAI-
deleted virus dl331 than after infection with the control dl309 (Figure 44, 
top row).  
In cells expressing VA-RNAI from the pAdVAntage plasmid, no 
induction of autophagy was seen after infection with either virus (Figure 44, 
bottom row). This result confirms that the VA-RNAs alone are sufficient to 
suppress virus-induced autophagy in this cell line. 
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Figure 44 - Expression of VA-RNAs from the plasmid pAdVAntage 
prevented virus-induced autophagy in Suit-2 cells. Suit-2 cells were 
transfected with pGEM or pAdVAntage then, after 24 hours, infected 
with dl331 or dl309. 28 hours after infection, cells were fixed and 
probed with antibodies against LC3 (green) and adenovirus E1A (red). 
 
5.8.3 Use of Acridine Orange to detect autophagy 
As discussed earlier, the dye Acridine Orange (AO) is often used to 
stain cells for detection of acidic vesicular organelles. While this is not a 
direct measure of autophagy, late stage autophagosomes do merge with 
lysosomes to form acidic “autolysosomes” and should cause AO to 
fluoresce. This provides an alternative method for quantification of 
autophagy in a cell population. 
To confirm that AO selectively stains acidic vesicular organelles and 
that AVOs are seen more in autophagic cells, Suit-2 cells were starved for 
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28 hours before fixing and staining with AO. Examination of the cells by 
confocal microscopy confirmed an increase in red fluorescent puncta in 
starved Suit-2 cells (Figure 45). This agrees with the expected result, the red 
puncta presumably being acidic vesicular organelles and possibly 
autophagosomes. Due to an incompatibility between the AO staining and 
LC3 immunofluorescence protocols, it was not possible to test how well the 
AO puncta co-localises with LC3-positive autophagic vesicles. 
 
 
Figure 45 - Confirmation that acridine orange (AO) fluoresces red in 
acidic vesicular organelles. Suit-2 cells were starved for 24 hours before 
fixing and staining with acridine orange solution. 
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5.8.4 Flow cytometry of Acridine Orange-labelled cells confirms 
the results from confocal microscopy 
Twenty-eight hours after infection, living cells were stained with 
acridine orange in the manner described previously (page 87) and then 
analysed by flow cytometry.  
For each cell line, mock-infected cells were used to establish a baseline 
for red fluorescence from acidified acridine orange. Because the lowest 
expression was expected from cells expressing VA-RNAI and VA-RNAII, 
this baseline was set using cells transfected with the pAdVAntage plasmid. 
Based on this, a threshold was set at which approximately 10% of cells 
would be detected. 
In Suit-2 cells (Figure 46), expression of VA-RNAI and VA-RNAII 
from the plasmid pAdVAntage prevented any increase in red fluorescence 
in infected cells. Cells transfected with the control plasmid pGEM had a 
higher background level of fluorescence than those transfected with 
pAdVAntage. Infection with dl309 increased red fluorescence above this 
high background; as expected, infection with dl331 produced the largest 
increase. These results confirm that expression of VA-RNAI is a strong 
suppressor of virus-induced autophagy in Suit-2 cells. 
MiaPaCa2 cells (Figure 47) transfected with pAdVAntage show a 
similar resistance to the formation of acidic vesicular organelles (AVOs) 
following viral infection. As expected from the confocal microscopy data 
(Figure 36, page 114), MiaPaCa2 cells not expressing VA-RNAI did show a 
small increase in AVOs. Somewhat unexpectedly, infection with dl331 led 
to a higher induction than dl309. While VA-RNAI does not seem to play a 
role in suppressing eIF2α phosphorylation or subsequent autophagosome 
formation in this cell line, it does appear to suppress the formation of AVOs 
induced via some other pathway. 
The results from HCT116 cells (Figure 48) matched those expected 
from the confocal microscopy data, with no increase in red fluorescence 
resulting from either viral infection, with or without expression of the VA-
RNAs. 
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Figure 46 - Suppression of AVO formation by VA-RNAI in Suit-2 cells.  
 
Figure 47 - Suppression of AVO formation by VA-RNAI in MiaPaCa2 
cells 
 
Figure 48 - Suppression of AVO formation by VA-RNAI in HCT116 
cells 
 Figure 46, Figure 47 & Figure 48 
 
Cells were transfected with pAdVAntage or pGEM then, 24 hours after 
transfection, infected with dl331 or dl309 or mock infected. Formation of AVOs 
was detected using the lysosomotropic dye acridine orange. Mean results of three 
experiments were subjected to two-tailed unpaired t-tests; significant differences 
are indicated. 
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5.9  VA-RNA expression affects autophagy-related proteins 
5.9.1 VA-RNA expression prevents conversion of LC3I to LC3II 
in Suit-2 cells 
As described previously, cells were transfected with pAdVAntage or 
control plasmid pGEM. Twenty-four hours after transfection, cells were 
infected with dl331, dl309 or mock-infected. Cell lysates were harvested 
twenty-eight hours after infection.  
In cells transfected with the control plasmid pGEM, no increase in the 
conversion on LC3I to LC3II was seen in response to infection in HCT116 
cells (Figure 49, left column) or MiaPaCa2 cells (Figure 49, centre column). 
In Suit-2 cells, levels of both LC3I and LC3II increased in response to 
dl331, compared to dl309 and mock infections (Figure 49, right column). 
While an increase in LC3II:LC3I ratio can indicate an increase in 
autophagosome formation (subject to the caveats described in the 
introduction; see page 56), the cause of this increase in both LC3I and 
LC3II is less clear.  
This accumulation of LC3I and LC3II was not observed in cells 
transfected with pAdVAntage (Figure 50). 
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Figure 49 – Ratio of LC3I : LC3II in cells transfected with control 
plasmid pGEM. Cells were transfected then, 24 hours later, infected 
with dl331 or dl309, mock infected or not treated. Lysates were 
harvested 24 hours after infection. 
 
 
Figure 50 - Ratio of LC3I : LC3II in cells transfected with 
pAdVAntage. Cells were transfected then, 24 hours later, infected with 
dl331 or dl309, mock infected or not treated. Lysates were harvested 24 
hours after infection. 
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5.9.2 VA-RNA expression prevents accumulation of Beclin 1 in 
MiaPaCa2 cells 
Although constitutively present in cells and regulated by its association 
with other proteins, Beclin 1 has been reported to accumulate in some cells 
in response to pro-autophagic signals. It may therefore be useful as an 
alternative marker of the induction of autophagy. 
In HCT116 cells transfected with control plasmid pGEM, Beclin 1 
expression was unaffected by viral infection (Figure 51, left column). 
MiaPaCa2 cells transfected with pGEM showed increased expression in 
response to dl331 when compared to dl309 or mock infection (Figure 51, 
middle column). Unexpectedly, Suit-2 cells transfected with pGEM showed 
higher expression of Beclin-1 in response to dl309 than dl331. (Figure 51, 
right column).  
As expected, HCT116 and Suit-2 cells transfected with pAdVAntage 
showed no difference in Beclin 1 expression in response to viral infection 
(Figure 53, left and right columns respectively). MiaPaCa2 cells transfected 
with pAdVAntage still showed a higher level of Beclin-1 expression in 
response to dl331 infection (Figure 53, centre column).  
This failure of VA-RNAI expression to restore the host reaction to 
dl331 to its reaction to dl309 suggests that there may be some additional 
difference between the two viruses. However, as this difference in Beclin-1 
expression is the only one so far not found to be dependent on VA-RNAI 
expression, it is extremely difficult to hypothesise on what may be causing 
it. 
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Figure 51 - Accumulation of Beclin-1 in cells transfected with control 
plasmid pGEM.  
 
 
Figure 52 - Western blot loading control; KU70 levels in the cell lysates 
used in the Western blot for Beclin-1 (Figure 51) 
 
 
 
Figure 53 - Accumulation of Beclin 1 in cells transfected with 
pAdVAntage 
 
 
Figure 54 - Western blot loading control; KU70 levels in the cell lysates 
used in the Western blot for Beclin 1 (Figure 53) 
Figure 51, Figure 52, Figure 53, Figure 54 
 
Cells were transfected with pGEM or pAdVAntage then, 24 hours later, 
infected with dl331 or dl309, mock infected or not treated. Cell lysates were 
harvested 28 hours after infection. 
 130 
 
5.10 VA-RNA expression from plasmid also rescues Suit-2 cells 
from starvation-induced autophagy 
As described in the introduction, the centre of a solid tumour is often a 
challenging environment for cancer cells. Cancer cells’ typically high levels 
of metabolic activity increase their requirements for nutrients and oxygen, 
while inadequate vascularisation severely limits the supply. Cancer cells 
have previously been shown to survive this starvation or lack of growth 
factors through the induction of autophagy. Given this potential importance 
of starvation-induced autophagy for a developing tumour’s survival, the 
effect of VA-RNAI expression on starvation-induced autophagy was 
investigated. 
Suit-2 and MiaPaCa2 cells growing on glass coverslips were starved by 
replacing their growth medium with Hanks Balanced Salt Solution (HBSS) 
for 24 hours. As in previous confocal microscopy experiments, they were 
then fixed and probed with LC3 antibody followed by a green fluorescent 
secondary antibody, before DAPI staining and mounting onto slides. 
 Representative images of starved cells are shown in Figure 55. As 
expected, starvation led to a dramatic upregulation of autophagy in 
untransfected Suit-2 cells and those transfected with the control plasmid 
pGEM. Suit-2 cells transfected with pAdVAntage and therefore expressing 
VA-RNAI were protected from starvation-induced autophagy. MiaPaCa2 
cells did not show significant upregulation of autophagy after starvation, 
with or without VA-RNAI expression. 
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Figure 55 - Suit-2 and MiaPaCa2 cells transfected with pAdVAntage or 
control plasmid pGEM then starved for 24 hours. Cells were then fixed 
and probed for LC3 (shown in green). 
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6 VA-RNAs as a potential therapeutic agent 
6.1  VA-RNAs sensitise Suit-2 cells to 5-FU treatment 
As described in the introduction, several cancer cell lines appear to rely 
on autophagy to survive treatment with certain chemotherapeutic drugs. One 
such agent is the pyrimidine analogue 5-fluorouracil (5-FU) which, after 
modifications within the cell, becomes incorporated into replicating DNA, 
causing single- and perhaps double-strand breaks. Examples of this include 
the inhibition of autophagy having been shown to enhance the cytotoxicity 
of 5-FU in human colon cancer cells and rat oral keratinocytes.210,211 
Autophagy’s role in aiding recovery from DNA damage is presumed to help 
cancer cells survive this crisis.  
Previous results have shown that VA-RNAI is a powerful inhibitor of 
virus- and starvation-induced autophagy in Suit-2 cells but has little effect 
in MiaPaCa2 cells. Therefore the effect of VA-RNAI expression on the 
cytotoxicity of 5-FU was tested. 
Cells were grown in 6-well plates until approximately 80% confluent 
then transfected with the commercial plasmid pAdVAntage or the vector 
control pGEM-7zf(+), following the Effectene transfection protocol 
described previously. After overnight incubation, cells were re-seeded into 
96-well plates at a density of 2000 cells/well.  
As described for the viral cytotoxicity assay (diagrammed in Figure 
11), the plate layout included outer wells filled with PBS to minimise loss 
through evaporation and a column containing medium but no cells, to serve 
as a blank for the spectrophotometer. 
Four rows of ten wells were seeded with each transfected line. Cells in 
the leftmost well of each row were treated with 5-fluorouracil at 2.5mg/ml, 
and this mixture diluted tenfold across the 10 wells of each row. To control 
for cytotoxic effects of the drug’s carrier solution, duplicate plates were 
prepared and treated with serial dilutions of the carrier solution, 6.79mg/ml 
NaOH in sterile distilled water. 
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After a further five days’ incubation, the cytotoxicity was measured by 
MTS assay. Curve fitting and calculation of EC50 values was performed 
using Prism statistical software. 
In Suit-2 cells, expression of VA-RNAs from the plasmid halved the 
dose of 5-FU required to kill 50% of cells (EC50) when compared to the 
control plasmid pGEM or untransfected cells (p=0.018) (Figure 56). The 
cell killing by the vehicle, NaOH dissolved in PBS, was identical in the 
three conditions, confirming that this was a sensitisation to 5-FU 
specifically, rather than a general weakening of the cells. 
 In MiaPaCa2 cells, expression of VA-RNAs from the plasmid did not 
produce any difference in EC50 of 5-FU. Unexpectedly, transfection with 
either plasmid may have sensitised the cells relative to untransfected cells, 
although this did not reach significance (p=0.053).  
There was no detectible cytotoxicity from NaOH in MiaPaCa2 cells. 
However, while it is possible that transfecting MiaPaCa2 with any plasmid 
creates a specific sensitivity to 5-FU treatment, it could also be the case that 
transfection simply makes the cells less robust generally, but that the 
difference in NaOH sensitivity was simply too small for this assay to detect.  
 
 
Figure 56 - VA-RNAI expression sensitised Suit-2 cells to treatment 
with the pyrimidine analogue 5-FU. 
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7 Affymetrix microarray analysis of gene expression 
in response to VA-RNAI 
7.1  Gene expression profile in NHBE cells after infection 
with dl309 and dl331 
None of the results gathered so far have shown a plausible mechanism 
for VA-RNAI’s ability to protect viral replication from the intracellular 
immune response. Additionally, this type of work performed in tumour cells 
is of limited use due to the frequent mutation of pathways involved in the 
anti-viral response. It is difficult to be certain whether interactions between 
VA-RNAI and the cell are truly representative of its normal mechanism. For 
example, the cell line-specific upregulation of IFNβ may be the result of cell 
lines’ different mutations in the complex pathways involved. 
In order to resolve this problem and to shed new light on the normal 
course of Adenovirus infection in its host bronchial epithelial cells, a 
microarray analysis was employed. NHBE cells infected with dl331 or 
dl309 and mock-infected cells were harvested for total RNA at regular 
timepoints after infection. Based on data from the timecourse experiment 
above, timepoints for analysis were selected before, after and during 
upregulation of VA-RNAI. 
7.1.1 Kinetics of VA-RNAI expression in normal cells 
In order to study further the effects of VA-RNAI expression on normal 
cells’ response to the virus, two normal epithelial cell cultures were 
selected. These were normal human prostate epithelial cells (PrEC) and 
Ad5’s normal target, normal human bronchial epithelial cells (NHBE). 
These cells were infected with dl331 or dl309; total RNA was harvested at 
regular timepoints after infection. 
Firstly, levels of VA-RNAI expression at each timepoint was measured 
by quantitative RT-PCR, normalised against 18s rRNA (Figure 58). 
Efficiency of the Taqman primer / probe combination was tested by 
analysing a standard curve (Figure 57). Although efficiency was relatively 
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low at 66%, this is sufficient to reliably observe large changes in VA-
RNAI’s expression levels over time. 
VA-RNAI was detected at a constant low level from 4 to 12 hours post-
infection. Expression then climbed rapidly between 18 – 24 hours before 
reaching a plateau at 28 hours post-infection. This suggests that in the 
course of a normal infection, VA-RNAI expression is upregulated at 
approximately 18 hours post-infection and it is not subsequently degraded. 
Because VA-RNAI is transcribed by RNA polymerase III, this timing of 
expression does not necessarily coincide with other genes in the L1 co-
termination region. 
As expected, cells infected with dl331 did not express detectable levels 
of VA-RNAI at any point in the timecourse. 
 
Figure 57 - Standard curve of Taqman primer / probe combination for 
VA-RNAI. The template for this reaction was total RNA extracted from 
NHBE cells 24 hours after infection with dl309. 
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Figure 58 - Expression levels of VA-RNAI in PrEC and NHBE cells 
infected with dl309. Data were normalised to levels of 18s rRNA. 
 
7.1.2 RNA quality and integrity 
Before analysis by microarray, all RNA preparations were checked for 
concentration, purity and integrity. Concentration and purity were assessed 
using the Nanodrop spectrophotometer. A sample of results from this 
analysis is presented in Table 21. 
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Table 21 - Typical results from Nanodrop analysis of whole RNA 
samples. 
Sample 
Name 
ng RNA / µ l Absorbance 
at 260nm 
A260 / 
A230  
A260 / 
A280 
Mock 24h 1305.0 32.626 2.14 1.99 
dl309 24h 1256.8 31.421 2.23 1.98 
dl331 24h 1305.1 32.629 1.96 2.00 
Mock 28h 1153.4 28.836 2.22 1.97 
dl309 28h 950.22 23.755 1.75 1.95 
dl331 28h 1219.0 30.476 2.23 1.99 
dl309 6h 
(rpt) 
1099.6 27.492 2.20 1.97 
dl331 6h 
(rpt) 
1237.4 30.936 2.23 1.97 
DEPC-Water 
(Blank) 
0.05 0.001 -0.18 0.59 
NB: "rpt" indicates that a sample is from the second biological repeat of this 
experiment. 
 
The ratio A260 / A280 gives an indication of protein contamination 
levels in a sample. A value of 1.8 upwards is generally considered pure. The 
ratio A260 / A230 indicates contamination with phenol and similar organic 
compounds. A value of 1.9 is generally considered completely pure. 
After establishing that samples are sufficiently concentrated and pure, 
the RNA’s integrity is checked by electrophoresis through a nuclease-free 
agarose gel and visualisation with ethidium bromide. A sample gel image 
(matching the samples in Table 21) is shown in Figure 59. The abundant 28s 
and 18s rRNA molecules form sharp bands in the gel, indicating that the 
RNA is intact; if degradation had occurred, the rRNA would be smeared 
down the gel. 
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Figure 59 - Example of RNA samples run on an agarose gel to check 
integrity. Visible bands are 18s and 16s rRNA. Samples marked "rpt" 
are from the second biological repeat of this experiment. 
 
The Affymetrix microarray chips contain inbuilt quality controls. 
Known quantities of control oligonucleotides are added to the RNA samples 
at the earliest stage of the preparation protocol to act as hybridisation 
controls, allowing the chips’ intensities to be normalised. In addition, the 
chips contain probes designed to hybridise to several sites along specific 
cellular cRNA molecules. The binding intensities of these controls are 
plotted against their position along the cRNA molecules. The gradient of 
this graph indicates how much degradation the cRNA has suffered.  
The results of this control are shown in Figure 60. All of the chips show 
a similar gradient, indicating similar levels of RNA degradation. Therefore 
any observed changes in gene expression levels are likely to be due to 
cellular changes rather than differential RNA degradation between samples. 
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Figure 60 - RNA degradation controls. Each line represents the mean 
values for a single chip. 
7.1.3 Unsupervised clustering 
The first stage of data analysis after the quality control checks was 
preliminary automated clustering of the data. Two clusters are reproduced 
here, based on the top 5000 (Figure 61) and top 1000 (Figure 62) most 
variable genes. In both analyses, cells infected by the two viruses tend to 
cluster together at 6, 12 and 20 hours post-infection. At 24 and 28 hours 
post-infection, dl331 and dl309 separate from each other (labelled 
“V331.[timepoint]” and “V309.[timepoint]” respectively). This suggests 
that between 20-24 hours the two viruses begin to evoke different patterns 
of cellular gene expression. This coincides with the accumulation of VAI, 
which was earlier shown to reach its highest levels between 20-24 hours 
(Figure 58). 
Looking at the cluster produced by the top 5000 genes, it seems that 
some of the most active genes are unrelated to the viral infections. The 
mock-infected samples (labelled “WT.[timepoint]”) cluster with the virus-
infected samples at 12 and 20 hours, indicating shared changes in gene 
expression. This may be due to the cells differentiating as they grew, or 
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responding in unison to stress induced by the infection protocol. However, 
as the infection progresses this becomes less significant: as time goes by, 
the mock-infected cells are separated from the virus-infected cells by 
increasing degrees.  
This effect is also apparent when focusing on the top 1000 genes. Here, 
the 6 and 12 hours timepoints of both virus- and mock-infections all cluster 
together, away from the later timepoints. However, for the later timepoints 
the mock-infected cells form a subgroup separate from the virus-infected 
cells. This suggests that more of the shared changes in expression between 
virus- and mock-infected have been discarded in this model. 
Finally, both analyses reveal a large difference between the mock- and 
virus-infected cells at 6 hours post-infection. This is presumably due to the 
cellular response to the endocytosis and eventual escape of viral particles. 
These events could be expected to provoke a large response from the cell, 
and occur before viral genes to suppress the host response have been 
expressed. It would be interesting to repeat this experiment using 
replication-incompetent viral particles to confirm this. 
 141 
 
Figure 61 - Clustering of microarray data based on top 5000 genes. “WT” are mock-infected, “V331” = dl331, “V309” = 
dl309. 
 
 
Figure 62 - Clustering of microarray data, based on top 1000 genes. “WT” are mock-infected, “V331” = dl331, “V309” = 
dl309. 
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The next stage of analysis was to take the top 5000 genes and compare 
their expression between different conditions. The first analysis examined 
genes whose expression had changed more than twofold since the previous 
timepoint. For example: for each infection levels of IFNB1 at 20 hours were 
compared to levels of IFNB1 at 12 hours; if a two-fold or greater difference 
was observed, the gene was scored as positive. The total numbers of genes 
whose expression had changed since the last timepoint is reported in the 
Venn diagrams in Figure 64. 
These diagrams show that the expression of a large number of genes is 
changed between 12 and 20 hours. 106 of these are common to dl331, dl309 
and mock-infected cells. A total of (427+98=) 525 genes respond differently 
to dl331 and dl309. Overall change in gene expression continues at a similar 
rate between 20 and 24 hours; 614 genes change over these 4 hours, 
compared with 1211 in the previous 8 hours. Similarly, genes that respond 
uniquely to either dl309 or dl331 appear at a similar rate: 247 in 4 hours 
compared to 525 in the previous 8. The most marked difference is seen 
between 24 and 28 hours, during which time only 189 genes are detected to 
change. Interestingly, this reduction in rate of gene regulation is also seen in 
the mock-infected cells. This suggests that this could be a consequence of 
continuing cellular differentiation, or some other response to tissue culture 
conditions. 
Figure 63 - Venn Diagrams showing differential gene expression between infections.  Mock-
infected cells are marked "WT". The timepoints shown are 20, 24 and 28 hours. 
Figure 64 - Venn Diagrams showing differential gene expression between infections.  Mock-
infected cells are marked "WT". The timepoints shown are 20, 24 and 28 hours. 
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An alternative analysis is to compare dl331- and dl309-infected cells 
directly, with changes due to culture conditions taken into account. This is 
based on a similar comparison to that used above, with gene expression 
levels at one timepoint being subtracted from those at the previous 
timepoint. In addition, the resulting list of genes from dl309 and dl331 are 
compared to mock-infected cells; this should remove most gene changes 
due purely to culture conditions. The resulting diagrams are shown in Figure 
65. 
 
This analysis produces much more manageable numbers of genes. 
Interestingly, the number of genes that change between 12 and 20 hours is 
disproportionately high when compared to either 20-24 or 24-28 hours: 891 
in 8 hours, compared to 210 or 213 in 4 hours. 
The proportion of genes that are similarly regulated in response to 
infection with dl309 and dl331 also changes over time. At 20 hours, 214 
genes respond similarly to the two viruses, 24% of the total changes. In 
contrast, during 20-24 hours and 24-28 hours this figure is reduced to 11%. 
This fits with the idea of VA-RNAI’s influence on the cell increasing 
between 20-24 hours, increasing the differences observed between the two 
viruses. 
7.1.4 Candidate Genes 
These analyses produced lists of genes whose expression changed after 
upregulation of VA-RNAI. Two of these lists are reproduced in the 
Figure 65 - Venn diagrams showing differential gene expression between 
dl331 and dl309 infected cells, normalised against mock-infected cells. 
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Appendix, in supplementary tables 1 and 2. These genes were filtered based 
on the criteria of: 
• Being regulated early after VA-RNAI expression (change in 
expression between 20-24 hours after infection); 
• This up- or down regulation is sustained through 24 and 28 
hours after infection; 
• A greater than 1.5-fold change in expression in response to the 
virus. 
 
From these lists of genes regulated in response to expression of VA-
RNAI, several genes were selected for further investigation. This selection 
was based on a combination of the magnitude and duration of the 
differential regulation and the known functions of the gene.  
Name Symbol Function 
 E2F Transcription 
Factor 1 
E2F1 Associated with driving Go-G1 
transition 
E2F Transcription 
Factor 8 
E2F8 Associated with driving Go-G1 
transition 
Cyclin E2 CCNE2 Associated with G1-S transition 
Inhibitor of 
Differentiation Factor 2 
ID2 Disrupts Rb proteins to allow cell 
cycle progression 
(Histone family member 
2 al) 
H2al A structural histone protein; one of 
many histone proteins strongly 
upregulated. 
 
The upregulation of these genes and an additional five Histone cluster 
genes after infection with dl331 suggest a link between VA-RNAI and 
control of the cell cycle. Specifically, the upregulation of VA-RNAI at 28 
hours after infection appears to selectively suppress transcription of host 
genes involved in cell cycle progression.  This is somewhat counterintuitive, 
as Adenovirus requires the cell to enter S phase for successful replication 
and eventual viral release.  
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7.1.5 Validation of gene expression data by qPCR 
Although gene expression analysis by microarray has become a robust 
process, the large number of genes whose expression are measured on the 
chip increases the expected number of false positive results. While 
extensive internal controls and statistical techniques are used to minimise 
this possibility, it is nevertheless prudent to confirm the results using an 
independent assay. 
NHBE cells from the same batch as those used for preparing the 
microarray samples were infected with dl331, dl309 or mock-infected, and 
the RNA harvested at 24 hours, using the same protocol and reagents as for 
the microarray experiment. 
PCR primers were designed against the five selected genes (see 
Methods section for primer sequences), and quantitative RT-PCR used to 
measure gene regulation in response to viral infection. The results observed 
(Figure 66) broadly match the expected pattern, with all five genes being 
upregulated to some degree in dl331-infected cells, when compared to those 
infected with dl309 or mock infected. 
 
 
Figure 66 - Regulation of host gene expression in infected NHBE cells. 
Cells were infected with dl331 or dl309 or mock infected, then total 
RNA harvested 28 hours after infection. Gene expression was analysed 
by RT-qPCR and normalised against 18s rRNA. 
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Gene p Value (comparing dl331 and dl309) 
Cyclin E2 p<0.0001 
E2F1 p=0.0015 
E2F8 p=0.0337 
H2al p=0.0006 
ID2 p=0.0005 
Table 22 – Unpaired two-tailed t-test results for gene expression 
regulation in infected NHBE cells; see Figure 66 for data and 
explanation of protocol. 
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7.1.6 Regulation of cell cycle-associated genes is similar between 
Suit-2 cells and NHBE cells 
Preliminary to investigating this finding further, these results were 
validated in Suit-2 and MiaPaCa2 cell lines. PCR primers were designed for 
these five genes (see Methods section for parameters and sequences). RNA 
was then harvested from cells 28 hours after infection, reverse transcribed 
and the resulting cDNA used as template for real-time PCR.  18s rRNA was 
used as an endogenous control. 
Results representative of two experiments are shown in Figure 67 and 
Figure 68. Each gene is normalised to its expression level in mock-infected 
cells, allowing comparison of gene induction by dl309 and dl331. Gene 
expression in Suit-2 cells appears to follow the trend established in the 
microarray data, with expression of the cell-cycle associated genes being 
elevated in dl331-infected cells. Although this trend was seen in two 
biological repeats of this experiment, in each case only Cyclin E2 (CCNE2) 
reached statistical significance between the two viruses, (p=0.0012 in the 
experiment shown here). 
Unsurprisingly, MiaPaCa2 cells did not follow this trend and showed 
no significant differences in regulation of these host genes between viruses. 
Interestingly, no difference was observed between the mock-infected cells 
and cells infected with either virus. Possibly, the cells’ constant growth state 
masks the virus’ early attempts to manipulate the cell cycle. 
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Figure 67 - Regulation of host gene expression in infected Suit-2 cells. 
Cells were infected with dl331 or dl309 or mock infected, then total 
RNA harvested 28 hours after infection. Gene expression was analysed 
by RT-qPCR and normalised against 18s rRNA. Statistical significance 
values are shown below, in Table 23. 
 
 
Gene p Value (Comparing dl331 with dl309) 
Cyclin E2 p<0.0001 
E2F1 p=0.0012 
E2F8 p=0.0387 
H2al p=0.1707 
ID2 p=0.0031 
Table 23 – Unpaired two-tailed t-test results for gene expression 
regulation in infected NHBE cells; see Figure 66 for data and 
explanation of protocol. 
 
 
Figure 68 - Regulation of host gene expression in infected MiaPaCa2 
cells. Cells were infected with dl331 or dl309 or mock infected, then 
total RNA harvested 28 hours after infection. Gene expression was 
analysed by RT-qPCR and normalised against 18s rRNA. The 
differences observed were not statistically significant. 
 149 
 
To validate further the expression of these genes in cancer cell lines, 
protein lysates harvested from infected cells were probed for ID2, one of the 
genes apparently suppressed by VA-RNAI expression (Figure 69). In 
lysates from Suit-2 cells, a small increase in ID2 is discernible in cells 
infected with dl331, when compared to those infected with dl309. Indeed, 
Suit-2 cells infected with dl309 express marginally less ID2 than mock-
infected cells.  
Unexpectedly, lysates from MiaPaCa2 cells infected with dl331 also 
appear to contain more ID2 than those from cells infected with dl309. 
Lysates from HCT116, however, do not show any discernible change in ID2 
levels in response to infection with either virus. 
 
 
Figure 69 - Western blot for ID2 in Suit-2, MiaPaCa2 and HCT116 
cells. Cells were infected with dl331 or dl309, and lysates collected after 
28 hours. 
 
Figure 70 - Western blot loading control; Beta-actin levels in the lysates 
used in the Western blot for ID2 (Figure 69). 
 
7.1.7 Expression of VA-RNAI alone does not induce cell cycle-
associated genes 
The downregulation of genes promoting cell cycle progression seems 
like an unintuitive step for the virus. It was important to determine whether 
this behaviour is a direct response from the cell to VA-RNAI expression, or 
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a (possibly unintended) consequence of VA-RNAI’s role in modulating the 
host cell’s response against the virus. 
Results are shown in Figure 71 and Figure 72. No significant 
differences in the expression of the genes examined was found in either cell 
line; the overall trend seen in previous experiments was also absent. This 
result confirms that VA-RNAI’s influence on these genes’ expression is part 
of its role in suppressing the host cell’s antiviral response, and not a direct 
response from the cell to accumulation of VA-RNAI. 
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Figure 71 - Regulation of host gene expression in transfected Suit-2 
cells. Cells were transfected with pAdVAntage, pGEM 7Z(f)+ or 
untransfected. 28 hours later, total RNA was collected and gene 
expression analysed by RT-qPCR. 
 
 
 
Figure 72 - Regulation of host gene expression in transfected MiaPaCa2 
cells. Cells were transfected with pAdVAntage, pGEM 7Z(f)+ or 
untransfected. 28 hours later, total RNA was collected and gene 
expression analysed by RT-qPCR. 
7.1.8 VA-RNAI expression does influence cell cycle progression 
in Suit-2 cells 
After establishing that VA-RNAI causes several key genes in the cell 
cycle regulatory pathway to be upregulated and that this pattern is at least 
partly reproduced in Suit-2 cells, cell cycle analysis was performed on 
infected Suit-2 and MiaPaCa2 cells. Cells were synchronised by growing in 
the presence of aphidicolin for 16 hours, then released from cell cycle arrest 
and immediately infected.  
Unexpectedly, analysis of harvested Suit-2 cells shows a transient but 
significant increase in S-phase cells 24 hours after infection with dl309 
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relative to dl331 (p=0.0167), with cells infected with dl331 showed a profile 
very similar to mock-infected cells. This increase in S-phase cells after 
infection with dl309 but not dl331 is surprising, given the upregulation of 
cell-cycle progressing genes originally seen in the microarray results for 
NHBE and seen as a trend in Suit-2 cells. 
In contrast, MiaPaCa2 cells do not show a significantly different cell 
cycle profile between the two viruses. This too is consistent with the 
microarray and qPCR results. While it is at odds with the elevated ID2 level 
shown in dl331-infected cells, the level of ID2 is not the only factor 
controlling the transition into S-phase.   
 
Figure 73 - Cell cycle analysis of Suit-2 cells infected with dl331, dl309 
or mock infected, then harvested after 24 or 28 hours. At 24 hours, 
infection with dl309 leads to higher induction of S-phase than dl331 
(p=0.0167) 
 
 
Figure 74 - Cell cycle analysis of MiaPaCa2 cells infected with dl331, 
dl309 or mock infected, then harvested after 24 or 28 hours. 
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8  Discussion 
 
Several types of modified adenovirus have been trialled as cancer 
therapies. Success as a monotherapy has been very limited so far.115,116,212 
However, the combination of cancer-selective viruses with conventional 
therapies shows some clinical efficacy. As our understanding of the 
interactions between adenovirus and cancers improves, new generations of 
adenovirus are showing increasing promise in animal studies and early 
clinical trials. 
The use of VA-RNAI-deleted adenovirus for cancer therapy has shown 
some success during in vivo studies.104,124 However, the basis of these 
viruses’ selectivity is not completely clear. Understanding this may make 
further enhancements of the virus possible, whether by suggesting 
techniques to improve selectivity or by informing a choice of “payload” 
gene to enhance toxicity. In the longer term, understanding the basis of the 
virus’ selectivity will allow clinicians to match the virus to susceptible 
tumour types. 
8.1  VA-RNAI deleted virus is selective for some cancer cell 
lines; this is not solely dependent on ras mutation 
The initial aim was to confirm that VA-RNAI-deleted adenovirus dl331 
selectively replicates in some cancer cell lines. In two lines of non-
transformed epithelial cells (NHBE and PrEC), dl331 replication was 
reduced more than 100-fold when compared with VA-RNA-intact control 
virus. By contrast, dl331 replication in cancer cell lines PANC-1 and 
HCT116 was comparable to wild-type virus. 
It has previously been suggested that dl331’s efficient replication in 
cancer cells is due to a mutation in K-ras complementing VA-RNAI’s 
function, or that a simple over-expression of ras is sufficient.112,124 It was 
theorised that the ras status of cell lines supporting replication of VA-RNAI 
deleted viruses contributed to suppressing the phosphorylation of eIF2α and 
thus obviating VA-RNAI’s best-characterised function. This theory is not 
limited to the virus-host interactions of adenoviruses. Reovirus infection 
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leads to the activation by phosphorylation of PKR, apparently in a ras-
controlled manner.213 In a closer analogy to dl331, an influenza virus with 
the eIF2α phosphatase NS1 deleted (dlNS1) shows a similar pattern of 
selective replication, also apparently rescued by over-expression or 
mutation of ras.214 Similarly, an HSV-1-derived oncolytic mutant, R3616, 
was found to replicate preferentially in cell lines where the ras pathway was 
upregulated.215 
PKR shows a reduced ability to autophosphorylate in murine cells with 
oncogenic ras, although whether this is a direct effect of ras itself or a 
currently unknown downstream effector remains unclear.216 Although the 
mechanism has not been determined, this supports the idea that the 
selectivity of VA-RNAI-deleted viruses for cancer cells is based on the 
common ras mutation. 
However, dl331 showed poor replication in K-ras mutated Suit-2 and 
PANC-1 cells. This confirmed that dl331 is not solely selective for K-ras 
mutated cells, re-opening the question of which cancer-associated 
mutation(s) are responsible for rescuing dl331’s replication. This result 
agrees with the findings of Schümann and Dobblestein, published after this 
work was begun, who were able to manipulate the ras status of cell lines to 
test its effect on the selectivity of VA-RNA-deleted adenoviruses.106 
Cytotoxicity studies in cancer cell lines showed that dl331 causes less 
cell death than dl309 per plaque-forming unit in three of the four cell lines 
tested, correlating with the virus replication results. This impaired cell 
killing activity is a potential weakness of dl331 as a cancer therapy. 
However, once the basis of the virus’s selectivity is better understood, it 
may be possible to increase the virus’s toxicity to cancer cells. Several 
approaches to increasing toxicity of an oncolytic virus have been explored 
previously. 
A virus can be armed with the ability to express directly cytotoxic or 
pro-apoptotic proteins such as p53. A related technique is to make the virus 
express a prodrug-converting enzyme such as nitroreductase to create an 
alkylating agent,217 or thymidine kinase to sensitise cells to nucleoside 
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analogues such as ganciclovir.218 The power of RNA interference (RNAi) 
techniques to silence expression of key oncogenes makes shRNA an 
appealing payload. Oncolytic adenoviruses have been constructed to carry 
shRNA targeting ras,219 hTERT220  and the mRNA encoding the tumour 
antigen Ki-67.221 In each case, the virus was successful in inducing 
apoptosis in infected cells, leading to the significant inhibition of xenograft 
tumour growth in nude mice. Similar results were achieved using an 
oncolytic adenovirus expressing shRNA targeting survivin to induce 
apoptosis.222 
VA-RNAI is known to be targeted by the Exportin 5 and DICER 
pathways necessary for the function of shRNAs98,111,223 and possibly to 
down-regulate siRNA and microRNA biogenesis.224 It therefore seems 
plausible that VA-RNAI-deleted adenoviruses could become selective and 
unusually efficient shRNA delivery vectors. 
Endogenous genes may also be modified to enhance anti-tumour 
efficacy. For example, previous studies have shown some success at 
enhancing virus toxicity in vitro by deleting the anti-apoptotic genes E1A 
CR2 or E1B-19kD.212 
While these techniques have shown considerable promise, as is 
common for gene therapy and oncolytic therapy approaches, efficient 
delivery to solid tumours remains challenging.  
8.2  VA-RNAI influences eIF2α  phosphorylation but this 
alone cannot explain its function 
VA-RNAI expression did suppress PKR upregulation and 
phosphorylation – presumed to be indicative of its activation – in Suit-2 
and, to a lesser extent, HCT116 cells. No difference in PKR expression or 
phosphorylation was observed in MiaPaCa2 cells. This matched the pattern 
suggested by the replication and toxicity results, in that upregulation and 
activation of PKR correlates with poor viral replication and toxicity. 
Presumably the unknown factor associated with ras mentioned above is 
present at high levels in MiaPaCa2 cells. 
 156 
As expected, phosphorylation of PKR’s target eIF2α was regulated by 
PKR activation in Suit-2 and HCT116 cells. Also as expected, MiaPaCa2 
cells, which showed no increase in PKR activation, showed no increase in 
eIF2α phosphorylation. These data follow the pattern expected from VA-
RNAI’s canonical function of protecting the virus from an intracellular 
response by blocking eIF2α phosphorylation.  
Unexpectedly, although VA-RNAI expression did significantly increase 
replication and toxicity in PANC-1 cells, it was not linked with eIF2α 
phosphorylation. This confirmed published results that support for viral 
replication is not necessarily controlled by VA-RNAI’s inhibition of eIF2α 
phosphorylation.106 Since this section of the work was performed, Zhang 
and Samuel have published evidence supporting the idea that PKR activity 
is not the sole mechanism of VA-RNAI activity. In agreement with the 
results shown here, their data confirm that knockdown of PKR is not 
sufficient to restore the replication efficiency of dl331.225 
One or more of PKR’s other proposed targets (e.g. STAT1 or the 
upregulation of c-fos, c-jun and NF-κB212) may be involved in the 
intracellular antiviral response, and therefore a target of VA-RNAI’s 
modulatory response. However, it also seems very likely that another 
pathway entirely is involved in VA-RNAI’s protection of the virus. 
Independent of PKR, the viral infection of a cell can trigger the production 
of various other defensive signals, most notably type I interferons and 
products of their signalling cascade such as TNF-α and NF-κB. 
8.3  VA-RNAI’s activity is not reliant on control of interferon 
production 
IFNβ transcription was suppressed by VA-RNAI in PANC-1 cells, but 
not in Suit-2, HCT116 or MiaPaCa2 cells. This suppression of IFNβ at 24 
hours post-infection did not result in an observable change in IFNβ 
secretion. Possibly the observed suppression of IFNβ transcription in 
PANC-1 cells was a transient effect, too brief to have a large impact on 
accumulation of secreted IFNβ. Alternatively, transcript availability of 
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IFNβ might not be the limiting factor. Instead, translation of IFNβ could be 
limited along with all other host genes by the virus-imposed switch to cap-
independent translation resulting from L4-100k’s interaction with the host 
kinase and translation initiation factor eIF4E.226 
Similarly, expression of the dsRNA-sensing RIG-i did not seem to be 
influenced by the presence of VA-RNAI. There was, however, an increase 
in RIG-i expression 24 hours after infection with Ad5 when compared to the 
other infections (mock, dl309 and dl331). This upregulation was not seen in 
either of the mutant viruses. This difference seems likely to be due to dl331 
and dl309’s shared deletions in the E3 region. Unfortunately, without 
detailed further study that is outside the scope of this project, it is 
impossible to ascertain exactly which genes are involved. 
As described in the Introduction, intracellular pathogens may be 
detected by their binding to pathogen-associated molecular pattern receptors 
(PAMPs or PRRs) such as the Toll-like receptors (TLRs). TLRs are more 
typically expressed in inflammatory and antigen-presenting cells than in 
somatic tissues.227 Activation of the TLRs is a powerful stimulus for the 
production of type I interferons and, during infections in dendritic cells, IL6 
and other inflammatory cytokines.228  
These receptors tend to be found in endosomes and, as such, may be fed 
peptide fragments by the autophagic and other degradative pathways. TLR3 
and TLR9 recognise dsRNA and unmethylated CpG motifs typical of viral 
DNA, respectively. TLR2 is also involved in detecting adenoviral infections 
in some cell types, although its ligand has not been identified. In order to 
determine whether their activation level is changed by expression of VA-
RNAI, the subcellular localisation of IRF3, a signalling molecule 
immediately downstream of these receptors, was monitored. Expression of 
VA-RNAI did not alter the proportion of IRF3 localised to the nucleus in 
Suit-2, the cell line that showed the most consistent difference between 
dl331 and dl309. It therefore seems unlikely that TLR signalling is one of 
the determining factors in a cell line’s support for replication of  VA-RNAI-
deleted virus.  
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The failure of VA-RNAI to activate TLR3 is somewhat surprising 
given that VA-RNAI has specifically evolved to be bound by the dsRNA-
binding domains of PKR and other dsRNA-sensing molecules.  
A low activation of TLR9 might be expected from an adenovirus 
infection, given the adenovirus genome’s low incidence of stimulating CpG 
motifs.48 
8.4  VA-RNAI and macroautophagy 
8.4.1 Virus-induced eIF2α  phosphorylation correlates with 
induction of macroautophagy 
Although my data have shown that the PKR - eIF2α pathway cannot be 
the sole mechanism for VA-RNAI’s activity, the established link between 
eIF2α phosphorylation and the induction of autophagy presented an 
attractive hypothesis. Specifically, that a novel function of VA-RNAI could 
be an inhibitor of macroautophagy in infected cells, protecting the virus 
from degradation and exposure to the adaptive immune system.  
Confocal microscopy of U20S cells expressing a GFP-LC3 fusion 
protein confirmed that autophagy is upregulated in cells infected with dl331 
when compared to those infected with dl309 or mock infected. These cells 
were probed with an antibody against phosphorylated eIF2α, and stronger 
signal was seen in cells infected with dl331 that dl309, confirming that VA-
RNAI inhibits eIF2α phosphorylation in those cells.  Additionally, high 
levels of phospho-eIF2α within a given cell correlated with high numbers of 
autophagosomes visible within that same cell; this supported the hypothesis 
that increased levels of autophagy would result from increased eIF2α 
phosphorylation.  
The mechanism of eIF2α’s induction of macroautophagy is currently 
unknown. Continued accumulation of eIF2α leads to a downregulation of 
cap-dependent translation within the cell, eventually leading to an increase 
in translation of ATF4 and, later, CHOP, also called GADD153. These act 
as pro-apoptotic signals, pushing the cell toward death.229,230 However 
apoptosis and autophagy appear to be mutually incompatible pathways; 
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each programme appears to down-regulate the other. It has therefore been 
suggested that the timing of eIF2α phosphorylation may play a role in 
determining its result, whether in terms of concurrence with other stress 
signals or simply duration of the signal.230  
In the case of a cell infected with dl331, the virus expresses several 
proteins to suppress induction of apoptosis. It seems plausible that these 
viral anti-apoptotic proteins play a determinative role in pushing the cell’s 
response to this stress signal toward autophagy rather than apoptosis, 
although further experimentation would be necessary to confirm this. 
eIF2α is also strongly associated with the collection of malformed 
proteins into endoplasmic reticulum quality control compartments (ERQC). 
ERQCs are pericentriolar enclosures in which misfolded or simply unfolded 
proteins are collected as part of the UPR.231,232 However, the role of eIF2α 
in aiding the formation of these enclosures does not seem related to its role 
in autophagy, as the contents are not processed into autophagosomes.232 
Indeed, by lowering the unfolded protein load in the cell, this activity of 
eIF2α seems likely to be removing a pro-autophagic signal from the cellular 
environment. 
Due to the concerns over GFP-LC3 becoming incorporated into 
aggresomes or becoming associated with membranes of the endoplasmic 
reticulum, fluorescent immunohistochemistry was used to confirm these 
result with endogenous levels of LC3 expression. The selectivity and 
specificity of both the primary and secondary antibodies were confirmed. 
VA-RNAI expression was necessary to suppress virus-induced 
autophagy in Suit-2 cells, although this suppression was not complete; 
although cells infected with dl309 had significantly fewer autophagosomes 
per cell than those infected by dl331, mock-infected cells had fewer still. 
MiaPaCa2 cells showed a small but significant upregulation of 
autophagy in response to both viruses when compared to mock-infected 
cells. No difference in the number of autophagosomes per cell was observed 
between the two viruses. 
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Western blotting for LC3 yeilded ambiguous results, showing an 
increase in both LC3I and LC3II in dl331-infected cells compared to dl309- 
and mock-infected cells. This does not match the expected pattern from 
induction of autophagy. While it is possible that this represents an 
upregulation of LC3II expression and its conversion to LC3II for 
incorporation into autophagosomes, this cannot be confirmed without 
further control experiments including performing a loading control for the 
Western blot and the use of bafilomycin as described in the Introduction. 
Unexpectedly, VA-RNAI expression was not sufficient to prevent the 
accumulation of Beclin 1 in MiaPaCa2 cells after infection with dl331, 
while infection with dl309 led to no such accumulation. This could indicate 
that there is some difference between the two viruses beyond the deletion of 
the VA-RNAI promoter in dl331. The complete sequence for dl331 has 
never been published, so such a small uncharted difference is possible. 
However, as this putative difference in the activity of the virus is very 
limited and cell-line dependent, it seems likely that this unexpected 
behaviour is due to the cell line more than the virus. For example, the 
prolonged and high expression of the VA-RNAs from the plasmid could be 
somehow priming the MiaPaCa2 cells to respond differently when a new 
source of the RNAs is established. Alternatively, the difference could be 
due to the rate of production of VA-RNAs, which might be expected to be 
higher in cells expressing it from the virus in addition to the plasmids. 
Unfortunately, at this stage the true cause of this difference is unknown and 
so these hypotheses remain purely speculative. 
Taken together, the results from Suit-2 and MiaPaCa2 cells appear to 
confirm the hypothesis that induction of autophagy is largely dependent on 
eIF2α phosphorylation status. The small increase in autophagy in the 
circumstances where extensive eIF2α phosphorylation is not expected (Suit-
2 infected with dl309; both MiaPaCa2 infections) could be accounted for by 
some other shared pathway involved in autophagy induction. For example, 
the PI3-K dependent active transport of adenovirus into the cell could be 
expected to have an effect on mTOR regulation.233 
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8.4.2 HCT116 cells appear totally resistant to autophagy 
Unexpectedly, HCT116 cells showed no induction of autophagy in 
response to infection with either virus. Later attempts to induce autophagy 
in HCT116 by starvation also failed, confirming that this deficiency is not 
due to viral autophagy inhibitors being unusually efficient in this cell line.  
Western blots probing for LC3 and Beclin 1 confirmed that these pro-
autophagic proteins are present at levels similar to those seen in Suit-2 and 
MiaPaCa2. The modified form of LC3 – LC3II – was detected by Western 
blot in HCT116 cells, confirming the presence and activity of ATG3 and 
ATG8, the proteins responsible for this modification. However, the 
conversion of LC3I to LC3II was not influenced by viral infection, 
suggesting that the deficiency could lie in one of the autophagy-inducing 
genes. 
 As described in the Introduction, it is not uncommon for 
tumourigenesis to involve the loss or suppression of pro-autophagic genes. 
However, it is unclear what the relevant mutation in HCT116 cells might be. 
This cell line has homozygous wild-type (pro-autophagic) PTEN234 and 
does not appear to have abnormally high expression of (anti-autophagic) 
Bcl-2.235 Unfortunately, no additional reports of autophagy gene expression 
in HCT116 cells are currently available in the literature. The resistant nature 
of this cell line against induction of autophagy is interesting, and certainly 
warrants further investigation. 
8.4.3 Infection with dl331 leads to more cells strongly expressing 
E1A than infection with dl309 
In Suit-2, MiaPaCa2 and HCT116 cells, only a minority of cells 
(between 30% and 5%) showed high levels of expression of adenovirus 
E1A. When viewed with a higher gain, all cells examined expressed some 
of the viral protein, confirming that this effect was not due to only a subset 
of cells becoming infected. 
Unexpectedly, a greater proportion of cells were high-expressing in 
dl331-infected cultures than in those infected with dl309, although this only 
reached statistical significance in Suit-2 cells (p<0.005).  
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As E1A is expected to accumulate rapidly at the early times in infection 
and then decrease to lower levels, the high-expressing cells could be in the 
early stages of a second wave of infection. In this case there are two 
possible explanations. Firstly, dl331 may have infected the cells less 
efficiently than dl309, leaving a larger population of uninfected cells to be 
targeted by the progeny virus when it is eventually released. This seems 
unlikely: VA-RNAI is not carried in the viral capsid and therefore its 
deletion from the genome should make no difference to the efficiency or 
speed of cell entry and early gene expression. The second possibility is that 
dl331 has a faster replication and release cycle than dl309. There is no 
obvious reason why such a difference would exist. A small shortening of the 
viral genome could lead to a dramatic increase in the speed at which 
genome copies accumulate, due to the PCR-like exponential increase in 
genome copies tending to amplify very minor differences in initial template 
availability. However, the genomes of dl331 and dl309 are very similar in 
length: the two viruses share deletion of the E3 region, and dl331 has an 
additional deletion of only 29 base pairs, in the intragenic promoter region 
of VA-RNAI.121 It therefore seems implausible to expect a faster replication 
cycle for dl331 than dl309 based on a difference in genome length. 
Expression of VA-RNAI appears to contribute to an effect limiting the 
accumulation of E1A in infected cells. Expression of proteins from the 
adenovirus major late transcription unit (MLTU) down-regulates expression 
of the early genes including E1A.236 As VA-RNAI expression is known to 
influence the expression patterns of other late genes,121 it is conceivable that 
VA-RNAI expression has an indirect effect on the expression of E1A during 
late stages of infection.  
It has previously been shown that the difference between mRNA levels 
of E1A from Ad2 and Ad5 could be partially determined by the relative 
efficiency of their export from the nucleus.121,237 Although this has yet to be 
confirmed, it seems possible that VA-RNAI’s near-saturation of the 
Exportin-5 nuclear mRNA export pathway could influence the export and 
stability of E1A mRNA at late times in infection. 
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8.4.4 Adenovirus E1A co-localises with autophagosomes 
Although only a minority of cells expressed high levels of E1A, all 
examined cells expressed E1A at a lower level. In cells with visible 
autophagosomes, E1A was often seen to co-localise with the 
autophagosomes. Several RNA viruses have been shown to rely on co-
localisation with autophagosomes or autophagosome-like structures for 
successful replication and exit from the cell, including coronaviruses, 
picornaviruses and murine hepatitis virus. However, DNA-based viruses 
that have been seen to associate with autophagosomes, such as Herpes 
Simplex Virus, do not seem to benefit from the association. Indeed, HSV-1 
is known to be degraded inside autophagosomes.74 
The HSV-1 neurovirulence protein ICP34.5 has been mentioned 
previously in this discussion as being analogous to VA-RNAI, as it redirects 
the host protein phosphatase 1α (PP1α) to dephosphorylate eIF2α. Work 
with an ICP34.5 deletion mutant has recently shed light on the importance 
of autophagy to HSV-1 infection. In cell culture, inhibiting autophagy via 
knockdown of ATG5 was not sufficient to restore the replication efficiency 
of the mutant virus to that of wild-type virus,238 suggesting that autophagy 
does not play a major role in controlling HSV-1 replication.  However, in 
vivo work with the same virus showed that inhibiting autophagy 
significantly enhanced the neurovirulence of the mutant virus in mice.239 It 
remains unclear whether this is due to changes in regulation and importance 
of autophagy between cell culture and in vivo experiments, or due to cell-
type specific variation in the same factors. 
The results from these studies of HSV-1 raise the question of whether 
E1A’s co-localisation with autophagosomes represents its sequestration for 
degradation and, if so, whether more proteins – or even entire viral particles 
– are similarly captured. The consequences of this interaction for the virus 
are unclear, as the cited work in HSV-1 demonstrated that the relationship 
between autophagy and viral load can be heavily dependent on some 
combination of cell type and environment. 
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8.4.5 VA-RNAI expression prevents starvation-induced 
autophagy in Suit-2 cells 
As described in the Introduction, solid tumours are often nutrient-poor 
and hypoxic environments. Broadly, this is due to an insufficiently 
developed or blocked vasculature, incapable of supplying sufficient fresh 
blood to densely packed and highly metabolically active cancer cells. Many 
tumour cells survive these conditions through the upregulation of 
macroautophagy, as a source of metabolites and ATP. 
VA-RNAI’s ability to block virus-induced autophagy in Suit-2 cells 
prompted the question of whether it could also block this tumour survival 
pathway. Starving untreated Suit-2 cells or Suit-2 cells transfected with a 
control plasmid induced high levels of autophagy. Cells expressing VA-
RNAI and the related VA-RNAII from a commercial plasmid were unable 
to induce autophagy. Interestingly, these cells showed noticeably more cell 
rounding and detachment indicative of cell death than those which had not 
had autophagy blocked. 
This presents a dilemma in the use of VA-RNAI-deleted viruses in 
cancer therapy. While the deletion does provide selectivity for certain 
cancer cell lines, expression of VA-RNAI could actually be advantageous in 
an oncolytic virus, by sensitising the tumour cells to nutrient deprivation so 
typical of the tumour environment. 
MiaPaCa2 cells did not show an increase in autophagy after starvation. 
Given that starvation-induced autophagy is regulated by the same pathway 
as virus-induced autophagy, this is not surprising. In the future, it could be 
fascinating to discover why MiaPaCa2 are so resistant to the induction of 
autophagy, and whether this is solely due to its resistance against eIF2α 
phosphorylation. 
8.4.6 VA-RNAI suppresses induction of AVOs 
The limitations of staining cells with acridine orange were described in 
the Introduction. Briefly, this dye is lysosomotropic and fluoresces red when 
in an acidic environment and so is not truly specific for monitoring 
autophagy.  
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The examination of starved Suit-2 cells demonstrated that brightly 
fluorescing red acridine orange was localised in roughly spherical 
compartments reminiscent of autophagosomes. Unfortunately, an 
incompatibility between protocols for acridine orange staining and 
immunofluorescence prevented a check for co-localisation of AO and LC3. 
Flow cytometry analysis of stained Suit-2 cells reflected the pattern 
expected from the confocal microscopy. Expression of VA-RNAI from the 
virus partially suppressed the virus-induced formation of acidic vesicular 
organelles (AVOs). Expression of VA-RNAI from the plasmid completely 
suppressed virus-induced AVOs. This stronger inhibitory effect is 
presumably due to a higher expression level from the plasmid, especially 
during the early stages of viral infection when VA-RNAI would typically be 
at low levels or entirely absent. 
The results for MiaPaCa2 were more unexpected. Expression of VA-
RNAI from the plasmid matched the confocal data by completely 
suppressing virus-induced AVOs. However, while some induction of AVOs 
was expected based on the confocal data, infection with dl331 led to a 
higher increase in AVOs than infection with dl309. Thus, although VA-
RNAI expression is not required to prevent phosphorylation of eIF2α or to 
inhibit virus-induced autophagy, it is required to prevent the creation of new 
acidified compartments within the cells. 
One possible explanation for this behaviour is the virus-dependent 
induction of the unfolded protein response. This involves the creation of 
double-membraned, low-pH compartments, which are effectively extensions 
of the endoplasmic reticulum. Induction of this pathway is dependant on 
phosphorylation of eIF2α, typically via PERK activation. The 
discriminating factor that determines whether eIF2α activation will lead to 
the UPR or to autophagy is currently unknown, although it has been 
speculated that the duration of the signal may be important. 209,230,232 
8.4.7 VA-RNAI in cancer therapy 
VA-RNAI sensitised Suit-2 cells to treatment with the common 
chemodrug 5-FU. Cancer cells have previously been shown to rely on 
 166 
autophagy as a mechanism to survive treatment with 5-FU.210,211 Given 5-
FU’s mechanism as a chain-terminating nucleoside analogue, presumably 
the autophagy pathway is called upon for its role in surviving single- and 
double-strand breaks in DNA.240,241  
The finding that VA-RNAI is able to sensitise Suit-2 cells to treatment 
with 5-FU raises the question of its mechanism. The route by which DNA 
damage leads to the induction of autophagy is not well known, although 
some details have been elucidated. Promisingly, inhibition of poly(ADP-
ribose) polymerase (PARP) activity can prevent autophagy induction.242 
PARP is an indirect target of active PKR via activation of cellular protease 
CPP32,243 presenting a clue to a possible mechanism by which VA-RNAI 
could influence the activation of this pathway. 
Taken together, the findings regarding VA-RNAI’s activities up to this 
point present a dilemma. While the exact basis of their selectivity remains 
unknown, VA-RNAI deletion mutants of adenovirus have well-established 
selectivity for some cancers. However, its ability to block virus-induced, 
starvation-induced and apparently 5-FU-induced autophagy suggest that 
VA-RNAI could be a powerful anti-tumour agent, suppressing a key 
survival pathway for the tumour. 
Based on these results, it would be fascinating to see VA-RNAI trialled 
as an anti-cancer agent, delivered to cells to sensitise them to starvation or 
lack of growth hormone, to viral infection or to treatment with 5-FU. Other 
treatments that induce autophagy, e.g. radiotherapy, would also warrant 
investigation. Currently, VA-RNAI shares the problems of other gene 
therapy “payload” toxic genes, most notably delivery. 
8.5  Microarray analysis of infected normal cells 
The cell line-dependent effects of VA-RNAI on factors such as eIF2α 
phosphorylation, IFNβ synthesis and autophagy induction highlight the 
limitations of working with cancer cell lines. It is extremely difficult to be 
sure whether observed effects and interactions are truly representative of the 
virus’ interactions with normal cells and therefore typical behaviour for the 
virus, or unique to a certain combination of mutations in a given cancer cell 
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line. In order to overcome this problem – and to learn more about normal 
cells’ response to viral infection – whole RNA from infected cells was 
subjected to microarray analysis. 
Firstly, levels of VA-RNAI expression were measured at regular 
intervals during infection. In the two epithelial cell types tested, VA-RNAI 
was detected at low levels until approximately 18 hours after infection. At 
this time, levels of VAI rapidly increased until reaching a plateau at 28 
hours. This plateau in VA-RNAI accumulation coincided with extensive 
cytopathic effect beginning to appear in the infected cells. Therefore it may 
be that VA-RNAI production is not downregulated at the end of infection, 
merely that synthesis is stopped due to cell death. Alternatively, cellular 
RNAses could begin to degrade VA-RNAI. However, maintaining a 
constant quantity of VA-RNAI over several hours could only happen if the 
production and degradation of VA-RNAI were closely balanced. This seems 
unlikely to occur by chance. 
Based on the known timing of VA-RNAI expression, several timepoints 
in the infection were chosen for analysis of cellular gene expression using 
an expression microarray. Two timepoints were chosen before high VA-
RNAI expression, at 6 and 12 hours. The purpose of these was to chart the 
cells’ initial response to viral infection. Comparing the VA-RNAI-deleted 
and control virus infections will confirm whether VA-RNAI only takes 
effect after the upregulation at 18 hours. Additionally, comparing the 
infected cells with mock-infected cells will provide invaluable – and so far 
unique – data on how the early genes of Adenovirus interact with healthy 
bronchial epithelial cells. 
Later timepoints were also chosen: 18, 24 and 28 hours, to coincide 
with the upregulation and stabilisation of VA-RNAI levels. Comparison of 
gene expression data from dl331 and dl309 infected cells will provide 
extensive information on the cellular response prompted by VA-RNAI.  
Automated clustering of the microarray data revealed some 
information. The six-hour timepoint shows the two viruses clustered 
together with the mock-infected cells. This indicates that the intracellular 
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response has not yet had made an obvious impact on cellular gene 
expression. From twelve hours onwards the mock-infected cells are 
grouped, separate from the virus-infected cells. This highlights the 
increasing scale of gene expression changes within the infected cells. The 
virus-infected cells are paired by timepoint. This confirms that the genes 
expressed in response to the infection are changing over time, and that this 
process is largely unaffected by VA-RNAI expression.  
More detailed analysis of the data yielded lists of genes whose 
expression varied over time. Comparison of the regulation of these genes in 
response to the viral infections resulted in final lists of genes that are 
differentially expressed at the time that VA-RNAI accumulates to high 
levels within the cell, and sustained until the last timepoint. Many of these 
genes were involved in cell cycle regulation, and so a subset of these were 
chosen for further validation. 
E2F1, E2F8, Cyclin E2, ID2 and the histone component H2al are all 
strongly associated with progression through the cell cycle. Their 
upregulation in cells infected with dl331 is somewhat counter-intuitive, as 
the consequences of VA-RNAI deletion – protein synthesis arrest, 
autophagy – could be expected to lead to the inhibition of cell cycle 
progression. 
Nevertheless, quantitative RT-PCR showed that all five of these genes 
were significantly upregulated in Suit-2 cells infected with dl331 when 
compared to those infected with dl309. MiaPaCa2 cells showed no 
significant upregulation in any of these genes; indeed, all five were reported 
as slightly lower values in dl331-infected cells, although these differences 
were not significant. The differential regulation of these genes is a 
consequence of VA-RNA’s modulation of the host response to the virus, as 
evidenced by the lack of differential gene regulation in cells expressing VA-
RNAs from the plasmid pAdVAntage but not infected with either virus. 
At the protein level, the key cell cycle control gene inhibitor of 
differentiation 2 (ID2) was upregulated in response to dl331 when compared 
to dl309 in Suit-2 cells. As expected, no such regulation was seen in 
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MiaPaCa2 cells. In general, ID2 expression is expected to favour 
proliferation, inhibit cellular differentiation and aid tumour angiogenesis.244 
Little has been reported regarding its interaction with viruses, although it is 
found to be commonly over-expressed in EBV-associated Hodgkin’s 
lymphoma, where it is hypothesised to play a role in preventing terminal 
differentiation of the B lymphocytes.244 Its over-expression has also been 
reported in association with portal vein invasion of hepatitis C virus-related 
hepatocellular carcinoma, although its exact function in this process is 
unknown.245 
Functional validation of these findings revealed that, at 24 hours after 
infection, cells infected with dl331 have a cell cycle profile very similar to 
mock-infected cells, while those infected with dl309 show an increase in S-
phase at the expense of G2/M phase. This difference was transient, having 
disappeared by 28 hour after infection, but repeatable. Possibly, the relative 
upregulation of cell cycle-advancing genes in the dl331-infected cells 
results in a faster transition through the S-phase analogue induced by the 
viral infection. A shorter time spent in S-phase before the accumulation of 
the cyclins required to push the cell into attempting to enter G2/M phase – 
and possibly a subsequent mitotic catastrophe – could allow less time for 
dl331 to replicate than dl309, resulting in a lower yield of viral progeny 
from the infection. 
This interaction of VA-RNAI with the host genes observed to be 
expressed is complex and, while the predominance of cell cycle regulatory 
genes was striking, the mechanism for their regulation is not clear. They do 
not fit the expected profile of gene regulation in response to the UPR, 
autophagic or apoptotic pathways most typically associated with VA-
RNAI’s most well established function of inhibiting eIF2α phosphorylation. 
Rather, they represent an emerging new pathway in VA-RNAI’s modulation 
of the host’s response against the virus.  
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9   Appendix: Gene Lists 
 
Comparison of mRNA levels in cells infected with dl331 and dl309. These data represent accumulation over time, normalised against mock-infected 
cells. Positive values indicate that mRNA levels are higher in cells infected with dl331 compared to dl309 (i.e. higher in absence of VAI) 
 
 
Table 24 - Earliest responses [-1.5 ≥  20h ≥  1.5 AND -1≥  24h ≥  1] 
NAME 6 HOURS 12 HOURS 20 HOURS 24 HOURS 28 HOURS 
PX domain containing serine/threonine kinase 0 0 5 1.128438959 0 
SEC31 homolog A (S. cerevisiae) 0 0 1.654742824 -1.39939952 0 
family with sequence similarity 111, member B 1.554230796 0 2.138064859 1.272571317 2.88895585 
B-cell CLL/lymphoma 2 0 0 1.58057891 1.3787149 1.665709233 
neurofilament, medium polypeptide 150kDa 0 0 2.67523975 2.893371654 1.546744543 
histone cluster 1, H3h -1.58589909 0.215381605 1.540490925 1.690959165 1.441054275 
zinc finger protein 239 0 0 1.599879515 1.6155161 0 
histone cluster 2, H4a 0 -1.01288904 2.299484032 2.158513445 0.856063565 
histone cluster 1, H3a 0 0 2.074250521 1.940475043 2.102196952 
histone cluster 1, H2aj 0 0 1.660517409 1.15259055 1.850082617 
heat shock 70kDa protein 2 0 0 1.602951934 1.702076425 0.688318496 
histone cluster 1, H2ai 0 0 1.749087654 1.196256988 1.039128338 
histone cluster 1, H2al 0 0 2.605586226 2.719489933 3.344029184 
hect domain and RLD 5 0 0 1.657661661 1.855130933 1.274931362 
X (inactive)-specific transcript 0 0 1.582002943 1.932871181 1.583120294 
doublesex and mab-3 related transcription factor 2 0 0 2.14378336 2.472678677 0.771401096 
hypothetical LOC387763 0 0 1.706268677 2.652177101 3.05398332 
hypothetical protein LOC645580 0 0 1.634234993 1.487782683 1.882322384 
zinc finger protein 711 0 0 1.653020668 1.863060301 1.63605671 
glyoxalase domain containing 1 0 0 1.749842316 1.754052685 1.265095701 
transmembrane protein 46 -1.04829724 0 1.947623881 2.033617389 3.025536179 
arylsulfatase G 0 0 1.552736688 1.458363375 1.257766821 
thioredoxin reductase 1 0 0 1.692239853 1.602468847 1.12289458 
G kinase anchoring protein 1 0 0 1.568873289 1.174174886 1.279305936 
 171 
nuclear localized factor 1 0 0 1.552028834 1.648835807 1.4649685 
chondroitin sulfate proteoglycan 5 (neuroglycan C) 0 0 1.592906503 1.003631037 0.814777719 
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Table 25 - Later responses: [-1 ≤  20h ≤  1 AND -1.5 ≥ 24h ≥ 1.5]  
NAME 6 HOURS 12 HOURS 20 HOURS 24 HOURS 28 HOURS 
chromosome 8 open reading frame 47 0 0 0 1.519089761 -1.02112867 
solute carrier family 19 (folate transporter), member 1 0 0 0 1.778661683 0.504498641 
schlafen family member 13 -0.441604475 0 0 1.693226446 1.045700173 
hypothetical protein LOC646762 1.053412927 0 0.066862587 1.577998069 0.356491591 
heat shock 70kDa protein 1B 0.217334572 1.127373304 0.884545179 1.921417662 1.169529652 
chromosome 1 open reading frame 107 0 0 0 1.583200678 1.269324737 
cyclin E2 -0.348058312 0 0 1.62375762 0.90733804 
solute carrier family 27 (fatty acid transporter), member 2 0 0 0.611507888 2.396500656 1.110016055 
solute carrier family 27 (fatty acid transporter), member 2 0 0 0.254171412 1.603487951 0.730194791 
zinc finger protein 165 -0.362292984 0 0 1.770450854 0 
distal-less homeobox 2 0 0 0 1.517969072 1.926493625 
peripheral myelin protein 22 0 0 0.092402791 1.947706367 0.947545689 
histone cluster 1, H2bg -0.273912355 0 0.975907613 1.608922088 1.28689101 
transmembrane protein 97 0 0 0 1.869629123 0.689908813 
v-myb myeloblastosis viral oncogene homolog (avian)-like 
1 -0.385082564 -1.04939238 0 1.531051858 1.59333635 
glypican 1 0 0 -0.07084755 -1.73423356 -0.63384358 
histone cluster 2, H2aa3 0 0 0.520812827 1.543640644 0.661240312 
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog B (avian) 0.090477317 1.209815218 0.81836236 1.65706072 1.265776358 
chromosome 1 open reading frame 109 0 0 0 1.554710552 1.015821039 
E2F transcription factor 8 -0.14562247 -1.02597981 0 1.541775644 1.235571679 
cell division cycle associated 7 0 0 0 1.531911019 0.620309498 
coiled-coil domain containing 77 -1.082506512 0 0 1.540611613 0 
cell division cycle associated 7-like -1.089280622 0 0 1.659266279 0.59147214 
ubiquitin-like, containing PHD and RING finger domains, 1 -0.080102248 0 0 1.775322046 0.708837821 
aspartate beta-hydroxylase domain containing 2 0 0 0 1.55837563 1.010022505 
similar to CG12314 gene product -0.242694707 0 0.596807318 1.871446942 1.487323886 
MAP7 domain containing 2 0 0 0 1.578698145 1.632968118 
ankyrin repeat domain 34 0 0 0.038454518 1.53354609 0.390863745 
 173 
hypothetical protein LOC201725 -0.008840566 -1.44254652 0 1.512685488 0 
transmembrane protein 56 0 0 0 1.628561337 1.578547976 
isoleucyl-tRNA synthetase 0 0 0 1.527206131 0 
KISS1 receptor 0 0 0 1.65457862 1.113503044 
hypothetical protein FLJ13305 -1.197169813 0 0 1.592710426 1.268057831 
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